[{"id": 243001, "ingredient1": "Cerivastatin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279121/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Bempedoic acid, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Pravastatin, Niacin, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243002, "ingredient1": "Cisapride", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279122/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Metoclopramide", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243003, "ingredient1": "Conjugated estrogens (topical)", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279123/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Chlorotrianisene, Diethylstilbestrol, Bazedoxifene", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 243004, "ingredient1": "Dienestrol (topical)", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279124/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243005, "ingredient1": "Ergometrine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279125/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Misoprostol, Dinoprostone", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243006, "ingredient1": "Estrone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279126/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Chlorotrianisene, Diethylstilbestrol, Bazedoxifene", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243007, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279127/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243008, "ingredient1": "Ezetimibe", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279128/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Ramipril, Lisinopril, Perindopril, Pravastatin, Acetylsalicylic acid, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Gemfibrozil, Fenofibric acid, More", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 243009, "ingredient1": "Finasteride", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279129/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Caffeine, Cromoglicic acid, Dupilumab, Tralokinumab, More", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243010, "ingredient1": "Gefitinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279130/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 243011, "ingredient1": "Glipizide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279131/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243012, "ingredient1": "Goserelin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279132/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Megestrol acetate, Diethylstilbestrol", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243013, "ingredient1": "Granisetron", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279133/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Scopolamine, Nabilone", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 243014, "ingredient1": "Guanfacine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279134/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 243015, "ingredient1": "Halofantrine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279135/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243016, "ingredient1": "Halothane", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279136/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243017, "ingredient1": "Histrelin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279137/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Megestrol acetate, Diethylstilbestrol", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 243018, "ingredient1": "Hydrocodone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279138/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Benzonatate, Clofedanol, Pentoxyverine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243019, "ingredient1": "Hydroxychloroquine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279139/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243020, "ingredient1": "Ibrutinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279141/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Dabrafenib, Dacomitinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Brigatinib, Axitinib, Lenvatinib, More", "updated_at": 1767369485}, {"id": 243021, "ingredient1": "Idarubicin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279142/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Bleomycin, Valrubicin, Plicamycin", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243022, "ingredient1": "Ifosfamide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279143/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Temozolomide, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, Melphalan flufenamide, Uracil mustard", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243023, "ingredient1": "Imipramine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279144/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243024, "ingredient1": "Indomethacin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279145/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Fenoprofen, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, More", "alternatives_b": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 243025, "ingredient1": "Isoetharine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279147/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243026, "ingredient1": "Isoprenaline", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279148/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 243027, "ingredient1": "Istradefylline", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279149/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243028, "ingredient1": "Ivermectin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279150/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Thiabendazole, Levamisole, Pyrantel, Piperazine, Mebendazole, Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243029, "ingredient1": "Pralsetinib", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279151/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "alternatives_b": "Tivozanib, Futibatinib, Fedratinib, Regorafenib, Trametinib, Neratinib, Nintedanib, Afatinib, Dacomitinib, Pexidartinib, Alectinib, More", "updated_at": 1767369485}, {"id": 243030, "ingredient1": "Pralsetinib", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279152/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Bleomycin, Valrubicin, Plicamycin", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243031, "ingredient1": "Pralsetinib", "ingredient2": "Ixazomib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279153/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 243032, "ingredient1": "Pralsetinib", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279154/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 243033, "ingredient1": "Pralsetinib", "ingredient2": "Lacosamide", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279155/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243034, "ingredient1": "Pralsetinib", "ingredient2": "Lactitol", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279156/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243035, "ingredient1": "Pralsetinib", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279157/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Futibatinib, Copanlisib, Dacomitinib, Erdafitinib, Abemaciclib, Trametinib, Afatinib, Duvelisib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243036, "ingredient1": "Pralsetinib", "ingredient2": "Lenalidomide", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279159/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 243037, "ingredient1": "Pralsetinib", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279160/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243038, "ingredient1": "Pralsetinib", "ingredient2": "Lesinurad", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279161/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pegloticase, Febuxostat, Sulfinpyrazone, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Dacomitinib, Pexidartinib, Fedratinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Regorafenib, Ruxolitinib, More", "updated_at": 1767369485}, {"id": 243039, "ingredient1": "Pralsetinib", "ingredient2": "Levosalbutamol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279162/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243040, "ingredient1": "Pralsetinib", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279163/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Chloroprocaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 243041, "ingredient1": "Pralsetinib", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279164/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Enoxacin, Trovafloxacin, Nalidixic acid, Cinoxacin, Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243042, "ingredient1": "Pralsetinib", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279166/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Varenicline, Nalmefene, Nicotine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243043, "ingredient1": "Pralsetinib", "ingredient2": "Linagliptin", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279167/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243044, "ingredient1": "Pralsetinib", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279168/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243045, "ingredient1": "Pralsetinib", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279169/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243046, "ingredient1": "Pralsetinib", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279171/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243047, "ingredient1": "Pralsetinib", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279172/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Romiplostim, Fostamatinib, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243048, "ingredient1": "Pralsetinib", "ingredient2": "Macimorelin", "severity": "Major", "effect": "Macimorelin can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.  A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279173/", "reference_text": "[1] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris  (2018):", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, Folic acid, More", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243049, "ingredient1": "Pralsetinib", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279174/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Metyrosine", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243050, "ingredient1": "Pralsetinib", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279175/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243051, "ingredient1": "Pralsetinib", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279176/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, Elbasvir, Famciclovir, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 243052, "ingredient1": "Pralsetinib", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279178/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Fenoprofen, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Rofecoxib, More", "alternatives_b": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 243053, "ingredient1": "Pralsetinib", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279179/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 243054, "ingredient1": "Pralsetinib", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279180/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 243055, "ingredient1": "Pralsetinib", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279181/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 243056, "ingredient1": "Pralsetinib", "ingredient2": "Meropenem", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279182/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 243057, "ingredient1": "Pralsetinib", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279183/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243058, "ingredient1": "Pralsetinib", "ingredient2": "Methylergometrine", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279184/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Misoprostol, Dinoprostone", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243059, "ingredient1": "Pralsetinib", "ingredient2": "Methylnaltrexone", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279185/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243060, "ingredient1": "Pralsetinib", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279186/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "alternatives_b": "Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243061, "ingredient1": "Pralsetinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279188/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243062, "ingredient1": "Pralsetinib", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279189/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Axitinib, Regorafenib, More", "updated_at": 1767369485}, {"id": 243063, "ingredient1": "Pralsetinib", "ingredient2": "Mineral oil", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279190/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243064, "ingredient1": "Pralsetinib", "ingredient2": "Mirabegron", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279191/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243065, "ingredient1": "Pralsetinib", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279192/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 243066, "ingredient1": "Pralsetinib", "ingredient2": "Mitomycin", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279194/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Bleomycin, Valrubicin, Plicamycin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 243067, "ingredient1": "Pralsetinib", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279195/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Bleomycin, Valrubicin, Plicamycin", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243068, "ingredient1": "Pralsetinib", "ingredient2": "Montelukast", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279196/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 243069, "ingredient1": "Pralsetinib", "ingredient2": "Naloxegol", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279197/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 243070, "ingredient1": "Pralsetinib", "ingredient2": "Nilutamide", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279198/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Anastrozole, Aminoglutethimide, Fulvestrant", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243071, "ingredient1": "Pralsetinib", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279199/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Clevidipine, Levamlodipine", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243072, "ingredient1": "Pralsetinib", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279200/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pacritinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 243073, "ingredient1": "Pralsetinib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279201/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243074, "ingredient1": "Pralsetinib", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279202/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243075, "ingredient1": "Pralsetinib", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279203/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Vandetanib, Afatinib, Tivozanib, Brigatinib, Encorafenib, Axitinib, Sunitinib, Regorafenib, More", "updated_at": 1767369485}, {"id": 243076, "ingredient1": "Pralsetinib", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279204/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 243077, "ingredient1": "Pralsetinib", "ingredient2": "Ospemifene", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279206/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Prasterone, Raloxifene, Bazedoxifene", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 243078, "ingredient1": "Pralsetinib", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279207/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 243079, "ingredient1": "Pralsetinib", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279208/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243080, "ingredient1": "Pralsetinib", "ingredient2": "Papaverine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279209/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 243081, "ingredient1": "Pralsetinib", "ingredient2": "Pemigatinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279210/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243082, "ingredient1": "Pralsetinib", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279211/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Miltefosine, Nifurtimox, Benznidazole", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 243083, "ingredient1": "Pralsetinib", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279212/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 243084, "ingredient1": "Pralsetinib", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279213/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243085, "ingredient1": "Pralsetinib", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279214/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Amisulpride, Loxapine, Molindone, Thiothixene", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243086, "ingredient1": "Pralsetinib", "ingredient2": "Pirbuterol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279215/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Epinephrine, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 243087, "ingredient1": "Pralsetinib", "ingredient2": "Pitavastatin", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279217/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Bempedoic acid, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Pravastatin, Niacin, More", "alternatives_b": "Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 243088, "ingredient1": "Pralsetinib", "ingredient2": "Polatuzumab vedotin", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279218/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243089, "ingredient1": "Pralsetinib", "ingredient2": "Pomalidomide", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279219/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 243090, "ingredient1": "Pralsetinib", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279220/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Entrectinib, Asciminib, Dacomitinib, Tepotinib, Selumetinib, Vandetanib, Capmatinib, Tivozanib, Axitinib, Sunitinib, Lenvatinib, More", "updated_at": 1767369485}, {"id": 243091, "ingredient1": "Pretomanid", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279222/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 243092, "ingredient1": "Primaquine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279223/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243093, "ingredient1": "Probucol", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279224/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Bempedoic acid, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Pravastatin, Niacin, More", "updated_at": 1767369485}, {"id": 243094, "ingredient1": "Procainamide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279225/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 243095, "ingredient1": "Promazine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279226/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Amisulpride, Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 243096, "ingredient1": "Propafenone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279227/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Acalabrutinib, Pexidartinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 243097, "ingredient1": "Prucalopride", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279228/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "alternatives_b": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 243098, "ingredient1": "Quinine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279229/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, More", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243099, "ingredient1": "Ramelteon", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279230/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 243100, "ingredient1": "Relugolix", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279232/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Afatinib, Duvelisib, Tivozanib, More", "alternatives_b": "Nafarelin, Elagolix, Cetrorelix, Ganirelix, Gonadorelin, Anastrozole, Aminoglutethimide, Fulvestrant", "updated_at": 1767369485}, {"id": 243101, "ingredient1": "Repaglinide", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279233/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "updated_at": 1767369485}, {"id": 243102, "ingredient1": "Revefenacin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279234/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Nedocromil, Tiotropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 243103, "ingredient1": "Rimegepant", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279235/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Zanubrutinib, Brigatinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243104, "ingredient1": "Ripretinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279236/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243105, "ingredient1": "Ritodrine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279237/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "alternatives_b": "Bremelanotide, Cabergoline", "updated_at": 1767369485}, {"id": 243106, "ingredient1": "Rolapitant", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279238/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Ribociclib, More", "alternatives_b": "Scopolamine, Nabilone", "updated_at": 1767369485}, {"id": 243107, "ingredient1": "Romidepsin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279239/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "updated_at": 1767369485}, {"id": 243108, "ingredient1": "Ropivacaine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279240/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, More", "alternatives_b": "Chloroprocaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "updated_at": 1767369485}, {"id": 243109, "ingredient1": "Ruxolitinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279241/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Encorafenib, More", "alternatives_b": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243110, "ingredient1": "Selumetinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279242/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243111, "ingredient1": "Sibutramine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279243/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dacomitinib, Tepotinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, More", "alternatives_b": "Dexfenfluramine, Ephedrine, Fenfluramine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 243112, "ingredient1": "Sildenafil", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279244/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More", "updated_at": 1767369485}, {"id": 243113, "ingredient1": "Siponimod", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279245/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dacomitinib, Tepotinib, Selumetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, Ripretinib, Regorafenib, Erlotinib, Neratinib, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 243114, "ingredient1": "Sitagliptin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279247/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "updated_at": 1767369485}, {"id": 243115, "ingredient1": "Solifenacin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279248/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 243116, "ingredient1": "Sulfamethoxazole", "ingredient2": "Pralsetinib", "severity": "Minor", "effect": "Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).  In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279250/", "reference_text": "[1] Wiener I, Rubin D, Martinez E, et al. \"QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration.\" Mt Sinai J Med 48 (1981):  53-5[2] Crouch MA, Limon L, Cassano AT \"Clinical relevance and management of drug-related QT interval prolongation.\" Pharmacotherapy 23 (2003):  881-908[3] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T \"QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole.\" Am J Cardiol 59 (1987):  376-7[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Darpo B \"Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes.\" Eur Heart J Suppl 3(Suppl K) (2001):  K70-80", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid, Sulfadiazine, More", "updated_at": 1767369485}, {"id": 243117, "ingredient1": "Tasimelteon", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279251/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 243118, "ingredient1": "Telavancin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279253/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 243119, "ingredient1": "Terbinafine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279256/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, More", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Griseofulvin", "updated_at": 1767369485}, {"id": 243120, "ingredient1": "Testosterone (topical)", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279257/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone", "updated_at": 1767369485}, {"id": 243121, "ingredient1": "Thioridazine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279258/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Amisulpride, Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 243122, "ingredient1": "Topotecan", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279259/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Lorlatinib, Axitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243123, "ingredient1": "Trametinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279260/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243124, "ingredient1": "Tretinoin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279261/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "updated_at": 1767369485}, {"id": 243125, "ingredient1": "Triazolam", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279262/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 243126, "ingredient1": "Triflupromazine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279263/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "alternatives_b": "Amisulpride, Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 243127, "ingredient1": "Alimemazine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279264/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 243128, "ingredient1": "Ubrogepant", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279265/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243129, "ingredient1": "Upadacitinib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279266/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Dacomitinib, Tepotinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 243130, "ingredient1": "Valbenazine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279267/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 243131, "ingredient1": "Vardenafil", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279268/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243132, "ingredient1": "Vasopressin", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279269/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243133, "ingredient1": "Vemurafenib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279270/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Futibatinib, Fedratinib, Regorafenib, Vemurafenib, Trametinib, Nintedanib, Cobimetinib, Dacomitinib, Alectinib", "alternatives_b": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More", "updated_at": 1767369485}, {"id": 243134, "ingredient1": "Venetoclax", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279271/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Cobimetinib, Zanubrutinib, Axitinib, Sunitinib, Ruxolitinib, Lenvatinib, Erlotinib, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, More", "updated_at": 1767369485}, {"id": 243135, "ingredient1": "Vibegron", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279272/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Lapatinib, Cobimetinib, Duvelisib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243136, "ingredient1": "Vilazodone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279273/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Asciminib, Dacomitinib, Tepotinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, More", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "updated_at": 1767369485}, {"id": 243137, "ingredient1": "Vinblastine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279275/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Pexidartinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243138, "ingredient1": "Vincristine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279276/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243139, "ingredient1": "Vincristine (liposome)", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279277/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243140, "ingredient1": "Vinorelbine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279278/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243141, "ingredient1": "Ziprasidone", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279280/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Amisulpride, Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 243142, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279282/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243143, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Obinutuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279330/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243144, "ingredient1": "Gefitinib", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.  Patients should be advised to contact their physician if they experience possible symptoms of gefitinib toxicity such as severe diarrhea, nausea, dyspnea, cough, and fever.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279337/", "reference_text": "[1] \"Product Information. Iressa (gefitinib).\" Astra-Zeneca Pharmaceuticals  (2003):[2] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007):  3731-7", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 243145, "ingredient1": "Gemcitabine", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279341/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243146, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Gemcitabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279347/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 243147, "ingredient1": "Gemcitabine", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279357/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Azacitidine, Pralatrexate, Trifluridine", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243148, "ingredient1": "Gemcitabine", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279393/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243149, "ingredient1": "Gemfibrozil", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 or moderate dual or combined inhibitors of CYP450 3A4 and CYP450 2C9 may increase the plasma concentrations of macitentan.  Macitentan is primarily metabolized by CYP450 3A4 and to a minor extent by CYP450 2C8, CYP450 2C9 and CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.  The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole).  The manufacturer of macitentan also recommends avoiding concomitant use with moderate dual inhibitors of CYP450 3A4 and 2C9 (e.g., fluconazole, amiodarone) or in combination with both a moderate CYP450 3A4 inhibitor and a moderate CYP450 2C9 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279394/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc  (2013):", "alternatives_a": "Cholestyramine, Rosuvastatin, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Niacin, Ezetimibe, Atorvastatin, Colesevelam, More", "alternatives_b": "Riociguat, Metyrosine, Tadalafil", "updated_at": 1767369485}, {"id": 243150, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279397/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243151, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279446/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243152, "ingredient1": "Etidocaine", "ingredient2": "Nitroglycerin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279450/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243153, "ingredient1": "Nitroglycerin", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279451/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243154, "ingredient1": "Procaine", "ingredient2": "Nitroglycerin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279453/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, More", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate, Nitroglycerin", "updated_at": 1767369485}, {"id": 243155, "ingredient1": "Pyrophosphoric acid", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279455/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243156, "ingredient1": "Ropivacaine", "ingredient2": "Nitroglycerin", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279456/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243157, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279457/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Nesiritide, Vericiguat, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243158, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279458/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Nesiritide, Vericiguat, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243159, "ingredient1": "Ziprasidone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279470/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 243160, "ingredient1": "Ziprasidone", "ingredient2": "Palbociclib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.", "source": "DDInter", "management_text": "Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.  In 14 healthy subjects, coadministration with the potent CYP450 3A4 inhibitor ketoconazole (400 mg orally once a day for 5 days) increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of ziprasidone (40 mg single oral dose) by approximately 1/3 compared to placebo.  These changes, although statistically significant, were not considered clinically important.  There were also no serious adverse events, laboratory or ECG abnormalities, or clinically significant alterations in vital signs throughout the study.  Likewise, in 10 healthy subjects, the nonspecific CYP450 inhibitor cimetidine (800 mg orally once a day for 3 days) increased the AUC of ziprasidone (40 mg single oral dose) by just 6% compared to when ziprasidone was administered alone.  These findings suggest that ziprasidone dose modifications are unlikely to be necessary in patients receiving potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279475/", "reference_text": "[1] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[2] Miceli JJ, Smith M, Robarge L, Morse T, Laurent A \"The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.\" Br J Clin Pharmacol 49(suppl 1) (2000):  s71-6[3] Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D \"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.\" Br J Clin Pharmacol 49(Suppl 1) (2000):  35S-42S[4] Wilner KD, Hansen RA, Folger CJ, Geoffroy P \"The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid.\" Br J Clin Pharmacol 49(Suppl 1) (2000):  57S-60S", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More", "updated_at": 1767369485}, {"id": 243161, "ingredient1": "Sermorelin", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279484/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Macimorelin, Methacholine, More", "updated_at": 1767369485}, {"id": 243162, "ingredient1": "Insulin human", "ingredient2": "Sermorelin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279485/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243163, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Sermorelin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279486/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243164, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Sermorelin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279487/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243165, "ingredient1": "Troglitazone", "ingredient2": "Sermorelin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279489/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, Galactose, Magnesium sulfate, Gonadorelin, Vitamin A, Caffeine, Metyrapone, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 243166, "ingredient1": "Acrivastine", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279506/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Dexchlorpheniramine, Trimethobenzamide, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Cisapride", "updated_at": 1767369485}, {"id": 243167, "ingredient1": "Etidocaine", "ingredient2": "Metoclopramide", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279509/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243168, "ingredient1": "Metoclopramide", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279512/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243169, "ingredient1": "Metoclopramide", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279513/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethchlorvynol, Thiopental", "alternatives_b": "Cisapride", "updated_at": 1767369485}, {"id": 243170, "ingredient1": "Procaine", "ingredient2": "Metoclopramide", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279516/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Cisapride", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 243171, "ingredient1": "Ropivacaine", "ingredient2": "Metoclopramide", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279518/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243172, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279519/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243173, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279520/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243174, "ingredient1": "Ginkgo biloba", "ingredient2": "Bromfenac", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279522/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "alternatives_b": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "updated_at": 1767369485}, {"id": 243175, "ingredient1": "Indomethacin", "ingredient2": "Ginkgo biloba", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279523/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Chondroitin sulfate, More", "updated_at": 1767369485}, {"id": 243176, "ingredient1": "Ginkgo biloba", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279524/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243177, "ingredient1": "Ginkgo biloba", "ingredient2": "Lacosamide", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures and may antagonize the effects of anticonvulsants.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation.  Patients treated with anticonvulsants should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Antagonism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279525/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001):  344[3] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001):  280-1[4] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002):  325-7[5] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005):  755-8[6] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006):  323-9[7] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001):  523-5[8] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001):  524-32", "alternatives_a": "Memantine, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243178, "ingredient1": "Ginkgo biloba", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279527/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243179, "ingredient1": "Ginkgo biloba", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279528/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 243180, "ingredient1": "Ginkgo biloba", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279529/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rivastigmine, Galantamine, Tacrine, Aducanumab", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 243181, "ingredient1": "Ginkgo biloba", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures and may antagonize the effects of anticonvulsants.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation.  Patients treated with anticonvulsants should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Antagonism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279530/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001):  344[3] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001):  280-1[4] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002):  325-7[5] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005):  755-8[6] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006):  323-9[7] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001):  523-5[8] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001):  524-32", "alternatives_a": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243182, "ingredient1": "Ginkgo biloba", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279531/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243183, "ingredient1": "Ginkgo biloba", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279532/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987):  248-51[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[11] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005):  725-6[19] Wolf HR \"Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?\" Drugs R D 7 (2006):  163-72", "alternatives_a": "Tacrine, Aducanumab", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 243184, "ingredient1": "Givosiran", "ingredient2": "Polymyxin B", "severity": "Moderate", "effect": "Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.", "source": "DDInter", "management_text": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "mechanism_text": "Synergism", "recommendation": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279538/", "reference_text": "[1] \"Product Information. Vancocin (vancomycin).\" Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Tetracycline, Rifamycin, Miconazole, Chloramphenicol, Chlorhexidine, Ofloxacin, Tetracycline, Chloramphenicol, Chlorhexidine, Tinidazole, Linezolid, More", "updated_at": 1767369485}, {"id": 243185, "ingredient1": "Givosiran", "ingredient2": "Telavancin", "severity": "Moderate", "effect": "Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.", "source": "DDInter", "management_text": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "mechanism_text": "Synergism", "recommendation": "If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279540/", "reference_text": "[1] \"Product Information. Vancocin (vancomycin).\" Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 243186, "ingredient1": "Imatinib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279544/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243187, "ingredient1": "Imatinib", "ingredient2": "Ibritumomab tiuxetan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279552/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 243188, "ingredient1": "Imatinib", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279565/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243189, "ingredient1": "Imatinib", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279610/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243190, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Cisapride", "severity": "Moderate", "effect": "Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4.  Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.", "source": "DDInter", "management_text": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy.  Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279625/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243191, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Dexfenfluramine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279626/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Naltrexone, Ephedrine, Bupropion, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 243192, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Ergometrine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279627/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals  (2010):", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 243193, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.  Pharmacologic response to lapatinib should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the lapatinib dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279629/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals  (2023):[2] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals Canada Inc  (2022):[3] \"Product Information. Tyverb (lapatinib).\" Novartis Pharmaceuticals UK Ltd  (2022):[4] \"Product Information. Tykerb (laPAtinib).\" Novartis Pharmaceuticals Australia Pty Ltd  (2022):[5] Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelan A \"Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.\" Br J Clin Pharmacol 67 (2009):  421-6", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Fedratinib, Bosutinib, Vemurafenib, Vandetanib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243194, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279631/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243195, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279633/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "updated_at": 1767369485}, {"id": 243196, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279634/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Thiothixene, Amisulpride, Loxapine, Molindone, Droperidol, Lurasidone", "updated_at": 1767369485}, {"id": 243197, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Oxamniquine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279636/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Triclabendazole", "updated_at": 1767369485}, {"id": 243198, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279637/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Atenolol, Nadolol, Esmolol, Betaxolol, Bisoprolol, Carteolol, Sotalol, Atenolol", "updated_at": 1767369485}, {"id": 243199, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279638/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 243200, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Drugs that can increase plasma ammonia levels such as corticosteroids, haloperidol, or the anticonvulsants carbamazepine, topiramate, and phenobarbital may interfere with the therapeutic effects of phenylbutyrate therapy in the management of urea cycle disorders.", "source": "DDInter", "management_text": "Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.", "mechanism_text": "Antagonism", "recommendation": "Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279640/", "reference_text": "[1] \"Product Information. Buphenyl (sodium phenylbutyrate).\" Horizon Therapeutics USA Inc  (2001):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "updated_at": 1767369485}, {"id": 243201, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279641/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Thiothixene, Amisulpride, Loxapine, Molindone, Droperidol, Lurasidone", "updated_at": 1767369485}, {"id": 243202, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279642/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "updated_at": 1767369485}, {"id": 243203, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279643/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, More", "updated_at": 1767369485}, {"id": 243204, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor", "source": "DDInter", "management_text": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "mechanism_text": "Synergism", "recommendation": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279644/", "reference_text": "[1] \"Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol).\" Amylyx Pharmaceuticals  (2022):[2] \"Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine).\" Innomar Strategies Inc.  (2022):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, Givosiran, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 243205, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279646/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Thiothixene, Amisulpride, Loxapine, Molindone, Droperidol, Lurasidone", "updated_at": 1767369485}, {"id": 243206, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279647/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 243207, "ingredient1": "Golimumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279659/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243208, "ingredient1": "Golimumab", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn's disease or ulcerative colitis.", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279675/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories  (2001):[3] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical  (2003):[4] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc  (2008):[5] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[6] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria.  http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm\"   (2012):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243209, "ingredient1": "Golimumab", "ingredient2": "Promazine", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn's disease or ulcerative colitis.", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279688/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories  (2001):[3] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical  (2003):[4] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc  (2008):[5] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[6] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria.  http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm\"   (2012):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 243210, "ingredient1": "Golimumab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279716/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243211, "ingredient1": "Guanadrel", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279739/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243212, "ingredient1": "Guanadrel", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279741/", "reference_text": "[1] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992):  520-3[2] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975):  431-6[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991):  926-31[4] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991):  919-25[5] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243213, "ingredient1": "Guanadrel", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279742/", "reference_text": "[1] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992):  520-3[2] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975):  431-6[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991):  926-31[4] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991):  919-25[5] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243214, "ingredient1": "Guanadrel", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279744/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[4] \"Product Information. Hylorel (guanadrel).\" Rhone Poulenc Rorer  (2001):[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[7] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[8] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[11] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[12] \"Product Information. Toprol-XL (metoprolol).\" Astra-Zeneca Pharmaceuticals  (2001):[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997):  225-6", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243215, "ingredient1": "Guanadrel", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279745/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243216, "ingredient1": "Guanadrel", "ingredient2": "Chlormezanone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279746/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Cyclobenzaprine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243217, "ingredient1": "Guanadrel", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279747/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243218, "ingredient1": "Guanadrel", "ingredient2": "Ephedrine (nasal)", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279749/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243219, "ingredient1": "Halazepam", "ingredient2": "Guanadrel", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279750/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243220, "ingredient1": "Guanadrel", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279751/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243221, "ingredient1": "Insulin human", "ingredient2": "Guanadrel", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279752/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243222, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Guanadrel", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279753/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243223, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Guanadrel", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279754/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243224, "ingredient1": "Guanadrel", "ingredient2": "Levmetamfetamine (nasal)", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279755/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243225, "ingredient1": "Guanadrel", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279756/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[4] \"Product Information. Hylorel (guanadrel).\" Rhone Poulenc Rorer  (2001):[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[7] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[8] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[11] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[12] \"Product Information. Toprol-XL (metoprolol).\" Astra-Zeneca Pharmaceuticals  (2001):[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997):  225-6", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243226, "ingredient1": "Guanadrel", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, may decrease the hypotensive effect of postganglionic adrenergic blocking agents such as guanadrel, guanethidine and rauwolfia alkaloids, which work by depleting catecholamine stores from adrenergic nerve endings.  CNS stimulants can have peripheral sympathetic activity, thus they may elevate blood pressure on their own as well as antagonize some of the antiadrenergic effect produced by these hypotensive agents.  Amphetamines reportedly also may displace the blocking agent, guanethidine, and inhibit its uptake by adrenergic neurons.  Other mechanisms have also been proposed.  In addition to diminished hypotensive response, the interaction has also been reported to produce hypotension and ventricular tachycardia in a patient stabilized on guanethidine shortly after initiating treatment with methylphenidate.", "source": "DDInter", "management_text": "Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279758/", "reference_text": "[1] Ober KF, Wang RI \"Drug interactions with guanethidine.\" Clin Pharmacol Ther 14 (1973):  190-5[2] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[3] Flegin OT, Morgan DH, Oates JA, Shand DG, Turner P \"The mechanism of the reversal of the effect of guanethidine by amphetamines in cat and man.\" Br J Pharmacol 39 (1970):  p253[4] Follenfant MJ, Robson RD \"The antagonism of adrenergic neurone blockade by amphetamine and dexamphetamine in the rat and guinea-pig.\" Br J Pharmacol 38 (1970):  792[5] Gerkens JF, McCulloch MW, Wilson J \"Mechanism of the antagonism between guanethidine and dexamphetamine.\" Br J Pharmacol 35 (1969):  563-72[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Obianwu HO \"Some studies on the mechanism by which d-amphetamine antagonizes guanethidine induced adrenergic neurone blockade.\" Acta Physiol Scand 75 (1969):  102-10[8] Deshmankar BS, Leewis JA \"Ventricular tachycardia associated with the administration of methylphenidate during guanethidine therapy.\" Can Med Assoc J 97 (1967):  1166-71", "alternatives_a": "Dexfenfluramine, Naltrexone, Fenfluramine, Orlistat, Lorcaserin, Sibutramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243227, "ingredient1": "Guanadrel", "ingredient2": "Mephentermine", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279759/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243228, "ingredient1": "Guanadrel", "ingredient2": "Metaraminol", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279760/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243229, "ingredient1": "Guanadrel", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279761/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243230, "ingredient1": "Guanadrel", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279762/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243231, "ingredient1": "Guanadrel", "ingredient2": "Methoxamine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279763/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243232, "ingredient1": "Guanadrel", "ingredient2": "Naphazoline (nasal)", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279764/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243233, "ingredient1": "Guanadrel", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279765/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243234, "ingredient1": "Guanadrel", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279766/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[4] \"Product Information. Hylorel (guanadrel).\" Rhone Poulenc Rorer  (2001):[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[7] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[8] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[11] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[12] \"Product Information. Toprol-XL (metoprolol).\" Astra-Zeneca Pharmaceuticals  (2001):[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997):  225-6", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243235, "ingredient1": "Guanadrel", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279767/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243236, "ingredient1": "Guanadrel", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279768/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243237, "ingredient1": "Guanadrel", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279769/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243238, "ingredient1": "Guanadrel", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279770/", "reference_text": "[1] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992):  520-3[2] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975):  431-6[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991):  926-31[4] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991):  919-25[5] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243239, "ingredient1": "Guanadrel", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279771/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243240, "ingredient1": "Guanadrel", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279772/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243241, "ingredient1": "Guanadrel", "ingredient2": "Xylometazoline (nasal)", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279774/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243242, "ingredient1": "Guanethidine", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279775/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More", "alternatives_b": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Brimonidine, More", "updated_at": 1767369485}, {"id": 243243, "ingredient1": "Guanethidine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279776/", "reference_text": "[1] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992):  520-3[2] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975):  431-6[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991):  926-31[4] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991):  919-25[5] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More", "updated_at": 1767369485}, {"id": 243244, "ingredient1": "Guanethidine", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279777/", "reference_text": "[1] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992):  520-3[2] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975):  431-6[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991):  926-31[4] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991):  919-25[5] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More", "updated_at": 1767369485}, {"id": 243245, "ingredient1": "Guanethidine", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279779/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[4] \"Product Information. Hylorel (guanadrel).\" Rhone Poulenc Rorer  (2001):[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[7] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[8] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[11] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[12] \"Product Information. Toprol-XL (metoprolol).\" Astra-Zeneca Pharmaceuticals  (2001):[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997):  225-6", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "Latanoprost, Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More", "updated_at": 1767369485}, {"id": 243246, "ingredient1": "Guanethidine", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279780/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 243247, "ingredient1": "Guanethidine", "ingredient2": "Ephedrine (nasal)", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279782/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, More", "alternatives_b": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "updated_at": 1767369485}, {"id": 243248, "ingredient1": "Guanethidine", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279783/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine", "alternatives_b": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 243249, "ingredient1": "Insulin human", "ingredient2": "Guanethidine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279784/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, More", "alternatives_b": "Liraglutide, Lixisenatide", "updated_at": 1767369485}, {"id": 243250, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Guanethidine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279785/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243251, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Guanethidine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279786/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243252, "ingredient1": "Guanethidine", "ingredient2": "Levmetamfetamine (nasal)", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279787/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243253, "ingredient1": "Guanethidine", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279788/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[4] \"Product Information. Hylorel (guanadrel).\" Rhone Poulenc Rorer  (2001):[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[7] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[8] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[11] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[12] \"Product Information. Toprol-XL (metoprolol).\" Astra-Zeneca Pharmaceuticals  (2001):[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997):  225-6", "alternatives_a": "Latanoprost, Methazolamide, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, Levobunolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243254, "ingredient1": "Guanethidine", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, may decrease the hypotensive effect of postganglionic adrenergic blocking agents such as guanadrel, guanethidine and rauwolfia alkaloids, which work by depleting catecholamine stores from adrenergic nerve endings.  CNS stimulants can have peripheral sympathetic activity, thus they may elevate blood pressure on their own as well as antagonize some of the antiadrenergic effect produced by these hypotensive agents.  Amphetamines reportedly also may displace the blocking agent, guanethidine, and inhibit its uptake by adrenergic neurons.  Other mechanisms have also been proposed.  In addition to diminished hypotensive response, the interaction has also been reported to produce hypotension and ventricular tachycardia in a patient stabilized on guanethidine shortly after initiating treatment with methylphenidate.", "source": "DDInter", "management_text": "Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Alternatives to postganglionic adrenergic blocking agents should be considered in hypertensive patients treated with CNS stimulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279790/", "reference_text": "[1] Ober KF, Wang RI \"Drug interactions with guanethidine.\" Clin Pharmacol Ther 14 (1973):  190-5[2] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[3] Flegin OT, Morgan DH, Oates JA, Shand DG, Turner P \"The mechanism of the reversal of the effect of guanethidine by amphetamines in cat and man.\" Br J Pharmacol 39 (1970):  p253[4] Follenfant MJ, Robson RD \"The antagonism of adrenergic neurone blockade by amphetamine and dexamphetamine in the rat and guinea-pig.\" Br J Pharmacol 38 (1970):  792[5] Gerkens JF, McCulloch MW, Wilson J \"Mechanism of the antagonism between guanethidine and dexamphetamine.\" Br J Pharmacol 35 (1969):  563-72[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Obianwu HO \"Some studies on the mechanism by which d-amphetamine antagonizes guanethidine induced adrenergic neurone blockade.\" Acta Physiol Scand 75 (1969):  102-10[8] Deshmankar BS, Leewis JA \"Ventricular tachycardia associated with the administration of methylphenidate during guanethidine therapy.\" Can Med Assoc J 97 (1967):  1166-71", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, More", "alternatives_b": "Dexfenfluramine, Naltrexone, Fenfluramine, Orlistat, Lorcaserin, Sibutramine", "updated_at": 1767369485}, {"id": 243255, "ingredient1": "Guanethidine", "ingredient2": "Mephentermine", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279791/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "updated_at": 1767369485}, {"id": 243256, "ingredient1": "Guanethidine", "ingredient2": "Metaraminol", "severity": "Moderate", "effect": "Sympathomimetic amines may decrease the hypotensive effect of postganglionic adrenergic blocking agents, while the latter may potentiate the pharmacologic effects of direct-acting sympathomimetic amines (e.g., dobutamine, epinephrine, methoxamine, norepinephrine) but inhibit those that are primarily indirect-acting (e.g., mephentermine).  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings.  Therefore, they may sensitize adrenergic receptors to direct-acting sympathomimetics, but blunt the effects of indirect-acting agents whose activity is mediated through the release of catecholamines.  Guanethidine and reserpine have been reported to attenuate the pharmacologic effects (mydriasis, pressor response) induced by ephedrine and dopamine, both of which exhibit direct and indirect sympathomimetic activities (i.e., mixed-acting).  However, guanethidine intensified the mydriasis produced by phenylephrine, which is also thought to be mixed-acting.  Conversely, ephedrine has been shown to partially reverse the hypotensive effect of guanethidine.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Alternatives to postganglionic adrenergic blocking agents should be considered if patients are treated with sympathomimetic amines, since effects of the latter may be intensified or diminished depending on whether they are direct- or indirect-acting.  Most agents with indirect sympathomimetic activity are mixed-acting, thus it may be difficult to predict how they will be affected by postganglionic adrenergic blocking agents.  If the combination is used, blood pressure and heart rate should be monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279792/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Ziegler CH, Lovette JB \"Operative complications after therapy with reserpine and reserpine compounds.\" JAMA 176 (1961):  114-7[3] Sneddon JM, Turner P \"Ephedrine mydriasis in hypertension and the response to treatment.\" Clin Pharmacol Ther 10 (1969):  64-71[4] Burn JH, Rand MJ \"The action of sympathomimetic amines in animals treated with reserpine.\" J Physiol (Lond) 144 (1958):  314-36[5] Sherman GP, Walton CA \"Adrenergic transmission and drug interaction.\" J Am Pharm Assoc 15 (1975):  86-90[6] Gulati OD, Dave BT, Gokhale SD, Shah KM \"Antagonism of adrenergic neuron blockade in hypertensive subjects.\" Clin Pharmacol Ther 7 (1966):  510-4[7] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[8] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "updated_at": 1767369485}, {"id": 243257, "ingredient1": "Guanethidine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279793/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "updated_at": 1767369485}, {"id": 243258, "ingredient1": "Guanethidine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279794/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 243259, "ingredient1": "Guanethidine", "ingredient2": "Methoxamine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279795/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine", "updated_at": 1767369485}, {"id": 243260, "ingredient1": "Guanethidine", "ingredient2": "Naphazoline (nasal)", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279796/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243261, "ingredient1": "Guanethidine", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279797/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "alternatives_b": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "updated_at": 1767369485}, {"id": 243262, "ingredient1": "Guanethidine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.  Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.  Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279798/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[4] \"Product Information. Hylorel (guanadrel).\" Rhone Poulenc Rorer  (2001):[5] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[7] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[8] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[11] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[12] \"Product Information. Toprol-XL (metoprolol).\" Astra-Zeneca Pharmaceuticals  (2001):[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997):  225-6", "alternatives_a": "Latanoprost, Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243263, "ingredient1": "Guanethidine", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279799/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Brimonidine, Levobunolol, More", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 243264, "ingredient1": "Guanethidine", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279800/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More", "alternatives_b": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "updated_at": 1767369485}, {"id": 243265, "ingredient1": "Guanethidine", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279801/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Bremelanotide, Flibanserin, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243266, "ingredient1": "Guanethidine", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279802/", "reference_text": "[1] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992):  520-3[2] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975):  431-6[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991):  926-31[4] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991):  919-25[5] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 243267, "ingredient1": "Guanethidine", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279803/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 243268, "ingredient1": "Guanethidine", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "Phenothiazines may inhibit the antihypertensive effect of guanethidine, probably through inhibition of guanethidine neuronal uptake.", "source": "DDInter", "management_text": "This combination should generally be avoided.  An alternative antihypertensive regimen may be necessary for patients who must take phenothiazine antipsychotics.  If patients do receive a phenothiazine with an adrenergic neurone blocker, their blood pressure should be monitored closely.  The dosage of the antihypertensive may require adjustment.", "mechanism_text": "Distribution", "recommendation": "This combination should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279804/", "reference_text": "[1] Janowsky DS, El-Yousef MK, Davis JM, Fann WE \"Antagonism of guanethidine by chlorpromazine.\" Am J Psychiatry 130 (1973):  808-12[2] Fann WE, Janowsky DS, Davis JM, Oates JA \"Chlorpromazine reversal of the antihypertensive action of guanethidine.\" Lancet 2 (1971):  436-7[3] Gilder DA, Fain W, Simpson LL \"A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine.\" J Pharmacol Exp Ther 198 (1976):  255-63[4] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, More", "updated_at": 1767369485}, {"id": 243269, "ingredient1": "Guanethidine", "ingredient2": "Xylometazoline (nasal)", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279806/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243270, "ingredient1": "Guanfacine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279808/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, Meclizine, More", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 243271, "ingredient1": "Guanfacine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279813/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Deserpidine", "alternatives_b": "Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Estazolam, Zopiclone, Tasimelteon, Valerian", "updated_at": 1767369485}, {"id": 243272, "ingredient1": "Guanidine", "ingredient2": "Ambenonium", "severity": "Moderate", "effect": "A synergistic effect may be expected when acetylcholinesterase inhibitors are administered concurrently with other cholinesterase inhibitors or cholinergic agonists.", "source": "DDInter", "management_text": "Monitoring for excessive cholinergic effects and seizure activity is recommended.  Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, increased salivation, cold sweats, slow or irregular heartbeat, muscle weakness or cramps, dizziness, headache, seizures, or respiratory distress.", "mechanism_text": "Synergism", "recommendation": "Monitoring for excessive cholinergic effects and seizure activity is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279823/", "reference_text": "[1] \"Product Information. Cognex (tacrine).\" Parke-Davis  (2001):[2] \"Product Information. Aricept (donepezil).\" Pfizer U.S. Pharmaceuticals  (2001):[3] \"Product Information. Reminyl (galantamine).\" Janssen Pharmaceuticals  (2001):", "alternatives_a": "Pilocarpine, Cevimeline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243273, "ingredient1": "Guanidine", "ingredient2": "Pyridostigmine", "severity": "Moderate", "effect": "A synergistic effect may be expected when acetylcholinesterase inhibitors are administered concurrently with other cholinesterase inhibitors or cholinergic agonists.", "source": "DDInter", "management_text": "Monitoring for excessive cholinergic effects and seizure activity is recommended.  Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, increased salivation, cold sweats, slow or irregular heartbeat, muscle weakness or cramps, dizziness, headache, seizures, or respiratory distress.", "mechanism_text": "Synergism", "recommendation": "Monitoring for excessive cholinergic effects and seizure activity is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279824/", "reference_text": "[1] \"Product Information. Cognex (tacrine).\" Parke-Davis  (2001):[2] \"Product Information. Aricept (donepezil).\" Pfizer U.S. Pharmaceuticals  (2001):[3] \"Product Information. Reminyl (galantamine).\" Janssen Pharmaceuticals  (2001):", "alternatives_a": "Pilocarpine, Cevimeline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243274, "ingredient1": "Guselkumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279826/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243275, "ingredient1": "Guselkumab", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279840/", "reference_text": "[1] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[4] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[5] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[6] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[7] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[9] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "updated_at": 1767369485}, {"id": 243276, "ingredient1": "Guselkumab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/279876/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243277, "ingredient1": "Acrivastine", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280130/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243278, "ingredient1": "Chlorcyclizine", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280133/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Temazepam, Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Amobarbital, Meprobamate, Butalbital, Eszopiclone, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 243279, "ingredient1": "Halazepam", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280136/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243280, "ingredient1": "Triazolam", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280143/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243281, "ingredient1": "Triazolam", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280144/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam", "alternatives_b": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ethchlorvynol, Zolpidem, Zopiclone, Pentobarbital, Zaleplon", "updated_at": 1767369485}, {"id": 243282, "ingredient1": "Triazolam", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280145/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam", "alternatives_b": "Nitrazepam, Paraldehyde, Ethchlorvynol, Zopiclone, Pentobarbital, Zaleplon", "updated_at": 1767369485}, {"id": 243283, "ingredient1": "Halofantrine", "ingredient2": "Abarelix", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280151/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243284, "ingredient1": "Halofantrine", "ingredient2": "Astemizole", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280152/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243285, "ingredient1": "Halofantrine", "ingredient2": "Bepridil", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280153/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243286, "ingredient1": "Halofantrine", "ingredient2": "Cisapride", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280155/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Metoclopramide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243287, "ingredient1": "Halofantrine", "ingredient2": "Grepafloxacin", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280156/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243288, "ingredient1": "Isoetharine", "ingredient2": "Halofantrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280157/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243289, "ingredient1": "Halofantrine", "ingredient2": "Letermovir", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias.  The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine.", "source": "DDInter", "management_text": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280159/", "reference_text": "[1] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[2] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[3] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002):  514-23[4] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[5] Baune B, Flinois JP, Furlan V, et al. \"Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.\" J Pharm Pharmacol 51 (1999):  419-26", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 243290, "ingredient1": "Halofantrine", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280161/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 243291, "ingredient1": "Halofantrine", "ingredient2": "Lomefloxacin", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280162/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 243292, "ingredient1": "Halofantrine", "ingredient2": "Methotrimeprazine", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280164/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243293, "ingredient1": "Halofantrine", "ingredient2": "Palbociclib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias.  The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine.", "source": "DDInter", "management_text": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280167/", "reference_text": "[1] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[2] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[3] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002):  514-23[4] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[5] Baune B, Flinois JP, Furlan V, et al. \"Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.\" J Pharm Pharmacol 51 (1999):  419-26", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Quinine, Primaquine, Proguanil, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243294, "ingredient1": "Halofantrine", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280168/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 243295, "ingredient1": "Halofantrine", "ingredient2": "Probucol", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280171/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243296, "ingredient1": "Halofantrine", "ingredient2": "Promazine", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280172/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243297, "ingredient1": "Halofantrine", "ingredient2": "Relugolix", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280173/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 243298, "ingredient1": "Halofantrine", "ingredient2": "Ritodrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280174/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243299, "ingredient1": "Halofantrine", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280175/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 243300, "ingredient1": "Halofantrine", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "Sulfadoxine-pyrimethamine may increase the extent of halofantrine absorption.", "source": "DDInter", "management_text": "The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280177/", "reference_text": "[1] Hombhanje FW \"Effect of a single oral dose of Fansidar on the pharmacokinetics of halofantrine in healthy volunteers: a preliminary report.\" Br J Clin Pharmacol 49 (2000):  283-4", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Tafenoquine, Atovaquone, Hydroxychloroquine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Proguanil, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "updated_at": 1767369485}, {"id": 243301, "ingredient1": "Halofantrine", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias.  The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine.", "source": "DDInter", "management_text": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280179/", "reference_text": "[1] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[2] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[3] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002):  514-23[4] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[5] Baune B, Flinois JP, Furlan V, et al. \"Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.\" J Pharm Pharmacol 51 (1999):  419-26", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 243302, "ingredient1": "Halofantrine", "ingredient2": "Triflupromazine", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280180/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243303, "ingredient1": "Halofantrine", "ingredient2": "Alimemazine", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280181/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[2] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[4] Nosten F, ter Kuile FO, Luxemburger C, et al. \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993):  1054-6[5] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001):  169-70, 179[6] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243304, "ingredient1": "Halofantrine", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias.  The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine.", "source": "DDInter", "management_text": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280182/", "reference_text": "[1] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001):  343-73[2] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[3] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002):  514-23[4] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001):  231-7[5] Baune B, Flinois JP, Furlan V, et al. \"Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.\" J Pharm Pharmacol 51 (1999):  419-26", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 243305, "ingredient1": "Halothane", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280190/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243306, "ingredient1": "Pyrophosphoric acid", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280246/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243307, "ingredient1": "Romidepsin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280255/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243308, "ingredient1": "Romidepsin", "ingredient2": "Phenylbutyric acid", "severity": "Moderate", "effect": "Coadministration of histone deacetylase (HDAC) inhibitors and phenylbutyrate may lead to excess inhibition of HDAC and additive adverse effects.  According to the prescribing information for sodium phenylbutyrate combined with taurursodiol (ursodoxicoltaurine), phenylbutyrate is a pan-HDAC inhibitor", "source": "DDInter", "management_text": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "mechanism_text": "Synergism", "recommendation": "The prescribing information for sodium phenylbutyrate combined with taurursodiol recommends avoiding concomitant use of phenylbutyrate and other HDAC inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280305/", "reference_text": "[1] \"Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol).\" Amylyx Pharmaceuticals  (2022):[2] \"Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine).\" Innomar Strategies Inc.  (2022):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, Givosiran, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 243309, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280314/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243310, "ingredient1": "Istradefylline", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280321/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243311, "ingredient1": "Dienestrol (topical)", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280328/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243312, "ingredient1": "Estrone", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280329/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Diethylstilbestrol, Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243313, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280330/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243314, "ingredient1": "Ethinylestradiol", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280331/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Dienogest, Estetrol, Etynodiol, Diethylstilbestrol, Diethylstilbestrol, Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243315, "ingredient1": "Finasteride", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280332/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Diclofenac, Cromoglicic acid, Dupilumab, Tralokinumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243316, "ingredient1": "Hydrocodone", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280333/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Benzonatate, Clofedanol, Pentoxyverine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243317, "ingredient1": "Ibrutinib", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.  Dosage reduction in accordance with ibrutinib product labeling may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280335/", "reference_text": "[1] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):[2] \"Product Information. Qelbree (viloxazine).\" Supernus Pharmaceuticals Inc  (2021):", "alternatives_a": "Futibatinib, Regorafenib, Copanlisib, Alpelisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243318, "ingredient1": "Ivermectin", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280337/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Mebendazole, Piperazine, Levamisole, Pyrantel, Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243319, "ingredient1": "Osilodrostat", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280338/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243320, "ingredient1": "Osilodrostat", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280339/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Etomidate", "alternatives_b": "Ketoconazole", "updated_at": 1767369485}, {"id": 243321, "ingredient1": "Osilodrostat", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 or moderate dual or combined inhibitors of CYP450 3A4 and CYP450 2C9 may increase the plasma concentrations of macitentan.  Macitentan is primarily metabolized by CYP450 3A4 and to a minor extent by CYP450 2C8, CYP450 2C9 and CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.  The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole).  The manufacturer of macitentan also recommends avoiding concomitant use with moderate dual inhibitors of CYP450 3A4 and 2C9 (e.g., fluconazole, amiodarone) or in combination with both a moderate CYP450 3A4 inhibitor and a moderate CYP450 2C9 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280343/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc  (2013):", "alternatives_a": "Riociguat, Ambrisentan, Metyrosine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243322, "ingredient1": "Osilodrostat", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.  Dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280344/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group  (2007):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243323, "ingredient1": "Osilodrostat", "ingredient2": "Megestrol acetate", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280345/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Dienogest, Etynodiol, Dienogest, Etynodiol, Dienogest, Estetrol, Etynodiol, Diethylstilbestrol", "alternatives_b": "Ketoconazole", "updated_at": 1767369485}, {"id": 243324, "ingredient1": "Osilodrostat", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280347/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243325, "ingredient1": "Osilodrostat", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280349/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Clevidipine, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243326, "ingredient1": "Osilodrostat", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280350/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Dienogest, Etynodiol, Dienogest, Estetrol, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243327, "ingredient1": "Osilodrostat", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors.  A dosage reduction may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280351/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals  (2014):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243328, "ingredient1": "Polatuzumab vedotin", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin.  MMAE is a substrate for CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors.  Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280354/", "reference_text": "[1] \"Product Information. Polivy (polatuzumab vedotin).\" Genentech  (2019):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243329, "ingredient1": "Progesterone (topical)", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280356/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243330, "ingredient1": "Quinestrol", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280357/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243331, "ingredient1": "Rimegepant", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280359/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243332, "ingredient1": "Ruxolitinib", "ingredient2": "Osilodrostat", "severity": "Minor", "effect": "Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.  In healthy subjects, administration of a single 10 mg dose of ruxolitinib following pretreatment with the moderate CYP450 3A4 inhibitor erythromycin (500 mg twice daily for four days) resulted in an 8% increase in ruxolitinib peak plasma concentration (Cmax) and a 27% increase in systemic exposure (AUC) compared to administration of ruxolitinib alone.  The change in the pharmacodynamic marker, pSTAT3 inhibition, was consistent with the corresponding exposure information.  No dosage adjustment is recommended when ruxolitinib is coadministered with mild or moderate CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280360/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation  (2011):", "alternatives_a": "Futibatinib, Regorafenib, Copanlisib, Alpelisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243333, "ingredient1": "Sildenafil", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.  Dosage adjustments may be appropriate for sildenafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects.  Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280361/", "reference_text": "[1] \"Product Information. Viagra (sildenafil).\" Pfizer U.S. Pharmaceuticals  (2001):[2] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ \"In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions.\" Drug Metab Disposition 28 (2000):  392-7[3] Hyland R, Roe GH, Jones BC, Smith DA \"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.\" Br J Clin Pharmaacol 51 (2001):  239-48[4] \"Product Information. Revatio (sildenafil).\" Pfizer U.S. Pharmaceuticals Group  (2005):", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243334, "ingredient1": "Testosterone (topical)", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280364/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Ketoconazole", "alternatives_b": "Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone", "updated_at": 1767369485}, {"id": 243335, "ingredient1": "Ubrogepant", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with moderate or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.  If needed, a second ubrogepant dose should be avoided within 24 hours of the initial dose when used with moderate CYP450 3A4 inhibitors.  When used with weak CYP450 3A4 inhibitors, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose, if needed.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280365/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc  (2019):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243336, "ingredient1": "Venetoclax", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when venetoclax is used with inhibitors of CYP450 3A4.  Close clinical and laboratory monitoring for the development of tumor lysis syndrome and myelosuppression is recommended following the addition of a CYP450 3A4 inhibitor, and the venetoclax dosage adjusted if necessary.  The dosage may be readjusted 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when venetoclax is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280366/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC  (2016):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243337, "ingredient1": "Vinblastine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280368/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Topotecan, Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243338, "ingredient1": "Vincristine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280369/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Topotecan, Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243339, "ingredient1": "Vincristine (liposome)", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280370/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Topotecan, Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243340, "ingredient1": "Vinorelbine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280371/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Topotecan, Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243341, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Ixabepilone", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280408/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243342, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280466/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243343, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Ixazomib", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280467/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243344, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Ixazomib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280523/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243345, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Ixekizumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280525/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243346, "ingredient1": "Melphalan flufenamide", "ingredient2": "Ixekizumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280539/", "reference_text": "[1] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[4] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[5] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[6] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[7] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[9] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "updated_at": 1767369485}, {"id": 243347, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Ixekizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280575/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243348, "ingredient1": "Ruxolitinib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280577/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243349, "ingredient1": "Heparin (flush)", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280583/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243350, "ingredient1": "Ruxolitinib", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280597/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Uracil mustard", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 243351, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280639/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243352, "ingredient1": "Sitagliptin", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with selumetinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3).  The proposed mechanism, based on in vivo data, is decreased clearance due to selumetinib-mediated inhibition of OAT3 transporter.", "source": "DDInter", "management_text": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate should be considered whenever selumetinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280645/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 243353, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Mitomycin", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280871/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243354, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Mitomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280877/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Ixabepilone, Valrubicin", "updated_at": 1767369485}, {"id": 243355, "ingredient1": "Mitomycin", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280886/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Uracil mustard", "alternatives_b": "Ixabepilone, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 243356, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Mitomycin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280922/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243357, "ingredient1": "Dezocine", "ingredient2": "Tolevamer", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280945/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 243358, "ingredient1": "Hydrocodone", "ingredient2": "Tolevamer", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280948/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 243359, "ingredient1": "Tolevamer", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280950/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243360, "ingredient1": "Tolevamer", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280959/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 243361, "ingredient1": "Tolevamer", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280960/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 243362, "ingredient1": "Tolevamer", "ingredient2": "Opium", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280961/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 243363, "ingredient1": "Tolevamer", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280962/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 243364, "ingredient1": "Tolevamer", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280963/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 243365, "ingredient1": "Botulinum toxin type A", "ingredient2": "Kanamycin", "severity": "Major", "effect": "The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280968/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243366, "ingredient1": "Botulinum toxin type B", "ingredient2": "Kanamycin", "severity": "Major", "effect": "The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.  These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning.  Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection.  Swallowing and breathing difficulties may be life-threatening or fatal.  Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280970/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243367, "ingredient1": "Telavancin", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280973/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Vancomycin, Trifluridine, Sulfamethizole, Benzylpenicillin, Ampicillin, Chloramphenicol, More", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 243368, "ingredient1": "Pyrophosphoric acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/280997/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243369, "ingredient1": "Acrivastine", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281006/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243370, "ingredient1": "Melatonin", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281009/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243371, "ingredient1": "Procyclidine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281014/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243372, "ingredient1": "Botulinum toxin type A", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281015/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243373, "ingredient1": "Procyclidine", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281016/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Entacapone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243374, "ingredient1": "Botulinum toxin type B", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281017/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243375, "ingredient1": "Axicabtagene ciloleucel", "ingredient2": "Palifermin", "severity": "Moderate", "effect": "In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.", "source": "DDInter", "management_text": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "mechanism_text": "Others", "recommendation": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281018/", "reference_text": "[1] \"Product Information. Kepivance (palifermin).\" Shire US Inc  (2004):", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 243376, "ingredient1": "Palifermin", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.", "source": "DDInter", "management_text": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "mechanism_text": "Others", "recommendation": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281019/", "reference_text": "[1] \"Product Information. Kepivance (palifermin).\" Shire US Inc  (2004):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243377, "ingredient1": "Ephedrine (nasal)", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281024/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Homatropine, Tropicamide, Methscopolamine, Ketorolac, Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, More", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "updated_at": 1767369485}, {"id": 243378, "ingredient1": "Ergometrine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281025/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Propofol, More", "updated_at": 1767369485}, {"id": 243379, "ingredient1": "Isoetharine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281026/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243380, "ingredient1": "Ketamine", "ingredient2": "Lacosamide", "severity": "Major", "effect": "Coadministration of ketamine with other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.", "source": "DDInter", "management_text": "During concomitant use of ketamine with other CNS depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.  Dosage adjustments should be considered according to the patient's clinical situation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of ketamine with other CNS depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281027/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Propofol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243381, "ingredient1": "Levmetamfetamine (nasal)", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281029/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243382, "ingredient1": "Mazindol", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281032/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Dexfenfluramine, Naltrexone, Bupropion, Orlistat, Lorcaserin", "updated_at": 1767369485}, {"id": 243383, "ingredient1": "Mephentermine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281033/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "Arbutamine, Amrinone, Milrinone, Angiotensin II", "updated_at": 1767369485}, {"id": 243384, "ingredient1": "Metaraminol", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281034/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "Arbutamine, Amrinone, Milrinone, Angiotensin II", "updated_at": 1767369485}, {"id": 243385, "ingredient1": "Methoxamine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281035/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "Arbutamine, Amrinone, Milrinone, Angiotensin II", "updated_at": 1767369485}, {"id": 243386, "ingredient1": "Modafinil", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281037/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Pemoline, Citicoline, Caffeine", "updated_at": 1767369485}, {"id": 243387, "ingredient1": "Naphazoline (nasal)", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281038/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243388, "ingredient1": "Phenylpropanolamine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281040/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243389, "ingredient1": "Pirbuterol", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281041/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Etomidate", "alternatives_b": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 243390, "ingredient1": "Ritodrine", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281043/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, More", "alternatives_b": "Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243391, "ingredient1": "Xylometazoline (nasal)", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281045/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243392, "ingredient1": "Obeticholic acid", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of the bile salt efflux pump (BSEP) may increase accumulation of conjugated bile salts in the liver, including the glycine and taurine conjugates of obeticholic acid.  Following daily administration of obeticholic acid, there was accumulation of the glycine and taurine conjugates, which have in vitro pharmacological activities similar to the parent drug.  The metabolite-to-parent ratios of the glycine and taurine conjugates of obeticholic acid were 13.8 and 12.3 respectively, with chronic administration.  In vitro data indicate that the taurine conjugate of obeticholic acid (tauro-obeticholic acid) is a substrate of BSEP.  Consequently, concomitant use of medications that inhibit the BSEP, a canalicular membrane bile acid transporter, may result in further accumulation of tauro-obeticholic acid and other conjugated bile salts in the liver.  Clinical symptoms and toxicities may occur.  Additionally, obeticholic acid and its conjugates are selective and potent agonists for the farnesoid X receptor (FXR), the activation of which leads to induction of BSEP.  Thus, inhibitors of BSEP may theoretically diminish the pharmacologic effects of obeticholic acid.", "source": "DDInter", "management_text": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.  If coadministration is required, serum transaminases and bilirubin should be closely monitored.", "mechanism_text": "Others", "recommendation": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281080/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Ocaliva (obeticholic acid).\" Intercept Pharmaceuticals, Inc.  (2016):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Maralixibat, Ursodeoxycholic acid, Cholic Acid, Odevixibat, Chenodeoxycholic acid", "updated_at": 1767369485}, {"id": 243393, "ingredient1": "Ranitidine (bismuth citrate)", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "H2 antagonists may reduce the bioavailability of ketoconazole by 75% to 80% resulting in decreased plasma ketoconazole concentrations and possible therapeutic failure.  The mechanism is related to an increase in gastric pH and a decrease in absorption of the antifungal agent.", "source": "DDInter", "management_text": "Some manufacturers of ketoconazole suggest administering ketoconazole with an acidic beverage (e.g., non-diet cola, orange juice) if used concomitantly with H2 antagonists (US, GB, CA, BR).  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever H2 antagonists are added to or withdrawn from therapy with ketoconazole.", "mechanism_text": "Absorption", "recommendation": "Some manufacturers of ketoconazole suggest administering ketoconazole with an acidic beverage (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281083/", "reference_text": "[1] Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ \"Effects of ranitidine and sucralfate on ketoconazole bioavailability.\" Antimicrob Agents Chemother 35 (1991):  1765-71[2] Blum RA, D'Andrea DT, Florentino BM, et al. \"Increased gastric pH and the bioavailability of fluconazole and ketoconazole.\" Ann Intern Med 114 (1991):  755-7[3] Van der Meer JW, Keuning JJ \"The influence of gastric acidity on the bio-availability of ketoconazole.\" J Antimicrob Chemother 6 (1980):  552-4[4] Carlson JA, Mann HJ, Canafax DM \"Effect of pH on disintegration and dissolution of ketoconazole tablets.\" Am J Hosp Pharm 40 (1983):  1334-6[5] Chin TWF, Loeb M, Fong IW \"Effects of an acidic beverage (coca-cola) on absorption of ketoconazole.\" Antimicrob Agents Chemother 39 (1995):  1671-5[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[8] Cerner Multum, Inc \"ANVISA Bulio Eletrico.\" O 0 (2015):[9] Adachi M, Hinatsu Y, et al. \"Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers.\" Eur J Pharm Sci 76 (2015):  225-30[10] \"Product Information. Ketoconazole (ketoconazole).\" Mylan Pharmaceuticals Inc  (2019):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243394, "ingredient1": "Relugolix", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally.  Relugolix is a substrate for intestinal P-gp.  In vitro, it is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should be avoided when possible.  In addition, the benefits of androgen deprivation therapy such as relugolix should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval, many of which are also P-gp inhibitors (e.g., amiodarone, azithromycin, bepridil, cabozantinib, clarithromycin, crizotinib, dronedarone, elagolix, erythromycin, ketoconazole, lapatinib, mifepristone, nilotinib, osimertinib, propafenone, quinidine, quinine, ranolazine, tacrolimus, telithromycin, valbenazine, vemurafenib).  If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.  Alternatively, when relugolix is used as monotherapy for the treatment of prostate cancer, the prescribing information states that treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.  Following interruption of relugolix for more than 7 days, the manufacturer recommends restarting therapy with a loading dose of 360 mg on the first day, then continuing with a dose of 120 mg once daily.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should be avoided when possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281085/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "updated_at": 1767369485}, {"id": 243395, "ingredient1": "Ritodrine", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281086/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Bremelanotide, Cabergoline", "updated_at": 1767369485}, {"id": 243396, "ingredient1": "Somatrem", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281088/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 243397, "ingredient1": "Telaprevir", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Coadministration of an azole antifungal agent and hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) may result in increased plasma concentrations of both drugs.  The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors.  Dosage adjustments may be required.  According to the product information for boceprevir and telaprevir, high dosages of ketoconazole and itraconazole (>200 mg/day) should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281091/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, More", "updated_at": 1767369485}, {"id": 243398, "ingredient1": "Triflupromazine", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281092/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 243399, "ingredient1": "Alimemazine", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281093/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 243400, "ingredient1": "Heparin (flush)", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281095/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243401, "ingredient1": "Selumetinib", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Coadministration with selumetinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3).  The proposed mechanism, based on in vivo data, is decreased clearance due to selumetinib-mediated inhibition of OAT3 transporter.", "source": "DDInter", "management_text": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate should be considered whenever selumetinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281106/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Rabeprazole, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243402, "ingredient1": "Sarilumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281111/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243403, "ingredient1": "Sarilumab", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281125/", "reference_text": "[1] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[4] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[5] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[6] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[7] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[9] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 243404, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Sarilumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281161/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243405, "ingredient1": "Oritavancin", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.  Pharmacologic response to lapatinib should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the lapatinib dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281236/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals  (2023):[2] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals Canada Inc  (2022):[3] \"Product Information. Tyverb (lapatinib).\" Novartis Pharmaceuticals UK Ltd  (2022):[4] \"Product Information. Tykerb (laPAtinib).\" Novartis Pharmaceuticals Australia Pty Ltd  (2022):[5] Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelan A \"Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.\" Br J Clin Pharmacol 67 (2009):  421-6", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, More", "alternatives_b": "Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Fosfomycin, Nitrofurantoin, Dalbavancin", "updated_at": 1767369485}, {"id": 243406, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Ribociclib", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281241/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243407, "ingredient1": "Ibrutinib", "ingredient2": "Ribociclib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The dosage of ibrutinib should be adjusted according to the indication in the product labeling whenever it is used in combination with a moderate CYP450 3A4 inhibitor such as amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir, diltiazem, dronedarone, erythromycin, fluconazole, fosamprenavir, fosaprepitant, imatinib, or verapamil.  All patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.", "mechanism_text": "Metabolism", "recommendation": "The dosage of ibrutinib should be adjusted according to the indication in the product labeling whenever it is used in combination with a moderate CYP450 3A4 inhibitor such as amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir, diltiazem, dronedarone, erythromycin, fluconazole, fosamprenavir, fosaprepitant, imatinib, or verapamil.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281250/", "reference_text": "[1] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):", "alternatives_a": "Futibatinib, Regorafenib, Trametinib, Erdafitinib, Nintedanib, Ribociclib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Dabrafenib, Dacomitinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Brigatinib, Axitinib, Lenvatinib, More", "updated_at": 1767369485}, {"id": 243408, "ingredient1": "Ribociclib", "ingredient2": "Obeticholic acid", "severity": "Moderate", "effect": "Coadministration with inhibitors of the bile salt efflux pump (BSEP) may increase accumulation of conjugated bile salts in the liver, including the glycine and taurine conjugates of obeticholic acid.  Following daily administration of obeticholic acid, there was accumulation of the glycine and taurine conjugates, which have in vitro pharmacological activities similar to the parent drug.  The metabolite-to-parent ratios of the glycine and taurine conjugates of obeticholic acid were 13.8 and 12.3 respectively, with chronic administration.  In vitro data indicate that the taurine conjugate of obeticholic acid (tauro-obeticholic acid) is a substrate of BSEP.  Consequently, concomitant use of medications that inhibit the BSEP, a canalicular membrane bile acid transporter, may result in further accumulation of tauro-obeticholic acid and other conjugated bile salts in the liver.  Clinical symptoms and toxicities may occur.  Additionally, obeticholic acid and its conjugates are selective and potent agonists for the farnesoid X receptor (FXR), the activation of which leads to induction of BSEP.  Thus, inhibitors of BSEP may theoretically diminish the pharmacologic effects of obeticholic acid.", "source": "DDInter", "management_text": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.  If coadministration is required, serum transaminases and bilirubin should be closely monitored.", "mechanism_text": "Others", "recommendation": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281266/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Ocaliva (obeticholic acid).\" Intercept Pharmaceuticals, Inc.  (2016):", "alternatives_a": "Odevixibat, Maralixibat, Chenodeoxycholic acid, Ursodeoxycholic acid", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 243409, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281305/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243410, "ingredient1": "Rimegepant", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of rimegepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of rimegepant with potent CYP450 3A4 inhibitors should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of rimegepant with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281318/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals  (2020):", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243411, "ingredient1": "Cefaclor", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with selumetinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3).  The proposed mechanism, based on in vivo data, is decreased clearance due to selumetinib-mediated inhibition of OAT3 transporter.", "source": "DDInter", "management_text": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate should be considered whenever selumetinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281323/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 243412, "ingredient1": "Ethinylestradiol", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with selumetinib may reduce the effectiveness of hormonal contraceptives.", "source": "DDInter", "management_text": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.  In addition, men with female partners of reproductive potential should also use effective contraception during treatment with selumetinib and for 1 week after the last dose.", "mechanism_text": "Antagonism", "recommendation": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281324/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Ulipristal, Estradiol, Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Triptorelin, Goserelin, Conjugated estrogens, Estrone, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 243413, "ingredient1": "Selumetinib", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281325/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Futibatinib, Copanlisib, Dacomitinib, Erdafitinib, Abemaciclib, Trametinib, Afatinib, Duvelisib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243414, "ingredient1": "Selumetinib", "ingredient2": "Meropenem", "severity": "Moderate", "effect": "Coadministration with selumetinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3).  The proposed mechanism, based on in vivo data, is decreased clearance due to selumetinib-mediated inhibition of OAT3 transporter.", "source": "DDInter", "management_text": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate should be considered whenever selumetinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281329/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 243415, "ingredient1": "Selumetinib", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "Coadministration with selumetinib may reduce the effectiveness of hormonal contraceptives.", "source": "DDInter", "management_text": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.  In addition, men with female partners of reproductive potential should also use effective contraception during treatment with selumetinib and for 1 week after the last dose.", "mechanism_text": "Antagonism", "recommendation": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281332/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Progesterone, Estradiol, Megestrol acetate, Ulipristal, Estradiol", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243416, "ingredient1": "Benzylpenicillin (sodium)", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with selumetinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 3 (OAT3).  The proposed mechanism, based on in vivo data, is decreased clearance due to selumetinib-mediated inhibition of OAT3 transporter.", "source": "DDInter", "management_text": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring of the OAT3 substrate should be considered whenever selumetinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if selumetinib is used concomitantly with drugs that are substrates of OAT3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281334/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 243417, "ingredient1": "Selumetinib", "ingredient2": "Risdiplam", "severity": "Moderate", "effect": "Theoretical concerns exist that oculotoxic effects of risdiplam, observed in monkeys, may be additive with those of other drugs that are associated with retinotoxicity.", "source": "DDInter", "management_text": "Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs.  These drugs may include infigratinib, selumetinib, cobimetinib, vigabatrin, chloroquine, hydroxychloroquine, thioridazine and deferoxamine.", "mechanism_text": "Synergism", "recommendation": "Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281335/", "reference_text": "[1] \"Product Information. Aralen (chloroquine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Desferal (deferoxamine).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Plaquenil (hydroxychloroquine).\" Apothecon Inc  (2022):[4] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation  (2001):[5] \"Product Information. Chloroquine Phosphate (chloroquine).\" West Ward Pharmaceutical Corporation  (2005):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Sabril (vigabatrin).\" Lundbeck Inc  (2009):[9] \"Product Information. Deferoxamine Mesylate (deferoxamine).\" Hospira Inc  (2015):[10] Cerner Multum, Inc \"ANVISA Bulio Eletrico.\" O 0 (2015):[11] \"Product Information. Cotellic (cobimetinib).\" Genentech  (2015):[12] \"Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine).\" Prasco Laboratories  (2017):[13] \"Product Information. Thioridazine Hydrochloride (thioridazine).\" Mylan Institutional (formerly UDL Laboratories)  (2019):[14] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):[15] \"Product Information. Truseltiq (infigratinib).\" QED Therapeutics Inc  (2021):", "alternatives_a": "Collagenase clostridium histolyticum, Quinine, Hyaluronic acid, Onasemnogene abeparvovec", "alternatives_b": "Entrectinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Lapatinib, Duvelisib, Brigatinib, More", "updated_at": 1767369485}, {"id": 243418, "ingredient1": "Pyrophosphoric acid", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281357/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243419, "ingredient1": "Lamotrigine", "ingredient2": "Lacosamide", "severity": "Moderate", "effect": "In vitro studies have shown that lamotrigine exhibits class IB antiarrhythmic activity at therapeutically relevant concentrations.  Lamotrigine has shown in vitro effects on the human cardiac sodium channels similar to that of other Class 1B antiarrhythmic drugs.  In healthy individuals, a thorough QT study did not show slowed ventricular conduction (widen QRS) with lamotrigine; however, the risk of slow ventricular conduction and proarrhythmias, including sudden death may be increased in patients with structural heart disease or myocardial ischemia.  Based on this data, there is a concern that concomitant use of other sodium channel blockers may increase the risk of proarrhythmias.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if concomitant use of other sodium channel blockers is needed.  Due to the potential for increased risk of proarrhythmias, the manufacturer recommends lamotrigine be avoided in patients who have cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies).  A joint task force of the International League Against Epilepsy and the American Epilepsy Society issued an advisory on Feb 25, 2021, for healthcare professionals in response to the FDA safety warning on the cardiac effects of lamotrigine.  For patients under 60 years with no cardiac risk factors, they advise that clinicians should prescribe lamotrigine as usual.  For patients with cardiac risk (over 60 years and under 60 years with known cardiac disease or significant risk factors), they advise clinicians to consider obtaining an ECG prior to initiating lamotrigine and repeating ECG as the serum lamotrigine level approaches the upper limit of the therapeutic range and/or with concomitant use of other sodium channel blockers or substances known to impair atrioventricular and/or intra-ventricular cardiac conduction.  They also advise clinicians to consider obtaining an ECG and/or cardiology consult in patients with sudden onset syncope or pre-syncope with loss of muscular tone without a clear vasovagal or orthostatic cause.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate an irregular heart rhythm such as dizziness, lightheadedness, fainting, palpitation, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if concomitant use of other sodium channel blockers is needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281365/", "reference_text": "[1] \"Product Information. Lamictal (lamotrigine).\" Glaxo Wellcome  (2001):[2] \"Product Information. LaMICtal XR (lamotrigine).\" GlaxoSmithKline  (2018):[3] American Epilepsy Society \"FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory from the Ad Hoc ILAE/AES Task Force\n  https://www.ilae.org/files/ilaeGuideline/ILAE_AES_Lamotrigine_advisory_final_EO_CLEAN_ASG2-2021-0225-2.pdf\"   (2021):", "alternatives_a": "Ethotoin, Methsuximide, Paramethadione, Phensuximide, Lamotrigine, Methylphenobarbital, Phenacemide, Trimethadione, Mephenytoin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "updated_at": 1767369485}, {"id": 243420, "ingredient1": "Levocetirizine", "ingredient2": "Lacosamide", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281367/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Fenfluramine", "alternatives_b": "Ketotifen, Mepyramine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, Clemastine, Fexofenadine, More", "updated_at": 1767369485}, {"id": 243421, "ingredient1": "Lorlatinib", "ingredient2": "Lacosamide", "severity": "Moderate", "effect": "Lacosamide has been shown to prolong the PR interval of the electrocardiogram in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, digoxin, atazanavir, mefloquine) may result in elevated risk of conduction disturbances and atrioventricular block.", "source": "DDInter", "management_text": "Caution is advised if lacosamide is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block, second-degree or higher AV block and sick sinus syndrome without pacemaker) or severe cardiac disease such as myocardial ischemia or heart failure.  An ECG should be obtained in these patients before initiating lacosamide and after titration to steady-state.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lacosamide is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281369/", "reference_text": "[1] \"Product Information. Vimpat (lacosamide).\" UCB Pharma Inc  (2008):", "alternatives_a": "Brivaracetam, Ezogabine, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Vigabatrin, Gabapentin, More", "alternatives_b": "Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243422, "ingredient1": "Olopatadine (nasal)", "ingredient2": "Lacosamide", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281371/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc  (2008):[2] \"Product Information. Ryaltris (mometasone-olopatadine nasal).\" Hikma Americas, Inc  (2022):", "alternatives_a": "Fenfluramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243423, "ingredient1": "Acrivastine", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281379/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243424, "ingredient1": "Chlorcyclizine", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281381/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "updated_at": 1767369485}, {"id": 243425, "ingredient1": "Cyclizine", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281383/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Thiethylperazine, Dexchlorpheniramine, Phenindamine, Astemizole, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide", "updated_at": 1767369485}, {"id": 243426, "ingredient1": "Levodopa", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281386/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine", "updated_at": 1767369485}, {"id": 243427, "ingredient1": "Melatonin", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281387/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Thiopental, Ethchlorvynol, Methylphenobarbital, Dichloralphenazone", "updated_at": 1767369485}, {"id": 243428, "ingredient1": "Lesinurad", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.  Pharmacologic response to lapatinib should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the lapatinib dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281403/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals  (2023):[2] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals Canada Inc  (2022):[3] \"Product Information. Tyverb (lapatinib).\" Novartis Pharmaceuticals UK Ltd  (2022):[4] \"Product Information. Tykerb (laPAtinib).\" Novartis Pharmaceuticals Australia Pty Ltd  (2022):[5] Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelan A \"Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.\" Br J Clin Pharmacol 67 (2009):  421-6", "alternatives_a": "Dacomitinib, Pexidartinib, Fedratinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Regorafenib, Ruxolitinib, More", "alternatives_b": "Pegloticase, Febuxostat, Rasburicase, Probenecid, Allopurinol", "updated_at": 1767369485}, {"id": 243429, "ingredient1": "Metreleptin", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.  Pharmacologic response to lapatinib should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the lapatinib dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of lapatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281407/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals  (2023):[2] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals Canada Inc  (2022):[3] \"Product Information. Tyverb (lapatinib).\" Novartis Pharmaceuticals UK Ltd  (2022):[4] \"Product Information. Tykerb (laPAtinib).\" Novartis Pharmaceuticals Australia Pty Ltd  (2022):[5] Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelan A \"Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.\" Br J Clin Pharmacol 67 (2009):  421-6", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 243430, "ingredient1": "Mitotane", "ingredient2": "Lapatinib", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lapatinib with potent CYP450 3A4 inducers should generally be avoided.  If coadministration is required, a gradual dosage increase of lapatinib should be considered.  The prescribing information recommends titrating the lapatinib dosage gradually from 1250 mg/day up to 4500 mg/day or from 1500 mg/day up to 5500 mg/day depending on the indication and patient tolerability.  Based on pharmacokinetic studies, this dosage recommendation is predicted to adjust the lapatinib systemic exposure (AUC) to the range observed without inducers.  However, clinical data are lacking.  The dosage of lapatinib should be reduced over approximately 2 weeks to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lapatinib with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281410/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals  (2023):[2] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals Canada Inc  (2022):[3] \"Product Information. Tyverb (lapatinib).\" Novartis Pharmaceuticals UK Ltd  (2022):[4] \"Product Information. Tykerb (laPAtinib).\" Novartis Pharmaceuticals Australia Pty Ltd  (2022):[5] Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelan A \"Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.\" Br J Clin Pharmacol 67 (2009):  421-6", "alternatives_a": "Futibatinib, Lenvatinib, Trametinib, Ribociclib, Afatinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Pertuzumab, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Niraparib, Selinexor, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 243431, "ingredient1": "Perampanel", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Mefloquine may increase the risk of seizures and decrease the effectiveness of anticonvulsant drugs in patients with epilepsy.", "source": "DDInter", "management_text": "Because it can increase the risk of seizures in patients with epilepsy, mefloquine should only be used for curative treatment of malaria in such patients and only if there are compelling medical reasons for its use.  Patient clinical status and anticonvulsant blood levels should be closely monitored if mefloquine is prescribed.  Dosage adjustments may be required.  Patients should be advised to notify their physician if they experience a loss of seizure control.  Mefloquine should not be prescribed for malaria prophylaxis in patients with a history of convulsions.", "mechanism_text": "Antagonism", "recommendation": "Because it can increase the risk of seizures in patients with epilepsy, mefloquine should only be used for curative treatment of malaria in such patients and only if there are compelling medical reasons for its use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281428/", "reference_text": "[1] Singh K, Shanks GD, Wilde H \"Seizures after mefloquine.\" Ann Intern Med 114 (1991):  994[2] Weinke T, Trautmann M, Held T, et al. \"Neuropsychiatric side effects after the use of mefloquine.\" Am J Trop Med Hyg 45 (1991):  86-91[3] Bem JL, Kerr L, Stuerchler D \"Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions.\" J Trop Med Hyg 95 (1992):  167-79[4] \"Product Information. Lariam (mefloquine).\" Roche Laboratories  (2002):[5] Ries S, Pohlmanneden B \"Seizures during malaria prophylaxis with mefloquine.\" Dtsch Med Wochenschr 118 (1993):  1911-2[6] Ruff TA, Sherwen SJ, Donnan GA \"Seizure associated with mefloquine for malaria prophylaxis.\" Med J Aust 161 (1994):  453[7] Pous E, Gascon J, Obach J, Corachan M \"Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject.\" Trans R Soc Trop Med Hyg 89 (1995):  434[8] Potasman I, Juven Y, Weller B, Schwartz E \"Does mefloquine prophylaxis affect electroencephalographic patterns?\" Am J Med 112 (2002):  147-9[9] Jimenez-Huete A, Gil-Nagel A, Franch O \"Multifocal myoclonus associated with mefloquine chemoprophylaxis.\" Clin Neuropharmacol 25 (2002):  243", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "Fenfluramine", "updated_at": 1767369485}, {"id": 243432, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Olaratumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281448/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243433, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Olaratumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281496/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243434, "ingredient1": "Melatonin", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281512/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243435, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281533/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243436, "ingredient1": "Methysergide", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281541/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243437, "ingredient1": "Pemigatinib", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281544/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Futibatinib, Copanlisib, Dacomitinib, Erdafitinib, Abemaciclib, Trametinib, Afatinib, Duvelisib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243438, "ingredient1": "Progesterone (topical)", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281546/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243439, "ingredient1": "Rimegepant", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281548/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Clonidine, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243440, "ingredient1": "Ripretinib", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281549/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Futibatinib, Copanlisib, Dacomitinib, Erdafitinib, Abemaciclib, Trametinib, Afatinib, Duvelisib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 243441, "ingredient1": "Testosterone (topical)", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281551/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone", "updated_at": 1767369485}, {"id": 243442, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Lenalidomide", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281668/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243443, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Lenalidomide", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281721/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243444, "ingredient1": "Ergometrine", "ingredient2": "Letermovir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme.  The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with potent CYP450 3A4 inhibitors is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281728/", "reference_text": "[1] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988):  249[2] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979):  476-7[3] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984):  243-6[4] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969):  42[5] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[6] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993):  291-6[7] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996):  456-8[8] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals  (2001):[9] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999):  987[10] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999):  771[11] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997):  1207[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000):  41-57[13] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000):  635-6[14] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001):  105-18[15] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001):  743-4[16] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001):  788-9[17] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999):  329[18] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999):  771[19] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001):  594[20] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999):  546-7[21] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001):  411-3[22] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002):  694-5[23] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals  (2004):[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals  (2010):[26] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila)  (2014):  1-4", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 243445, "ingredient1": "Estrone", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.  In vitro and in vivo studies have shown that both estrogens and progestins are partially metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Monitor estrogen/progestin therapy for altered pharmacologic response and adjust dosage(s) accordingly whenever letermovir is added to or withdrawn from therapy.  When choosing an oral contraceptive, consider choosing an ethinyl estradiol-levonorgestrel product as this combination has been studied with letermovir and no clinically significant interaction has been found.", "mechanism_text": "Metabolism", "recommendation": "Monitor estrogen/progestin therapy for altered pharmacologic response and adjust dosage(s) accordingly whenever letermovir is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281729/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Prevymis (letermovir).\" Merck & Co., Inc  (2017):", "alternatives_a": "Ethinylestradiol, Diethylstilbestrol, Bazedoxifene", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 243446, "ingredient1": "Sargramostim", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established.  Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Others", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281737/", "reference_text": "[1] \"Product Information. Neupogen (filgrastim).\" Amgen  (2002):[2] \"Product Information. Leukine (sargramostim).\" Immunex Corporation  (2001):[3] \"Product Information. Stemgen (ancestim).\" Amgen  (2001):[4] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA  (2013):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243447, "ingredient1": "Anisindione", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "Significantly increased INR and prothrombin times have been reported in patients receiving concomitant warfarin, fluorouracil, and levamisole.", "source": "DDInter", "management_text": "If concomitant therapy is necessary, close monitoring of the INR or PT is recommended.  Anticoagulant dose adjustments may be necessary.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, nosebleeds, bleeding of gums from brushing, red or brown urine, red or black stools, or unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "If concomitant therapy is necessary, close monitoring of the INR or PT is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281745/", "reference_text": "[1] Scarfe MA, Israel MK \"Possible drug interaction between warfarin and combination of levamisole and fluorouracil.\" Ann Pharmacother 28 (1994):  464-7[2] Wehbe TW, Warth JA \"A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole.\" Clin Pharmacol Ther 59 (1996):  360-2", "alternatives_a": "Thiabendazole, Pyrantel, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243448, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Levamisole", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281746/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243449, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281747/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243450, "ingredient1": "Candida albicans", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity.  Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Antagonism", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281749/", "reference_text": "[1] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc  (2001):[2] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc  (2001):[3] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc  (2001):[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals  (2001):[6] \"Product Information. Tuberculin Tine Test (tuberculin purified protein derivative).\" Connaught Laboratories Inc", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243451, "ingredient1": "Vibrio cholerae CVD 103-HgR strain live antigen", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281750/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243452, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity.  Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Antagonism", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281751/", "reference_text": "[1] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc  (2001):[2] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc  (2001):[3] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc  (2001):[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals  (2001):[6] \"Product Information. Tuberculin Tine Test (tuberculin purified protein derivative).\" Connaught Laboratories Inc", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243453, "ingredient1": "Dicoumarol", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "Significantly increased INR and prothrombin times have been reported in patients receiving concomitant warfarin, fluorouracil, and levamisole.", "source": "DDInter", "management_text": "If concomitant therapy is necessary, close monitoring of the INR or PT is recommended.  Anticoagulant dose adjustments may be necessary.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, nosebleeds, bleeding of gums from brushing, red or brown urine, red or black stools, or unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "If concomitant therapy is necessary, close monitoring of the INR or PT is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281752/", "reference_text": "[1] Scarfe MA, Israel MK \"Possible drug interaction between warfarin and combination of levamisole and fluorouracil.\" Ann Pharmacother 28 (1994):  464-7[2] Wehbe TW, Warth JA \"A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole.\" Clin Pharmacol Ther 59 (1996):  360-2", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Thiabendazole, Pyrantel, Piperazine, Mebendazole, Albendazole", "updated_at": 1767369485}, {"id": 243454, "ingredient1": "Efalizumab", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.  Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression.  The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281753/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech  (2003):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "updated_at": 1767369485}, {"id": 243455, "ingredient1": "Mumps virus strain B level jeryl lynn live antigen", "ingredient2": "Levamisole", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281767/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243456, "ingredient1": "Rubella virus vaccine", "ingredient2": "Levamisole", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281778/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243457, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Levamisole", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281802/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243458, "ingredient1": "Axicabtagene ciloleucel", "ingredient2": "Levofloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281804/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin, Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, More", "updated_at": 1767369485}, {"id": 243459, "ingredient1": "Melphalan flufenamide", "ingredient2": "Levofloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281820/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Bendamustine", "updated_at": 1767369485}, {"id": 243460, "ingredient1": "Acetohexamide", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.  Nevertheless, caution is advised if they are prescribed to patients treated with insulin or oral antidiabetic agents that can cause hypoglycemia (e.g., insulin secretagogues), as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents.  Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked.  However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.  The same precautions are applicable in diabetic patients treated with ophthalmic beta-blockers.", "mechanism_text": "Synergism", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281832/", "reference_text": "[1] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981):  357-8[2] Micossi P, Pollavini G, Raggi U, et al. \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984):  59-63[3] Popp DA, Tse TF, Shah SD, et al. \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984):  243-7[4] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984):  2427-8[5] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982):  7-12[6] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980):  873-9[7] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980):  866-72[8] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976):  447-9[9] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978):  1467[10] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982):  507-12[11] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985):  85-9[12] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983):  69-77[13] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977):  1255-7[14] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989):  1152-7[15] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990):  699-702[16] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975):  28-32", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243461, "ingredient1": "Anisindione", "ingredient2": "Penbutolol", "severity": "Minor", "effect": "Some oral beta-blockers may increase serum levels of oral anticoagulants and enhance anticoagulant effects.  The mechanism is unknown .  Data have been conflicting.  Case reports exist for propranolol, while acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, metoprolol, and pindolol reportedly do not interact.  Hypoprothrombinemic effects are expected to be minimal.", "source": "DDInter", "management_text": "It is recommended that PT or INR be monitored when a beta-blocker is added to or deleted from the medical regimen of a patient receiving an oral anticoagulant.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Others", "recommendation": "It is recommended that PT or INR be monitored when a beta-blocker is added to or deleted from the medical regimen of a patient receiving an oral anticoagulant.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281835/", "reference_text": "[1] Ku LL, Ward CO, Durgin SJ \"A clinical study of drug interaction and anticoagulant therapy.\" Drug Intell Clin Pharm 4 (1970):  300-6[2] Ryan JR \"Clinical pharmacology of acebutolol.\" Am Heart J 109 (1985):  1131-6[3] Bax ND, Lennard MS, Tucker GT, et al. \"The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose.\" Br J Clin Pharmacol 17 (1984):  553-7[4] Spahn H, Kirch W, Mutschler E, et al. \"Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol.\" Br J Clin Pharmacol 17 (1984):  s97-102[5] Bax ND, Lennard MS, Sl-Asady S, Deacon CS, Tucker GT, Woods HF \"Inhibition of drug metabolism by B-adrenoceptor antagonists.\" Drugs 25 Suppl 2 (1983):  121-6[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83", "alternatives_a": "Pindolol, Metoprolol, Atenolol, Acebutolol, Nadolol, Metoprolol, Carvedilol, Esmolol, Betaxolol, Nebivolol, Bisoprolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243462, "ingredient1": "Penbutolol", "ingredient2": "Arbutamine", "severity": "Moderate", "effect": "Beta-blockers will attenuate the desired effects of arbutamine.", "source": "DDInter", "management_text": "Beta-blockers should be discontinued at least 48 hours before arbutamine is administered.", "mechanism_text": "Antagonism", "recommendation": "Beta-blockers should be discontinued at least 48 hours before arbutamine is administered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281837/", "reference_text": "[1] \"Product Information. GenESA (arbutamine).\" Gensia Inc, San Diego, CA.", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Nebivolol, Carteolol", "updated_at": 1767369485}, {"id": 243463, "ingredient1": "Penbutolol", "ingredient2": "Attapulgite", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting.  The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH.", "source": "DDInter", "management_text": "Based on available data, the clinical significance of this potential interaction is difficult to determine.  As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "mechanism_text": "Absorption", "recommendation": "Based on available data, the clinical significance of this potential interaction is difficult to determine.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281838/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981):  429-35[2] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  244-6[4] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977):  887-92[5] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981):  79-87[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990):  210-9[7] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997):  269-72", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Esmolol, Carteolol", "updated_at": 1767369485}, {"id": 243464, "ingredient1": "Bepridil", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.  The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281839/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985):  334-6[2] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986):  943-9[3] Tateishi T, Nakashima H, Shitou T, et al. \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989):  67-70[4] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986):  489-97[5] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992):  292-4[6] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986):  905-7[7] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982):  953-4[8] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985):  363-6[9] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985):  149-54[10] Bauer LA, Murray K, Horn JR, et al. \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989):  257-60[11] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985):  16-25[12] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983):  548[13] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987):  155-6[14] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990):  1525-32[15] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987):  575-8[16] Pouleur H, Etienne J, Van Mechelen H, et al. \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984):  23-8[17] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990):  497-501[18] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987):  21-5[19] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988):  425-31[20] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985):  b69-80[21] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989):  709-18[22] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988):  570-81[23] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988):  39-48[24] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980):  1251-2[25] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992):  1099-104[26] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986):  153-8[27] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993):  631-7", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243465, "ingredient1": "Bromfenac", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281841/", "reference_text": "[1] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984):  s108-11[2] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985):  443-9[3] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987):  628-35[4] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986):  997-1001[5] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977):  1005-7[6] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991):  363-6[7] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982):  197-201[8] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977):  1005-7[9] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984):  s108-11[10] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995):  494-8", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243466, "ingredient1": "Chloral hydrate", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281844/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Zopiclone, Melatonin, Valerian", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243467, "ingredient1": "Chlormezanone", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281845/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Timolol, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243468, "ingredient1": "Chlorphenesin", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281846/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, Flucytosine, More", "alternatives_b": "Carvedilol, Timolol, Carteolol", "updated_at": 1767369485}, {"id": 243469, "ingredient1": "Dicoumarol", "ingredient2": "Penbutolol", "severity": "Minor", "effect": "Some oral beta-blockers may increase serum levels of oral anticoagulants and enhance anticoagulant effects.  The mechanism is unknown .  Data have been conflicting.  Case reports exist for propranolol, while acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, metoprolol, and pindolol reportedly do not interact.  Hypoprothrombinemic effects are expected to be minimal.", "source": "DDInter", "management_text": "It is recommended that PT or INR be monitored when a beta-blocker is added to or deleted from the medical regimen of a patient receiving an oral anticoagulant.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Others", "recommendation": "It is recommended that PT or INR be monitored when a beta-blocker is added to or deleted from the medical regimen of a patient receiving an oral anticoagulant.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281848/", "reference_text": "[1] Ku LL, Ward CO, Durgin SJ \"A clinical study of drug interaction and anticoagulant therapy.\" Drug Intell Clin Pharm 4 (1970):  300-6[2] Ryan JR \"Clinical pharmacology of acebutolol.\" Am Heart J 109 (1985):  1131-6[3] Bax ND, Lennard MS, Tucker GT, et al. \"The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose.\" Br J Clin Pharmacol 17 (1984):  553-7[4] Spahn H, Kirch W, Mutschler E, et al. \"Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol.\" Br J Clin Pharmacol 17 (1984):  s97-102[5] Bax ND, Lennard MS, Sl-Asady S, Deacon CS, Tucker GT, Woods HF \"Inhibition of drug metabolism by B-adrenoceptor antagonists.\" Drugs 25 Suppl 2 (1983):  121-6[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83", "alternatives_a": "Betrixaban, Clopidogrel, Cilostazol, Apixaban, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "alternatives_b": "Pindolol, Metoprolol, Atenolol, Acebutolol, Nadolol, Metoprolol, Carvedilol, Esmolol, Betaxolol, Nebivolol, Bisoprolol, More", "updated_at": 1767369485}, {"id": 243470, "ingredient1": "Digitoxin", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Concomitant use of digitalis glycosides and beta-blockers may increase the risk of bradycardia.  These agents slow atrioventricular conduction and decrease heart rate, hence they may have additive cardiac effects during coadministration.  Some beta-blockers such as carvedilol, esmolol, and talinolol have also been reported to increase the systemic bioavailability of digoxin.  The mechanism may involve enhanced absorption as well as reduced renal excretion of digoxin due to inhibition of intestinal and renal P-glycoprotein efflux transporter.", "source": "DDInter", "management_text": "Caution is advised during coadministration of digitalis glycosides and beta-blockers.  Serum digitalis levels, heart rate, and blood pressure should be monitored closely, particularly during the first few weeks of concomitant therapy.  Patients should be advised to notify their physician if they experience anorexia, nausea, visual changes, irregular heartbeat, slow pulse, dizziness, or syncope.  Beta-blockers should not be used in patients with overt or decompensated congestive heart failure, as sympathetic stimulation may be a vital component in maintaining hemodynamic function in these patients and its inhibition by beta blockade may worsen the heart failure.", "mechanism_text": "Excretion", "recommendation": "Caution is advised during coadministration of digitalis glycosides and beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281849/", "reference_text": "[1] LeWinter MM, Crawford MH, O'Rourke RA, Karliner JS \"The effects of oral propranolol, digoxin and combination therapy on the resting and exercise electrocardiogram.\" Am Heart J 93 (1977):  202-9[2] Watt DA \"Sensitivity to propranolol after digoxin intoxication.\" Br Med J 2 (1968):  413-4[3] De Mey C, Brendel E, Enterling D \"Carvedilol increases the systemic bioavailability of oral digoxin.\" Br J Clin Pharmacol 29 (1990):  486-90[4] Lowenthal DT, Porter RS, Saris SD, Bies CM, Slegowski MB, Staudacher A \"Clinical pharmacology, pharmacodynamics and interactions with esmolol.\" Am J Cardiol 56 (1985):  f14-8[5] \"Product Information. Inderal (propranolol).\" Wyeth-Ayerst Laboratories  (2001):[6] Lowenthal DT, Porter RS, Achari R, Turlapaty P, Laddu AR, Matier WL \"Esmolol-digoxin drug interaction\" J Clin Pharmacol 27 (1987):  561-6[7] \"Product Information. Zebeta (bisoprolol).\" Lederle Laboratories  (2001):[8] Wermeling DP, Field CJ, Smith DA, Chandler MH, Clifton GD, Boyle DA \"Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension.\" Pharmacotherapy 14 (1994):  600-6[9] \"Product Information. Coreg (carvedilol).\" SmithKline Beecham  (2001):[10] Eichhorn EJ, Lukas MA, Wu B, Shusterman N \"Effect of concomitant digoxin and carvedilol therapy of mortality and morbidity in patients with chronic heart failure.\" Am J Cardiol 86 (2000):  1032-5[11] Ratnapalan S, Griffiths K, Costei AM, Benson L, Koren G \"Digoxin-carvedilol interactions in children.\" J Pediatr 142 (2003):  572-574[12] Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K \"Interaction of digoxin with antihypertensive drugs via MDR 1.\" Life Sci 70 (2002):  1491-1500", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243471, "ingredient1": "Ergometrine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids.  The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation.  In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.", "source": "DDInter", "management_text": "Except for increased awareness of the interaction, no specific intervention appears to be necessary.  Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Except for increased awareness of the interaction, no specific intervention appears to be necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281851/", "reference_text": "[1] Gandy W \"Dihydroergotamine interaction with propranolol .\" Ann Emerg Med 19 (1990):  221[2] Baumrucker JF \"Drug interaction: propranolol and cafergot.\" N Engl J Med 288 (1973):  916-7[3] Venter CP, Joubert PH, Buys AC \"Severe peripheral ischaemia during concomitant use of beta blockers and ergot alkaloids.\" Br Med J 289 (1984):  288-9[4] Blank NK, Rieder MJ \"Paradoxical response to propranolol in migraine.\" Lancet 2 (1973):  1336[5] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals  (2004):", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243472, "ingredient1": "Gadodiamide", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281853/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ferumoxsil", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243473, "ingredient1": "Gadoteric acid", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281855/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ferumoxsil", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243474, "ingredient1": "Gadoteridol", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281856/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ferumoxsil", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243475, "ingredient1": "Gadoversetamide", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281857/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ferumoxsil", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243476, "ingredient1": "Halazepam", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281858/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Timolol, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243477, "ingredient1": "Diamorphine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281859/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243478, "ingredient1": "Insulin human", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.  Nevertheless, caution is advised if they are prescribed to patients treated with insulin or oral antidiabetic agents that can cause hypoglycemia (e.g., insulin secretagogues), as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents.  Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked.  However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.  The same precautions are applicable in diabetic patients treated with ophthalmic beta-blockers.", "mechanism_text": "Synergism", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281861/", "reference_text": "[1] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981):  357-8[2] Micossi P, Pollavini G, Raggi U, et al. \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984):  59-63[3] Popp DA, Tse TF, Shah SD, et al. \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984):  243-7[4] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984):  2427-8[5] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982):  7-12[6] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980):  873-9[7] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980):  866-72[8] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976):  447-9[9] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978):  1467[10] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982):  507-12[11] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985):  85-9[12] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983):  69-77[13] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977):  1255-7[14] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989):  1152-7[15] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990):  699-702[16] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975):  28-32", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243479, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.  Nevertheless, caution is advised if they are prescribed to patients treated with insulin or oral antidiabetic agents that can cause hypoglycemia (e.g., insulin secretagogues), as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents.  Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked.  However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.  The same precautions are applicable in diabetic patients treated with ophthalmic beta-blockers.", "mechanism_text": "Synergism", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281862/", "reference_text": "[1] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981):  357-8[2] Micossi P, Pollavini G, Raggi U, et al. \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984):  59-63[3] Popp DA, Tse TF, Shah SD, et al. \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984):  243-7[4] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984):  2427-8[5] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982):  7-12[6] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980):  873-9[7] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980):  866-72[8] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976):  447-9[9] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978):  1467[10] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982):  507-12[11] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985):  85-9[12] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983):  69-77[13] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977):  1255-7[14] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989):  1152-7[15] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990):  699-702[16] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975):  28-32", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243480, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.  Nevertheless, caution is advised if they are prescribed to patients treated with insulin or oral antidiabetic agents that can cause hypoglycemia (e.g., insulin secretagogues), as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents.  Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked.  However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.  The same precautions are applicable in diabetic patients treated with ophthalmic beta-blockers.", "mechanism_text": "Synergism", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281863/", "reference_text": "[1] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981):  357-8[2] Micossi P, Pollavini G, Raggi U, et al. \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984):  59-63[3] Popp DA, Tse TF, Shah SD, et al. \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984):  243-7[4] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984):  2427-8[5] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982):  7-12[6] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980):  873-9[7] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980):  866-72[8] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976):  447-9[9] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978):  1467[10] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982):  507-12[11] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985):  85-9[12] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983):  69-77[13] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977):  1255-7[14] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989):  1152-7[15] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990):  699-702[16] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975):  28-32", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243481, "ingredient1": "Iodipamide", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281865/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243482, "ingredient1": "Iodixanol", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281866/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243483, "ingredient1": "Iopanoic acid", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281868/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243484, "ingredient1": "Iopodic acid", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281870/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243485, "ingredient1": "Isoetharine", "ingredient2": "Penbutolol", "severity": "Major", "effect": "Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases.  The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors.  The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.  Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose.  Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.", "source": "DDInter", "management_text": "Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.  If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred.  Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents.  In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281871/", "reference_text": "[1] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983):  583-5[2] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986):  251-60[3] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988):  s18-24[4] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986):  264-8[5] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991):  1215-8[6] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989):  748-51[7] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986):  169-74[8] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985):  1211-3[9] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979):  536-40[10] \"Product Information. Normodyne (labetalol).\" Schering Corporation  (2002):[11] \"Product Information. Corgard (nadolol).\" Bristol-Myers Squibb  (2002):[12] \"Product Information. Inderal (propranolol).\" Wyeth-Ayerst Laboratories  (2001):[13] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975):  175-80[14] \"Product Information. Blocadren (timolol).\" Merck & Co., Inc  (2001):[15] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989):  353-5[16] Herschman Z, Kaufman B \"Complications arising from the use of ophthalmologic medications in an intensive care unit patient.\" N Y State J Med 89 (1989):  537-8[17] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976):  163-70[18] \"Product Information. OptiPranolol (metipranolol ophthalmic).\" Bausch and Lomb Americas, Inc.  (2022):[19] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994):  701-3[20] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992):  208-21[21] \"Product Information. Betagan (levobunolol ophthalmic).\" Allergan Inc  (2022):[22] \"Product Information. Coreg (carvedilol).\" SmithKline Beecham  (2001):[23] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996):  947-53[24] \"Product Information. Timoptic (timolol ophthalmic).\" Merck & Co., Inc  (2001):[25] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999):  974-8[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999):  99-105[27] \"Product Information. Volmax (albuterol).\" Muro Pharmaceuticals Inc  (2001):[28] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002):  CD0003566[29] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002):  715-25[30] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005):  818-24[31] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005):  165S-168S[32] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[33] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002):  230-41[34] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000):  1322-6[35] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988):  279-84[36] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005):  236-41[37] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005):  472-3[38] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[39] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[40] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243486, "ingredient1": "Penbutolol", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.  Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.", "source": "DDInter", "management_text": "Blood pressure and intraocular pressure monitoring is recommended during concurrent use.  Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Blood pressure and intraocular pressure monitoring is recommended during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281872/", "reference_text": "[1] \"Product Information. Acupress (carteolol ophthalmic).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Timoptic (timolol ophthalmic).\" Merck & Co., Inc  (2001):", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243487, "ingredient1": "Penbutolol", "ingredient2": "Magaldrate", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting.  The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH.", "source": "DDInter", "management_text": "Based on available data, the clinical significance of this potential interaction is difficult to determine.  As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "mechanism_text": "Absorption", "recommendation": "Based on available data, the clinical significance of this potential interaction is difficult to determine.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281873/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981):  429-35[2] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  244-6[4] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977):  887-92[5] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981):  79-87[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990):  210-9[7] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997):  269-72", "alternatives_a": "Esmolol, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243488, "ingredient1": "Penbutolol", "ingredient2": "Mephentermine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.  A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281874/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company  (2002):[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals  (2002):[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979):  371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243489, "ingredient1": "Penbutolol", "ingredient2": "Metaraminol", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.  A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281875/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company  (2002):[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals  (2002):[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979):  371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243490, "ingredient1": "Penbutolol", "ingredient2": "Methacholine", "severity": "Major", "effect": "Patients who are concurrently receiving beta blockers may have exaggerated or prolonged responses (i.e., bronchoconstriction) to methacholine challenge and may not respond readily to treatment.  Beta-2-adrenergic blockade increases airway resistance.  Ophthalmically applied beta blockers undergo some systemic absorption and potentially may also interact.", "source": "DDInter", "management_text": "Administration of methacholine to a patient on any beta blocker therapy is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Administration of methacholine to a patient on any beta blocker therapy is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281876/", "reference_text": "[1] \"Product Information. Provocholine (methacholine).\" Methapharm Inc  (2002):", "alternatives_a": "Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "alternatives_b": "Nebivolol, Carteolol", "updated_at": 1767369485}, {"id": 243491, "ingredient1": "Penbutolol", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281877/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243492, "ingredient1": "Penbutolol", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281878/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243493, "ingredient1": "Penbutolol", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "The antihypertensive effects of methoxyflurane and beta blockers may be additive.  The combination may cause profound hypotension.  Older anesthetics such as methoxyflurane have more severe circulatory depressant effects in the presence of beta-blockade.", "source": "DDInter", "management_text": "It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery.  However, in general, patients taking beta blockers should not be anaesthetized with methoxyflurane.  Instead, an anesthetic with minimal negative inotropic activity may be considered.  If methoxyflurane must be used, beta blocker therapy should be withdrawn gradually and generally completed 24 to 48 hours before anesthesia.", "mechanism_text": "Synergism", "recommendation": "It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281879/", "reference_text": "[1] Hunter JM \"Synergism between halothane and labetalol.\" Anaesthesia 34 (1979):  257-9[2] Scott DB, Buckley FP, Littlewood DG, Macrae WR, Arthur GR, Drummond GB \"Circulatory effects of labetalol during halothane anaesthesia.\" Anaesthesia 33 (1978):  145-56[3] \"Product Information. Lopressor (metoprolol).\" Novartis Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acetaminophen, Ziconotide", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243494, "ingredient1": "Penbutolol", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.  Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281880/", "reference_text": "[1] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984):  293[2] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984):  728-9[3] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975):  834-5[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986):  351-7[5] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970):  406-10[6] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972):  467-8[7] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983):  s17-22[8] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997):  90-1", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243495, "ingredient1": "Penbutolol", "ingredient2": "Oxtriphylline", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite.  Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation.  Ophthalmic beta-blockers undergo significant systemic absorption and may also interact.  In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases.  Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm.  If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Metabolism, Distribution", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281885/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991):  135-50[2] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980):  463-7[3] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978):  1-6[4] Mue S, Sasaki T, Shibahara S, et al. \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979):  346-50[5] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987):  523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243496, "ingredient1": "Penbutolol", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281886/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Zopiclone, Melatonin, Valerian", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243497, "ingredient1": "Phenylbutazone", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281888/", "reference_text": "[1] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984):  s108-11[2] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985):  443-9[3] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987):  628-35[4] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986):  997-1001[5] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977):  1005-7[6] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991):  363-6[7] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982):  197-201[8] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977):  1005-7[9] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984):  s108-11[10] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995):  494-8", "alternatives_a": "Carteolol", "alternatives_b": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243498, "ingredient1": "Pipecuronium", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.  Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281889/", "reference_text": "[1] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984):  293[2] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984):  728-9[3] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975):  834-5[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986):  351-7[5] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970):  406-10[6] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972):  467-8[7] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983):  s17-22[8] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997):  90-1", "alternatives_a": "Carteolol", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 243499, "ingredient1": "Promazine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281891/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Carteolol", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 243500, "ingredient1": "Propiomazine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281892/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Carteolol", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Zopiclone, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 243501, "ingredient1": "Pyrophosphoric acid", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281893/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243502, "ingredient1": "Rapacuronium", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.  Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281895/", "reference_text": "[1] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984):  293[2] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984):  728-9[3] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975):  834-5[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986):  351-7[5] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970):  406-10[6] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972):  467-8[7] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983):  s17-22[8] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997):  90-1", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243503, "ingredient1": "Ritodrine", "ingredient2": "Penbutolol", "severity": "Major", "effect": "The use of a nonselective beta blocker with ritodrine (a beta-2 agonist) may result in mutually antagonistic effects, negating the effect of one or both drugs.", "source": "DDInter", "management_text": "In general, the use of beta blockers with ritodrine is discouraged.  Selective beta blockers (e.g. acebutolol, atenolol, betaxolol, bisoprolol, metoprolol) may be preferable if the use of a beta blocker is unavoidable.", "mechanism_text": "Antagonism", "recommendation": "In general, the use of beta blockers with ritodrine is discouraged.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281897/", "reference_text": "[1] \"Product Information. Yutopar (ritodrine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Bremelanotide, Black cohosh, Flibanserin, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243504, "ingredient1": "Trichlormethiazide", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes.  In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.  Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281901/", "reference_text": "[1] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985):  123-6[2] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983):  801-6[3] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985):  29-33[4] \"Product Information. Lozol (indapamide).\" Rhone Poulenc Rorer  (2002):[5] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006):  49-58", "alternatives_a": "Carteolol", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 243505, "ingredient1": "Triflupromazine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281902/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Carteolol", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 243506, "ingredient1": "Alimemazine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281903/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Carteolol", "updated_at": 1767369485}, {"id": 243507, "ingredient1": "Tubocurarine", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.  Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281904/", "reference_text": "[1] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984):  293[2] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984):  728-9[3] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975):  834-5[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986):  351-7[5] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970):  406-10[6] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972):  467-8[7] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983):  s17-22[8] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997):  90-1", "alternatives_a": "Carteolol", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 243508, "ingredient1": "Tyropanoic acid", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281905/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12", "alternatives_a": "Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243509, "ingredient1": "Acrivastine", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281920/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243510, "ingredient1": "Levorphanol", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281925/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243511, "ingredient1": "Melatonin", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281926/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243512, "ingredient1": "Perampanel", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/281932/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Fenfluramine", "updated_at": 1767369485}, {"id": 243513, "ingredient1": "Acrivastine", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282259/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 243514, "ingredient1": "Lofexidine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282262/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 243515, "ingredient1": "Melatonin", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282263/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Estazolam, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243516, "ingredient1": "Minoxidil (topical)", "ingredient2": "Minoxidil", "severity": "Moderate", "effect": "Theoretically, topical administration of minoxidil may potentiate the hypotensive effects of systemic minoxidil and other vasodilators.", "source": "DDInter", "management_text": "Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.", "mechanism_text": "Synergism", "recommendation": "Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282481/", "reference_text": "[1] Leenen FH, Smith DL, Unger WP \"Topical minoxidil: cardiac effects in bald men.\" Br J Clin Pharmacol 26 (1988):  481-5[2] \"Product Information. Rogaine (minoxidil topical).\" Johnson and Johnson/McNeil Consumer  (2002):", "alternatives_a": "Tacrolimus, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 243517, "ingredient1": "Maprotiline", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282501/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cabergoline", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 243518, "ingredient1": "Melatonin", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282503/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Ethchlorvynol, Zopiclone, Thiopental, Nitrazepam", "updated_at": 1767369485}, {"id": 243519, "ingredient1": "Botulinum toxin type A", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282506/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 243520, "ingredient1": "Botulinum toxin type B", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282509/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243521, "ingredient1": "Rizatriptan", "ingredient2": "Maprotiline", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282510/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Viloxazine, Esketamine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243522, "ingredient1": "Inotersen", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Coadministration of inotersen with other nephrotoxic agents may increase the risk of renal impairment due to additive adverse effects on the kidney.", "source": "DDInter", "management_text": "Caution is advised when inotersen is prescribed with nephrotoxic drugs and other drugs that may impair renal function (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, cidofovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) .  Serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), and a urinalysis should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling.  Inotersen should generally not be initiated in patients with a UPCR of 1000 mg/g or higher, or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines.  Patients or their caregivers should be apprised of the signs and symptoms of glomerulonephritis and to seek medical attention if they occur, including edema, shortness of breath, coughing, hematuria, and decreased urination.  Inotersen should be withheld in patients who develop a UPCR of 1000 mg/g or higher, or eGFR below 45 mL/minute/1.73 m2, pending further evaluation of the cause.  Weekly dosing may be resumed once eGFR increases to at least 45 mL/minute/1.73 m2, UPCR decreases to below 1000 mg/g, or the underlying cause of the renal function decline is corrected.  In patients with UPCR of 2000 mg/g or higher, perform further evaluation for acute glomerulonephritis as clinically indicated.  If acute glomerulonephritis is confirmed, inotersen should be permanently discontinued.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when inotersen is prescribed with nephrotoxic drugs and other drugs that may impair renal function (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282632/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Tegsedi (inotersen).\" Akcea Therapeutics  (2018):", "alternatives_a": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243523, "ingredient1": "Iodipamide", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282634/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243524, "ingredient1": "Iodixanol", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282635/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243525, "ingredient1": "Iohexol", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282636/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243526, "ingredient1": "Iopamidol", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282638/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243527, "ingredient1": "Iopromide", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282639/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243528, "ingredient1": "Ioversol", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282640/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243529, "ingredient1": "Ioxilan", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282642/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243530, "ingredient1": "Moxetumomab Pasudotox", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "Coadministration of methoxyflurane with other nephrotoxic agents may increase the risk of renal impairment.", "source": "DDInter", "management_text": "Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282643/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Diflunisal, Salsalate, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243531, "ingredient1": "Remdesivir", "ingredient2": "Moxetumomab Pasudotox", "severity": "Moderate", "effect": "Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient, sulfobutylether-beta-cyclodextrin sodium (SBECD).  Both GS-441524 and SBECD are primarily eliminated by the kidneys, thus renal impairment secondary to the use of nephrotoxic agents may reduce their clearance and increase the risk of accumulation.", "source": "DDInter", "management_text": "Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function.  Caution is advised if remdesivir is used in patients who have recently received potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function (estimated glomerular filtration rate, or eGFR, for adult and pediatric patients older than 28 days; serum creatinine for full-term neonates at least 7 days up to 28 days old) should be evaluated prior to starting remdesivir and monitored daily during treatment or as clinically appropriate.  Remdesivir should not be initiated in patients with an eGFR below 30 mL/min (or serum creatinine >=1 mg/dL in full-term neonates), and should be discontinued immediately if eGFR falls to less than 30 mL/min during treatment (or renal function substantially declines in full-term neonates).", "mechanism_text": "Excretion", "recommendation": "Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282645/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Gilead Sciences, Inc \"About Remdesivir.  https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir\"   (2020):[4] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead.  https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf\"   (2020):[5] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)  https://www.fda.gov/media/137566/download\"   (2020):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243532, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Lurbinectedin", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282961/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243533, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282967/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "updated_at": 1767369485}, {"id": 243534, "ingredient1": "Melphalan flufenamide", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/282975/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243535, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283013/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243536, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established.", "source": "DDInter", "management_text": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "mechanism_text": "Others", "recommendation": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283014/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Fostamatinib, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 243537, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Lutetium Lu 177 dotatate", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283018/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243538, "ingredient1": "Valaciclovir", "ingredient2": "Lutetium Lu 177 dotatate", "severity": "Moderate", "effect": "The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283071/", "reference_text": "[1] \"Product Information. Valtrex (valacyclovir).\" Glaxo Wellcome  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243539, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Lutetium Lu 177 dotatate", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283073/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243540, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Olaparib", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283159/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243541, "ingredient1": "Olaparib", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.  Complete blood counts should be performed at baseline and monthly thereafter.  Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.  For prolonged hematologic toxicities, olaparib should be interrupted and blood counts monitored weekly until recovery.  If the levels have not recovered to CTCAE Grade 1 or less after 4 weeks, a haematologist should be consulted for further investigations, including bone marrow analysis and blood sample for cytogenetics.  If MDS/AML is confirmed, discontinue olaparib.  Patients should be advised to contact their physician if they experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283172/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals  (2014):", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243542, "ingredient1": "Palbociclib", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors.  A dosage reduction may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283178/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals  (2014):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Vandetanib, Afatinib, Tivozanib, Brigatinib, Encorafenib, Axitinib, Sunitinib, Regorafenib, More", "updated_at": 1767369485}, {"id": 243543, "ingredient1": "Promazine", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.  Complete blood counts should be performed at baseline and monthly thereafter.  Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.  For prolonged hematologic toxicities, olaparib should be interrupted and blood counts monitored weekly until recovery.  If the levels have not recovered to CTCAE Grade 1 or less after 4 weeks, a haematologist should be consulted for further investigations, including bone marrow analysis and blood sample for cytogenetics.  If MDS/AML is confirmed, discontinue olaparib.  Patients should be advised to contact their physician if they experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283187/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals  (2014):", "alternatives_a": "Pertuzumab, Bortezomib, Tisagenlecleucel, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Thioridazine, Lumateperone, Trifluoperazine, Cariprazine, Paliperidone, More", "updated_at": 1767369485}, {"id": 243544, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283215/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243545, "ingredient1": "Acrivastine", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283217/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243546, "ingredient1": "Chlorcyclizine", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283219/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Azelastine, Ketotifen, Terfenadine, Astemizole", "alternatives_b": "Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More", "updated_at": 1767369485}, {"id": 243547, "ingredient1": "Pregabalin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283221/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243548, "ingredient1": "Pregabalin", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283222/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243549, "ingredient1": "Perampanel", "ingredient2": "Mitotane", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283228/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 243550, "ingredient1": "Nitisinone", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 or moderate dual or combined inhibitors of CYP450 3A4 and CYP450 2C9 may increase the plasma concentrations of macitentan.  Macitentan is primarily metabolized by CYP450 3A4 and to a minor extent by CYP450 2C8, CYP450 2C9 and CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.  The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole).  The manufacturer of macitentan also recommends avoiding concomitant use with moderate dual inhibitors of CYP450 3A4 and 2C9 (e.g., fluconazole, amiodarone) or in combination with both a moderate CYP450 3A4 inhibitor and a moderate CYP450 2C9 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283237/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc  (2013):", "alternatives_a": "Riociguat, Ambrisentan, Metyrosine, Tadalafil", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 243551, "ingredient1": "Oxandrolone", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 or moderate dual or combined inhibitors of CYP450 3A4 and CYP450 2C9 may increase the plasma concentrations of macitentan.  Macitentan is primarily metabolized by CYP450 3A4 and to a minor extent by CYP450 2C8, CYP450 2C9 and CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.  The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole).  The manufacturer of macitentan also recommends avoiding concomitant use with moderate dual inhibitors of CYP450 3A4 and 2C9 (e.g., fluconazole, amiodarone) or in combination with both a moderate CYP450 3A4 inhibitor and a moderate CYP450 2C9 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283239/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc  (2013):", "alternatives_a": "Riociguat, Ambrisentan, Bosentan, Metyrosine", "alternatives_b": "Stanozolol, Nandrolone, Oxymetholone, Prasterone", "updated_at": 1767369485}, {"id": 243552, "ingredient1": "Anisindione", "ingredient2": "Hemin", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided.  Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283289/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243553, "ingredient1": "Anistreplase", "ingredient2": "Hemin", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided.  Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283290/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 243554, "ingredient1": "Hemin", "ingredient2": "Dicoumarol", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided.  Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283292/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 243555, "ingredient1": "Hemin", "ingredient2": "Dienestrol (topical)", "severity": "Major", "effect": "Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin.  In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.", "source": "DDInter", "management_text": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283293/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243556, "ingredient1": "Hemin", "ingredient2": "Diethylstilbestrol", "severity": "Major", "effect": "Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin.  In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.", "source": "DDInter", "management_text": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283294/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin, Bazedoxifene", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 243557, "ingredient1": "Hemin", "ingredient2": "Estrone", "severity": "Major", "effect": "Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin.  In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.", "source": "DDInter", "management_text": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283295/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Bazedoxifene", "alternatives_b": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 243558, "ingredient1": "Hemin", "ingredient2": "Plicamycin", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided.  Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283296/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Idarubicin, Valrubicin, Ixabepilone, Mitoxantrone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "updated_at": 1767369485}, {"id": 243559, "ingredient1": "Hemin", "ingredient2": "Quinestrol", "severity": "Major", "effect": "Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin.  In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.", "source": "DDInter", "management_text": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283297/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Voxelotor, Betibeglogene autotemcel, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243560, "ingredient1": "Hemin", "ingredient2": "Thiopental", "severity": "Major", "effect": "Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin.  In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.", "source": "DDInter", "management_text": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283298/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Halothane, Alfentanil, Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Fentanyl, Desflurane, Sufentanil, Propofol, Enflurane, More", "updated_at": 1767369485}, {"id": 243561, "ingredient1": "Hemin", "ingredient2": "Tinzaparin", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided.  Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283299/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Protein C, Acenocoumarol, Selexipag, Desirudin", "updated_at": 1767369485}, {"id": 243562, "ingredient1": "Hemin", "ingredient2": "Tositumomab", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided.  Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283300/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 243563, "ingredient1": "Hemin", "ingredient2": "Urokinase", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided.  Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283301/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc  (2001):", "alternatives_a": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Protein C, Acenocoumarol, Selexipag, Desirudin", "updated_at": 1767369485}, {"id": 243564, "ingredient1": "Heparin", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283304/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag, Pentosan polysulfate, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone", "alternatives_b": "Selexipag, Heparin, Heparin, Nandrolone, Ascorbic acid, Potassium Iodide, Heparin", "updated_at": 1767369485}, {"id": 243565, "ingredient1": "Heparin (flush)", "ingredient2": "Alprostadil", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283310/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Ranolazine, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "updated_at": 1767369485}, {"id": 243566, "ingredient1": "Anisindione", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283311/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243567, "ingredient1": "Anistreplase", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283312/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Alteplase, Dicoumarol, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase, Alteplase, More", "updated_at": 1767369485}, {"id": 243568, "ingredient1": "Heparin (flush)", "ingredient2": "Bromfenac", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283313/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "alternatives_b": "Abciximab, Tirofiban, Dicoumarol, Eptifibatide, Protein C, Acenocoumarol, Selexipag, Anistreplase, Pentosan polysulfate, Ascorbic acid, Cyclosporine, More", "updated_at": 1767369485}, {"id": 243569, "ingredient1": "Heparin (flush)", "ingredient2": "Dextran (-1)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283314/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Argatroban, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243570, "ingredient1": "Heparin (flush)", "ingredient2": "Dextran (high molecular weight)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283315/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Argatroban, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243571, "ingredient1": "Heparin (flush)", "ingredient2": "Dextran (low molecular weight)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283316/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Argatroban, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243572, "ingredient1": "Heparin (flush)", "ingredient2": "Dicoumarol", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283317/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine", "updated_at": 1767369485}, {"id": 243573, "ingredient1": "Hydroxychloroquine", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283318/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 243574, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283319/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 243575, "ingredient1": "Ibrutinib", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283320/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243576, "ingredient1": "Iloprost", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283321/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Iloprost, Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "alternatives_b": "Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 243577, "ingredient1": "Indomethacin", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283322/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Nandrolone, Ascorbic acid", "alternatives_b": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Chondroitin sulfate, More", "updated_at": 1767369485}, {"id": 243578, "ingredient1": "Inotersen", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283323/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 243579, "ingredient1": "Ipilimumab", "ingredient2": "Heparin (flush)", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283324/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Prasugrel, Streptokinase, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 243580, "ingredient1": "Heparin (flush)", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283325/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243581, "ingredient1": "Heparin (flush)", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283326/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Tirofiban, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 243582, "ingredient1": "Heparin (flush)", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283327/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 243583, "ingredient1": "Heparin (flush)", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283328/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Iloprost, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Treprostinil, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243584, "ingredient1": "Heparin (flush)", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283329/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Clopidogrel, Dicoumarol, Protein C, Acenocoumarol, Selexipag, Anistreplase, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Acetylcysteine", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243585, "ingredient1": "Heparin (flush)", "ingredient2": "Plicamycin", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283331/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Clopidogrel, Cilostazol, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Desirudin, More", "alternatives_b": "Idarubicin, Valrubicin, Ixabepilone, Mitoxantrone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "updated_at": 1767369485}, {"id": 243586, "ingredient1": "Heparin (flush)", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283332/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243587, "ingredient1": "Heparin (flush)", "ingredient2": "Protein C", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283333/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Acenocoumarol, Cangrelor, Dipyridamole, Prasugrel, Eptifibatide, Selexipag, Vorapaxar, More", "alternatives_b": "Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 243588, "ingredient1": "Heparin (flush)", "ingredient2": "Reteplase", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283334/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase, Alteplase, Ascorbic acid, More", "alternatives_b": "Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 243589, "ingredient1": "Heparin (flush)", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283335/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Drotrecogin alfa, Selexipag, Desirudin, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone, Potassium Iodide", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 243590, "ingredient1": "Heparin (flush)", "ingredient2": "Tinzaparin", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283336/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Tinzaparin, Acenocoumarol, Selexipag, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone", "alternatives_b": "Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 243591, "ingredient1": "Heparin (flush)", "ingredient2": "Tositumomab", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283337/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Dicoumarol, Desirudin, Protein C, Acenocoumarol, Selexipag, Anistreplase, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, More", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 243592, "ingredient1": "Heparin (flush)", "ingredient2": "Urokinase", "severity": "Moderate", "effect": "Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.", "source": "DDInter", "management_text": "Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283338/", "reference_text": "[1] Passannante A, Macik BG \"The heparin flush syndrome: a cause of iatrogenic hemorrhage.\" Am J Med Sci 296 (1988):  71-3[2] \"Product Information. Heparin Sodium in Sodium Chloride (heparin flush).\" Baxter Healthcare Corporation  (2022):[3] \"Product Information. Canusal (heparin flush).\" Wockhardt UK Ltd  (2018):[4] \"Product Information. Heparinised Saline (Pfizer) (heparinised saline).\" Pfizer Australia Pty Ltd  (2022):", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase, Alteplase, Ascorbic acid, More", "alternatives_b": "Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 243593, "ingredient1": "Trastuzumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283339/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243594, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Trastuzumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283389/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243595, "ingredient1": "Acrivastine", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283391/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243596, "ingredient1": "Tasimelteon", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283394/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243597, "ingredient1": "Tasimelteon", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283395/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tasimelteon, Nitrazepam, Zopiclone", "alternatives_b": "Melatonin, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243598, "ingredient1": "Insulin human", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "Coadministration of a sulfonylurea with insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "Caution and close blood glucose monitoring are advised during coadministration of these agents.  A lower dosage of sulfonylurea or insulin may be required.  Patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician.  Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Caution and close blood glucose monitoring are advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283530/", "reference_text": "[1] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[2] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[4] \"Product Information. Humulin N (insulin isophane).\" Lilly, Eli and Company  (2002):[5] \"Product Information. Humulin R (insulin regular).\" Lilly, Eli and Company  (2002):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[9] \"Product Information. NovoLIN R (insulin regular).\" Novo Nordisk Pharmaceuticals Inc  (2015):[10] American Diabetes Association \"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes?019\" Diabetes Care 42 (2019):  S90-S102", "alternatives_a": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243599, "ingredient1": "Insulin human", "ingredient2": "Aloe Vera Leaf", "severity": "Moderate", "effect": "Concomitant use of oral products containing aloe vera gel may potentiate the hypoglycemic effect of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia.  Patients should be monitored for changes in diabetic medication requirements.", "mechanism_text": "Synergism", "recommendation": "Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283531/", "reference_text": "[1] Tanaka M, Misawa E, Yousuke I, et al. \"Identification of five phytosterols from Aloe vera gel as anti-diabetic compounds.\" Biol Pharm Bull 29 (2006):  1418-22[2] Vogller BK \"Aloe vera: a systematic review of its clinical effectiveness.\" Br J Gen Pract 49 (1999):  823-8[3] Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS \"Systemic review of herbs and dietary supplements for glycemic control in diabetes.\" Diabetes Care 26 (2003):  1277-94", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243600, "ingredient1": "Insulin human", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283532/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243601, "ingredient1": "Insulin human", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283533/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243602, "ingredient1": "Insulin human", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.  Nevertheless, caution is advised if they are prescribed to patients treated with insulin or oral antidiabetic agents that can cause hypoglycemia (e.g., insulin secretagogues), as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents.  Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked.  However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.  The same precautions are applicable in diabetic patients treated with ophthalmic beta-blockers.", "mechanism_text": "Synergism", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283534/", "reference_text": "[1] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981):  357-8[2] Micossi P, Pollavini G, Raggi U, et al. \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984):  59-63[3] Popp DA, Tse TF, Shah SD, et al. \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984):  243-7[4] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984):  2427-8[5] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982):  7-12[6] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980):  873-9[7] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980):  866-72[8] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976):  447-9[9] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978):  1467[10] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982):  507-12[11] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985):  85-9[12] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983):  69-77[13] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977):  1255-7[14] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989):  1152-7[15] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990):  699-702[16] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975):  28-32", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol", "alternatives_b": "Liraglutide, Lixisenatide", "updated_at": 1767369485}, {"id": 243603, "ingredient1": "Insulin human", "ingredient2": "Deserpidine", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the hypoglycemic effects of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Limited data have demonstrated possible hypoglycemic activity with agents such as guanethidine and reserpine.  The mechanism may involve depletion of catecholamine stores from adrenergic nerve endings, which can interfere with glycogenolysis and other mechanisms related to regulation of blood glucose levels.", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  Insulin and oral antidiabetic dosages may require adjustment if an interaction is suspected.  Patients should be instructed about the need for regular monitoring of blood glucose levels and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked during antiadrenergic therapy.  However, other symptoms such as headache, dizziness, drowsiness, nausea, hunger, and sweating may be unaffected.  Patients should be observed for loss of glycemic control when antiadrenergic therapy is withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended when postganglionic adrenergic blocking agents are coadministered with insulin or insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283536/", "reference_text": "[1] Gupta KK \"Guanethidine and diabetes.\" Br Med J 2 (1968):  697-8[2] Gupta KK \"The antidiabetic action of guanethidine.\" Postgrad Med J 45 (1969):  455-6[3] Gupta KK \"Guanethidine and glucose tolerance in diabetics.\" Br Med J 3 (1968):  679", "alternatives_a": "Prazosin, Hydralazine, Guanfacine, Methyldopa", "alternatives_b": "Liraglutide, Lixisenatide", "updated_at": 1767369485}, {"id": 243604, "ingredient1": "Insulin human", "ingredient2": "Dexamethasone (topical)", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use.  Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.", "source": "DDInter", "management_text": "Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "mechanism_text": "Antagonism", "recommendation": "Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283537/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[3] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977):  522[4] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973):  11 passim[5] \"Product Information. Ultravate (halobetasol topical).\" Apothecon Inc  (2022):[6] \"Product Information. Diprolene (betamethasone topical).\" Schering Corporation  (2001):[7] \"Product Information. Temovate (clobetasol topical).\" Glaxo Wellcome[8] \"Product Information. Psorcon (diflorasone topical).\" Rhone Poulenc Rorer  (2001):", "alternatives_a": "Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243605, "ingredient1": "Insulin human", "ingredient2": "Dexfenfluramine", "severity": "Moderate", "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283538/", "reference_text": "[1] \"Product Information. Xenical (orlistat).\" Roche Laboratories  (2001):[2] \"Product Information. Didrex (benzphetamine).\" Pharmacia and Upjohn  (2001):[3] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals  (2012):[4] \"Product Information. Belviq (lorcaserin).\" Eisai Inc  (2012):", "alternatives_a": "Bupropion, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243606, "ingredient1": "Insulin human", "ingredient2": "Dienestrol (topical)", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283539/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243607, "ingredient1": "Insulin human", "ingredient2": "Diethylstilbestrol", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283540/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Bicalutamide, Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243608, "ingredient1": "Insulin human", "ingredient2": "Enoxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283541/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243609, "ingredient1": "Insulin human", "ingredient2": "Estrone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283542/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243610, "ingredient1": "Insulin human", "ingredient2": "Grepafloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283543/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243611, "ingredient1": "Insulin human", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.  Nevertheless, caution is advised if they are prescribed to patients treated with insulin or oral antidiabetic agents that can cause hypoglycemia (e.g., insulin secretagogues), as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents.  Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked.  However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.  The same precautions are applicable in diabetic patients treated with ophthalmic beta-blockers.", "mechanism_text": "Synergism", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283546/", "reference_text": "[1] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981):  357-8[2] Micossi P, Pollavini G, Raggi U, et al. \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984):  59-63[3] Popp DA, Tse TF, Shah SD, et al. \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984):  243-7[4] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984):  2427-8[5] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982):  7-12[6] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980):  873-9[7] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980):  866-72[8] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976):  447-9[9] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978):  1467[10] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982):  507-12[11] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985):  85-9[12] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983):  69-77[13] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977):  1255-7[14] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989):  1152-7[15] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990):  699-702[16] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975):  28-32", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243612, "ingredient1": "Insulin human", "ingredient2": "Lomefloxacin", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283547/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243613, "ingredient1": "Insulin human", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283550/", "reference_text": "[1] \"Product Information. Xenical (orlistat).\" Roche Laboratories  (2001):[2] \"Product Information. Didrex (benzphetamine).\" Pharmacia and Upjohn  (2001):[3] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals  (2012):[4] \"Product Information. Belviq (lorcaserin).\" Eisai Inc  (2012):", "alternatives_a": "Bupropion, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243614, "ingredient1": "Insulin human", "ingredient2": "Mecasermin rinfabate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283551/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243615, "ingredient1": "Insulin human", "ingredient2": "Mephentermine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283552/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243616, "ingredient1": "Insulin human", "ingredient2": "Metaraminol", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283553/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243617, "ingredient1": "Insulin human", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283554/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243618, "ingredient1": "Insulin human", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283555/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243619, "ingredient1": "Insulin human", "ingredient2": "Methoxamine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283556/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243620, "ingredient1": "Insulin human", "ingredient2": "Methylcellulose", "severity": "Minor", "effect": "Large doses of soluble dietary fibers such as guar gum, psyllium, or methylcellulose may add to the hypoglycemic effect of insulin and oral antidiabetic agents.  Soluble fibers slow the rate of carbohydrate degradation and glucose absorption during digestion, thus they can reduce postprandial blood glucose when taken in large amounts.", "source": "DDInter", "management_text": "Soluble dietary fibers are often considered beneficial as an adjunct to insulin and oral antidiabetic agents in the management of diabetes.  However, patients should be monitored for changes in diabetic medication requirements following initiation of fiber therapy.", "mechanism_text": "Synergism", "recommendation": "Soluble dietary fibers are often considered beneficial as an adjunct to insulin and oral antidiabetic agents in the management of diabetes.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283557/", "reference_text": "[1] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[2] Anderson JW, Allgood LD, Turner J, Oeltgen PR, Daggy BP \"Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia.\" Am J Clin Nutr 70 (1999):  466-73[3] Jenkins DJ, Wolever TM, Leeds AR, et al. \"Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity.\" Br Med J 1 (1978):  1392-4", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 243621, "ingredient1": "Insulin human", "ingredient2": "Nalidixic acid", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283558/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243622, "ingredient1": "Insulin human", "ingredient2": "Nicotinamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283560/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Pyridoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243623, "ingredient1": "Insulin human", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283561/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Ulipristal, Norelgestromin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243624, "ingredient1": "Insulin human", "ingredient2": "Potassium perchlorate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis.  The effect of insulin may be potentiated, and the risk of hypoglycemia increased.  The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis.  The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis.  The effect of insulin may be potentiated, and the risk of hypoglycemia increased.  The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis.  The implications for glucose intolerance in patients without liver cirrhosis are not known.", "mechanism_text": "Synergism", "recommendation": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283565/", "reference_text": "[1] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970):  394-404[2] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972):  64-8[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975):  845-55", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Methimazole, Propylthiouracil", "updated_at": 1767369485}, {"id": 243625, "ingredient1": "Insulin human", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283566/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243626, "ingredient1": "Insulin human", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283567/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243627, "ingredient1": "Insulin human", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283568/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243628, "ingredient1": "Insulin human", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283570/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243629, "ingredient1": "Insulin human", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283573/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243630, "ingredient1": "Insulin human", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283574/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Tamsulosin, More", "updated_at": 1767369485}, {"id": 243631, "ingredient1": "Insulin human", "ingredient2": "Sulfamethizole", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283575/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Trimethoprim, Sorbitol, Sodium citrate, Magnesium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Tamsulosin, Tinidazole, More", "updated_at": 1767369485}, {"id": 243632, "ingredient1": "Insulin human", "ingredient2": "Testosterone (topical)", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283576/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Prasterone", "updated_at": 1767369485}, {"id": 243633, "ingredient1": "Insulin human", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283578/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243634, "ingredient1": "Insulin human", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283579/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243635, "ingredient1": "Insulin human", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283580/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243636, "ingredient1": "Insulin human", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration of a thiazolidinedione in combination with insulin may increase the risk of edema compared to insulin alone.  The mechanism is unknown but may involve enhancement of the antinatriuretic and/or peripheral vasodilatory effects of insulin.", "source": "DDInter", "management_text": "Caution is advised during coadministration of thiazolidinedione and insulin therapy.  Patients at risk for heart failure should be closely monitored.  Patients should be advised to notify their physician immediately if they experience signs and symptoms of heart failure such as fluid retention, edema, rapid weight gain, or shortness of breath.  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of thiazolidinedione and insulin therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283581/", "reference_text": "[1] Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J \"A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.\" Diabetes Care 24 (2001):  1226-32[2] King KA, Levi VE \"Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione.\" Am J Health Syst Pharm 61 (2004):  390-3[3] Rosenstock J, Einhorn D, Hershon K, Glazer NB \"Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.\" Int J Clin Pract 56 (2002):  251-7", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 243637, "ingredient1": "Topotecan", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283583/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243638, "ingredient1": "Topotecan", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents.  Dosage reductions may be required, and bone marrow function should be closely monitored.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283596/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham  (2001):", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243639, "ingredient1": "Topotecan", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents.  Dosage reductions may be required, and bone marrow function should be closely monitored.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283609/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham  (2001):", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Teniposide, Irinotecan, Vinorelbine, Etoposide, Docetaxel", "updated_at": 1767369485}, {"id": 243640, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283635/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243641, "ingredient1": "Hydrocodone", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283637/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 243642, "ingredient1": "Hydrocodone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283642/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243643, "ingredient1": "Hydrocodone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283643/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243644, "ingredient1": "Hydroxychloroquine", "ingredient2": "Risdiplam", "severity": "Moderate", "effect": "Theoretical concerns exist that oculotoxic effects of risdiplam, observed in monkeys, may be additive with those of other drugs that are associated with retinotoxicity.", "source": "DDInter", "management_text": "Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs.  These drugs may include infigratinib, selumetinib, cobimetinib, vigabatrin, chloroquine, hydroxychloroquine, thioridazine and deferoxamine.", "mechanism_text": "Synergism", "recommendation": "Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283658/", "reference_text": "[1] \"Product Information. Aralen (chloroquine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Desferal (deferoxamine).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Plaquenil (hydroxychloroquine).\" Apothecon Inc  (2022):[4] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation  (2001):[5] \"Product Information. Chloroquine Phosphate (chloroquine).\" West Ward Pharmaceutical Corporation  (2005):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Sabril (vigabatrin).\" Lundbeck Inc  (2009):[9] \"Product Information. Deferoxamine Mesylate (deferoxamine).\" Hospira Inc  (2015):[10] Cerner Multum, Inc \"ANVISA Bulio Eletrico.\" O 0 (2015):[11] \"Product Information. Cotellic (cobimetinib).\" Genentech  (2015):[12] \"Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine).\" Prasco Laboratories  (2017):[13] \"Product Information. Thioridazine Hydrochloride (thioridazine).\" Mylan Institutional (formerly UDL Laboratories)  (2019):[14] \"Product Information. Koselugo (selumetinib).\" Astra-Zeneca Pharmaceuticals  (2020):[15] \"Product Information. Truseltiq (infigratinib).\" QED Therapeutics Inc  (2021):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid", "updated_at": 1767369485}, {"id": 243645, "ingredient1": "Axitinib", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.  Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible.  Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283766/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inlyta (axitinib).\" Pfizer U.S. Pharmaceuticals Group  (2012):", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 243646, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Palbociclib", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283767/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243647, "ingredient1": "Ibrutinib", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.  Dosage reduction in accordance with ibrutinib product labeling may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283773/", "reference_text": "[1] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):[2] \"Product Information. Qelbree (viloxazine).\" Supernus Pharmaceuticals Inc  (2021):", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More", "alternatives_b": "Dabrafenib, Dacomitinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Brigatinib, Axitinib, Lenvatinib, More", "updated_at": 1767369485}, {"id": 243648, "ingredient1": "Palbociclib", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil).  Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine).  Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283782/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine).\" Organon  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 243649, "ingredient1": "Palbociclib", "ingredient2": "Naloxegol", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.", "source": "DDInter", "management_text": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.  When a single 25 mg dose of naloxegol was administered with a single 600 mg dose of quinidine, a potent P-gp inhibitor and weak CYP450 3A4 inhibitor, naloxegol peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 147% and 39%, respectively.  These changes are not considered clinically significant; therefore, no dosage adjustments are necessary.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283787/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals  (2014):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 243650, "ingredient1": "Ropivacaine", "ingredient2": "Palbociclib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine.  Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "CYP450 3A4 inhibitors have a significant effect on the pharmacokinetics of ropivacaine only in the presence of CYP450 1A2 inhibitors such as fluvoxamine, ciprofloxacin, or mexiletine. Therefore, the combination of ropivacaine and the above drugs is not recommended.", "mechanism_text": "Metabolism", "recommendation": "CYP450 3A4 inhibitors have a significant effect on the pharmacokinetics of ropivacaine only in the presence of CYP450 1A2 inhibitors such as fluvoxamine, ciprofloxacin, or mexiletine.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283800/", "reference_text": "[1] Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M \"Metabolism and excretion of ropivacaine in humans.\" Drug Metab Dispos 24 (1996):  962-8[2] Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y \"Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.\" Anesthesiology 82 (1995):  214-20[3] \"Product Information. Naropin (ropivacaine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] McClure JH \"Ropivacaine.\" Br J Anaesth 76 (1996):  300-7[5] Ekstrom G, Gunnarsson UB \"Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.\" Drug Metab Dispos 24 (1996):  955-61[6] Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL \"Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.\" Clin Pharmacol Ther 64 (1998):  484-91[7] Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT \"The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.\" Anesth Analg 91 (2000):  1207-12", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, More", "alternatives_b": "Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "updated_at": 1767369485}, {"id": 243651, "ingredient1": "Sibutramine", "ingredient2": "Palbociclib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.  Inhibitors such as ketoconazole, cimetidine, and erythromycin have caused moderate increases in the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the active metabolites.  The data suggest that although the potential for such interaction exists, the magnitude appears to be small.  No special precaution appears necessary; however, dosage adjustments as well as clinical and laboratory monitoring may be appropriate in some cases when a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283817/", "reference_text": "[1] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):", "alternatives_a": "Dacomitinib, Tepotinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, More", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 243652, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283825/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243653, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283827/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243654, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Darbepoetin alfa", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established.", "source": "DDInter", "management_text": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "mechanism_text": "Others", "recommendation": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283829/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Luspatercept, Daprodustat", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 243655, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Erythropoietin", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established.", "source": "DDInter", "management_text": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "mechanism_text": "Others", "recommendation": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283830/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Luspatercept, Daprodustat", "alternatives_b": "Tositumomab, Iodide I-131", "updated_at": 1767369485}, {"id": 243656, "ingredient1": "Idarubicin", "ingredient2": "Ibritumomab tiuxetan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283837/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Ixabepilone, Valrubicin", "updated_at": 1767369485}, {"id": 243657, "ingredient1": "Ifosfamide", "ingredient2": "Ibritumomab tiuxetan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283838/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243658, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Ibritumomab tiuxetan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283842/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243659, "ingredient1": "Interferon alfa-2b", "ingredient2": "Ibritumomab tiuxetan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283843/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Interferon alfa-n1, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "updated_at": 1767369485}, {"id": 243660, "ingredient1": "Isatuximab", "ingredient2": "Ibritumomab tiuxetan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283844/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 243661, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Mechlorethamine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283849/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243662, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283850/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243663, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Mercaptopurine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283852/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, More", "updated_at": 1767369485}, {"id": 243664, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283853/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Ixabepilone, Valrubicin", "updated_at": 1767369485}, {"id": 243665, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Oprelvekin", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established.", "source": "DDInter", "management_text": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "mechanism_text": "Others", "recommendation": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283855/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Interferon alfa-n1, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "updated_at": 1767369485}, {"id": 243666, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Peginesatide", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established.", "source": "DDInter", "management_text": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "mechanism_text": "Others", "recommendation": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283856/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Luspatercept, Daprodustat", "updated_at": 1767369485}, {"id": 243667, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Pentostatin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283857/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "updated_at": 1767369485}, {"id": 243668, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Romiplostim", "severity": "Moderate", "effect": "The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established.", "source": "DDInter", "management_text": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "mechanism_text": "Others", "recommendation": "Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283868/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Fostamatinib, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 243669, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283891/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "updated_at": 1767369485}, {"id": 243670, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283892/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Tositumomab, Iodide I-131", "alternatives_b": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "updated_at": 1767369485}, {"id": 243671, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283893/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Iodide I-131", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243672, "ingredient1": "Ibrutinib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283895/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243673, "ingredient1": "Ibrutinib", "ingredient2": "Dextran (-1)", "severity": "Major", "effect": "Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.  Close clinical and laboratory observation for bleeding complications is recommended during therapy.  The INR should be monitored more frequently during coadministration of warfarin.  In addition, some authorities recommend avoiding the use of supplements that have an inhibitory effect on platelet function such as fish oil (omega-3 polyunsaturated fatty acids), flaxseed, and vitamin E preparations (AU, CA, UK) because of an increased risk of bleeding.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283897/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[3] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243674, "ingredient1": "Ibrutinib", "ingredient2": "Dextran (high molecular weight)", "severity": "Major", "effect": "Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.  Close clinical and laboratory observation for bleeding complications is recommended during therapy.  The INR should be monitored more frequently during coadministration of warfarin.  In addition, some authorities recommend avoiding the use of supplements that have an inhibitory effect on platelet function such as fish oil (omega-3 polyunsaturated fatty acids), flaxseed, and vitamin E preparations (AU, CA, UK) because of an increased risk of bleeding.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283898/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[3] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243675, "ingredient1": "Ibrutinib", "ingredient2": "Dextran (low molecular weight)", "severity": "Major", "effect": "Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.  Close clinical and laboratory observation for bleeding complications is recommended during therapy.  The INR should be monitored more frequently during coadministration of warfarin.  In addition, some authorities recommend avoiding the use of supplements that have an inhibitory effect on platelet function such as fish oil (omega-3 polyunsaturated fatty acids), flaxseed, and vitamin E preparations (AU, CA, UK) because of an increased risk of bleeding.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283899/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[3] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243676, "ingredient1": "Ibrutinib", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.  Dosage reduction in accordance with ibrutinib product labeling may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283926/", "reference_text": "[1] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc  (2013):[2] \"Product Information. Qelbree (viloxazine).\" Supernus Pharmaceuticals Inc  (2021):", "alternatives_a": "Regorafenib, Copanlisib, Abemaciclib, Erlotinib, Dabrafenib, Trametinib, Nintedanib, Dacomitinib, Alectinib", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 243677, "ingredient1": "Ibrutinib", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283950/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243678, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Ponatinib", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/283953/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243679, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284005/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243680, "ingredient1": "Idarubicin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284006/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243681, "ingredient1": "Idarubicin", "ingredient2": "Bevacizumab", "severity": "Major", "effect": "Coadministration of bevacizumab and anthracyclines may increase the risk of cardiac dysfunction.  Bevacizumab and anthracyclines are individually cardiotoxic and may have additive effects during coadministration.", "source": "DDInter", "management_text": "Bevacizumab is not indicated for use with anthracycline-based chemotherapy.  Some authorities recommend avoiding bevacizumab during and for at least 12 months after stopping anthracycline-containing treatment.", "mechanism_text": "Synergism", "recommendation": "Bevacizumab is not indicated for use with anthracycline-based chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284007/", "reference_text": "[1] \"Product Information. Avastin (bevacizumab).\" Genentech  (2004):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, More", "alternatives_b": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 243682, "ingredient1": "Idarubicin", "ingredient2": "Melphalan flufenamide", "severity": "Minor", "effect": "Limited anecdotal data suggest an increased risk of doxorubicin-induced cardiomyopathy in patients who have previously received melphalan.", "source": "DDInter", "management_text": "Limited anecdotal data suggest an increased risk of doxorubicin-induced cardiomyopathy in patients who have previously received melphalan.  The mechanism of this suspected interaction is unknown.   Although conclusive proof that melphalan sensitizes the myocardium is lacking, anthracyclines should be administered cautiously to patients who have had extensive melphalan therapy.", "mechanism_text": "Synergism", "recommendation": "Limited anecdotal data suggest an increased risk of doxorubicin-induced cardiomyopathy in patients who have previously received melphalan.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284022/", "reference_text": "[1] Bitran JD \"Doxorubicin cardiotoxicity and melphalan\" Ann Intern Med 95 (1981):  243-4", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243683, "ingredient1": "Idarubicin", "ingredient2": "Pyrophosphoric acid", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284035/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243684, "ingredient1": "Idarubicin", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284060/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243685, "ingredient1": "Idelalisib", "ingredient2": "Axicabtagene ciloleucel", "severity": "Moderate", "effect": "The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.", "source": "DDInter", "management_text": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.  Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.  Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.  Patients should be advised to contact their physician immediately if the number of bowel movements per day increases by six or more, and to promptly report any new or worsening abdominal pain, chills, fever, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284062/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences  (2014):", "alternatives_a": "Hydroxyurea, Cisplatin, Porfimer sodium, Estramustine, Aminolevulinic acid, Procarbazine, Altretamine, Anagrelide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 243686, "ingredient1": "Idelalisib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284063/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243687, "ingredient1": "Idelalisib", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284131/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243688, "ingredient1": "Tildrakizumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284144/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243689, "ingredient1": "Tildrakizumab", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284158/", "reference_text": "[1] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[4] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[5] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[6] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[7] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[9] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 243690, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Tildrakizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284193/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243691, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Etidocaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284197/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243692, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284198/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243693, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Procaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284199/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 243694, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Pyrophosphoric acid", "severity": "Moderate", "effect": "Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.", "source": "DDInter", "management_text": "Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of the possibility of a diagnostic interference.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284201/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Pyrophosphate (pyrophosphate).\" Pharmalucence Inc  (2012):", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243695, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284202/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243696, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Silver nitrate (topical)", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284203/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243697, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Silver sulfadiazine (topical)", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284204/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243698, "ingredient1": "Imipramine", "ingredient2": "Botulinum toxin type A", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284218/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 243699, "ingredient1": "Imipramine", "ingredient2": "Botulinum toxin type B", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284223/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243700, "ingredient1": "Imipramine", "ingredient2": "Rizatriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284224/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Viloxazine, Esketamine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243701, "ingredient1": "Talimogene laherparepvec", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus.  Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284230/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA  (2015):", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243702, "ingredient1": "Acrivastine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284292/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 243703, "ingredient1": "Azatadine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284294/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Entacapone, Cabergoline", "updated_at": 1767369485}, {"id": 243704, "ingredient1": "Butalbital", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284295/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243705, "ingredient1": "Pentoxyverine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284297/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Amantadine, Cabergoline", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 243706, "ingredient1": "Chloral hydrate", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284298/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243707, "ingredient1": "Chlorcyclizine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284299/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 243708, "ingredient1": "Chlormezanone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284300/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243709, "ingredient1": "Chlorphenesin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284301/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243710, "ingredient1": "Cyclizine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284302/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 243711, "ingredient1": "Dezocine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284303/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243712, "ingredient1": "Ethotoin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284305/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243713, "ingredient1": "Diamorphine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284306/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243714, "ingredient1": "Levodopa", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284308/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243715, "ingredient1": "Melatonin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284309/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243716, "ingredient1": "Mephenytoin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284310/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243717, "ingredient1": "Methylphenobarbital", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284311/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243718, "ingredient1": "Meprobamate", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284312/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243719, "ingredient1": "Metaxalone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284313/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243720, "ingredient1": "Methocarbamol", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284314/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243721, "ingredient1": "Mirtazapine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284316/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 243722, "ingredient1": "Nalbuphine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284321/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Safinamide, Amantadine, Cabergoline", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 243723, "ingredient1": "Oliceridine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284322/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 243724, "ingredient1": "Opium", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284323/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 243725, "ingredient1": "Oxymorphone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284324/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 243726, "ingredient1": "Paraldehyde", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284325/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243727, "ingredient1": "Paramethadione", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284326/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243728, "ingredient1": "Pentobarbital", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284327/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243729, "ingredient1": "Perampanel", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284328/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243730, "ingredient1": "Pergolide", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284329/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Pergolide", "alternatives_b": "Levodopa, Amantadine, Rotigotine, Cabergoline", "updated_at": 1767369485}, {"id": 243731, "ingredient1": "Phenacemide", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284330/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243732, "ingredient1": "Phenindamine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284331/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 243733, "ingredient1": "Phensuximide", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284332/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243734, "ingredient1": "Primidone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284333/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone, Lacosamide", "updated_at": 1767369485}, {"id": 243735, "ingredient1": "Mepyramine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284334/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cabergoline", "alternatives_b": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 243736, "ingredient1": "Ramelteon", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284335/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243737, "ingredient1": "Remifentanil", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284338/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 243738, "ingredient1": "Ropinirole", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284339/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole", "alternatives_b": "Levodopa, Amantadine, Rotigotine, Cabergoline", "updated_at": 1767369485}, {"id": 243739, "ingredient1": "Sibutramine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284340/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Bromocriptine, Pramipexole, Amantadine", "alternatives_b": "Dexfenfluramine, Naltrexone, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 243740, "ingredient1": "Thiopental", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284341/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Ropinirole, Cabergoline", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243741, "ingredient1": "Tripelennamine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284342/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cabergoline", "alternatives_b": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "updated_at": 1767369485}, {"id": 243742, "ingredient1": "Triprolidine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284343/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cabergoline", "alternatives_b": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 243743, "ingredient1": "Valbenazine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284344/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 243744, "ingredient1": "Valerian", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284345/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243745, "ingredient1": "Vigabatrin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284346/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 243746, "ingredient1": "Anisindione", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.", "source": "DDInter", "management_text": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "mechanism_text": "Others", "recommendation": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284347/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[5] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[6] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):[7] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals  (2013):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243747, "ingredient1": "Bepridil", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitor, telaprevir, may significantly increase the plasma concentrations of certain antiarrhythmic agents such as amiodarone, bepridil, disopyramide, and quinidine.  The mechanism involves inhibition of CYP450 3A4 metabolism, as telaprevir is a potent inhibitor.", "source": "DDInter", "management_text": "Caution is advised if telaprevir must be used with antiarrhythmic agents that are primarily metabolized by CYP450 3A4.  Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever the HCV NS3/4A protease inhibitor is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if telaprevir must be used with antiarrhythmic agents that are primarily metabolized by CYP450 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284348/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243748, "ingredient1": "Cerivastatin", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including telaprevir may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors and their pharmacologically active metabolites that are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for severe interaction, concomitant use of atorvastatin, lovastatin, or simvastatin with telaprevir is considered contraindicated.  Red yeast rice, which contains lovastatin, should also be avoided during treatment with telaprevir.  Fluvastatin, pravastatin, and pitavastatin may be safer alternatives, since they are not metabolized by CYP450 3A4.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for severe interaction, concomitant use of atorvastatin, lovastatin, or simvastatin with telaprevir is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284350/", "reference_text": "[1] Spach DH, Bauwens JE, Clark CD, Burke WG \"Rhabdomyolysis associated with lovastatin and erythromycin use.\" West J Med 154 (1991):  213-5[2] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988):  682-3[3] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988):  239-41[4] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988):  47-8[5] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995):  664-5[6] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996):  54-61[7] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996):  1254[8] Jacobson RH, Wang P, Glueck CJ \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997):  296[9] Jody DN \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997):  296-7[10] Grunden JW, Fisher KA \"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.\" Ann Pharmacother 31 (1997):  859-63[11] Wong PW, Dillard TA, Kroenke K \"Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy.\" South Med J 91 (1998):  202-5[12] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998):  332-41[13] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998):  49-53[14] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998):  58-65[15] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999):  851-5[16] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA \"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.\" Am J Cardiol 84 (1999):  811-5[17] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999):  295-7[18] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000):  41-57[19] Lee AJ, Maddix DS \"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\" Ann Pharmacother 35 (2001):  26-31[20] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F \"New insights into the pharmacodynamic and pharmacokinetic properties of statins.\" Pharmacol Ther 84 (1999):  413-28[21] Garnett WR \"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.\" Am J Health Syst Pharm 52 (1995):  1639-45[22] Omar MA, Wilson JP \"FDA adverse event reports on statin-associated rhabdomyolysis.\" Ann Pharmacother 36 (2002):  288-95[23] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. \"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.\" AIDS 16 (2002):  569-577[24] Piliero PJ \"Interaction between ritonavir and statins.\" Am J Med 112 (2002):  510-1[25] Cheng CH, Miller C, Lowe C, Pearson VE \"Rhabdomyolysis due to probable interaction between simvastatin and ritonavir.\" Am J Health Syst Pharm 59 (2002):  728-30[26] Williams D, Feely J \"Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors.\" Clin Pharmacokinet 41 (2002):  343-70[27] Thompson M, Samuels S \"Rhabdomyolysis with simvastatin and nefazodone.\" Am J Psychiatry 159 (2002):  1607[28] Huynh T, Cordato D, Yang F, et al. \"HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions.\" Intern Med J 32(9-10) (2002):  486-90[29] Hare CB, Vu MP, Grunfeld C, Lampiris HW \"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.\" Clin Infect Dis 35 (2002):  E111-2[30] Itakura H, Vaughn D, Haller DG, O'Dwyer PJ \"Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.\" J Urol 169 (2003):  613[31] Paoletti R, Corsini A, Bellosta S \"Pharmacological interactions of statins.\" Atheroscler Suppl 3 (2002):  35-40[32] Sipe BE, Jones RJ, Bokhart GH \"Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction.\" Ann Pharmacother 37 (2003):  808-11[33] Skrabal MZ, Stading JA, Monaghan MS \"Rhabdomyolysis associated with simvastatin-nefazodone therapy.\" South Med J 96 (2003):  1034-5[34] Jacobson TA \"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\" Am J Cardiol 94 (2004):  1140-6[35] Chouhan UM, Chakrabarti S, Millward LJ \"Simvastatin interaction with clarithromycin and amiodarone causing myositis.\" Ann Pharmacother 39 (2005):  1760-1[36] Karnik NS, Maldonado JR \"Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis.\" Psychosomatics 46 (2005):  565-8[37] Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y \"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\" J Am Board Fam Med 20 (2007):  411-6[38] Stein CA, Goel S, Ghavamian R \"Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.\" Invest New Drugs 25 (2007):  277-8[39] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008):  463-74[40] Watkins JL, Atkinson BJ, Pagliaro LC \"Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin:  case report and review of the literature.\" Ann Pharmacother 45 (2011):  e9[41] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 243749, "ingredient1": "Cisapride", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of cisapride.  The mechanism is PI inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of cisapride.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, concomitant use with protease inhibitors is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, concomitant use with protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284352/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995):  765-8[3] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[4] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[5] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996):  279-81[6] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[7] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[8] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998):  1053-6[9] Gray VS \"Syncopal episodes associated with cisapride and concurrent drugs.\" Ann Pharmacother 32 (1998):  648-51[10] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999):  147-69[11] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000):  41-57[13] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000):  789-800[14] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[15] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[16] Gill J, Feinberg J \"Saquinavir soft gelatin capsule - A comparative safety review.\" Drug Safety 24 (2001):  223-32[17] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001):  1352-63[18] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[19] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[20] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[21] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[22] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Metoclopramide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 243750, "ingredient1": "Dexamethasone (nasal)", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme.  The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations.  Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy.  Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.  Some authorities advise against concomitant use unless the potential benefit outweighs the risk.  If the combination is considered necessary, a lower dosage of the corticosteroid may be required.  When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required.  Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders.  Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents.  Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.  Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma).", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284353/", "reference_text": "[1] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989):  366-72[2] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991):  558-70[3] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992):  487-90[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987):  465-70[5] Glynn AM, Slaughter RL, Brass C, et al. \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986):  654-9[6] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970):  146-62[7] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983):  34-9[8] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998):  325-6[9] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998):  363-8[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999):  1803[11] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000):  57-60[12] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000):  215-21[13] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000):  1826-7[14] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001):  443-50[15] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001):  109-12[16] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002):  E69-71[17] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002):  362-369[18] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002):  1008-11[19] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002):  127-33[20] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003):  652-6[21] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004):  46-9[22] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004):  803-21[23] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005):  4394-8[24] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005):  67-8[25] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005):  573-80[26] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[27] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007):  1306-9[28] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008):  561-6[29] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 243751, "ingredient1": "Dicoumarol", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.", "source": "DDInter", "management_text": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "mechanism_text": "Others", "recommendation": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284354/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[5] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[6] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):[7] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals  (2013):", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, Cobicistat, More", "updated_at": 1767369485}, {"id": 243752, "ingredient1": "Dienestrol (topical)", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with telaprevir may increase the plasma concentrations of drugs that are metabolized by CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telaprevir.", "source": "DDInter", "management_text": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telaprevir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284355/", "reference_text": "[1] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243753, "ingredient1": "Ergometrine", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of ergot derivatives.  The mechanism is PI inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs.", "source": "DDInter", "management_text": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with protease inhibitors is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284356/", "reference_text": "[1] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[2] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[3] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[4] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[5] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals  (2001):[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999):  987[7] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999):  771[8] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[9] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997):  1207[10] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[11] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001):  105-18[12] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001):  743-4[13] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001):  1352-63[14] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001):  788-9[15] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999):  329[16] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999):  771[17] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001):  594[18] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999):  546-7[19] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003):  676-8[20] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002):  694-5[21] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[22] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[23] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals  (2004):[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[26] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[27] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[28] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):[29] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila)  (2014):  1-4", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 243754, "ingredient1": "Estrone", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with telaprevir may increase the plasma concentrations of drugs that are metabolized by CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telaprevir.", "source": "DDInter", "management_text": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telaprevir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284357/", "reference_text": "[1] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Diethylstilbestrol, Bazedoxifene", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 243755, "ingredient1": "Telaprevir", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil).  Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine).  Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284359/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine).\" Organon  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 243756, "ingredient1": "Telaprevir", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and duration of action of levomethadyl acetate, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284360/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate).\" Roxane Laboratories Inc  (2001):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 243757, "ingredient1": "Telaprevir", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.  Close clinical monitoring of the virologic response to the HCV NS3/4A protease inhibitor is recommended.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284365/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "Lamivudine, Paritaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 243758, "ingredient1": "Telaprevir", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "Coadministration with telaprevir may increase the plasma concentrations of drugs that are metabolized by CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telaprevir.", "source": "DDInter", "management_text": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telaprevir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284366/", "reference_text": "[1] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243759, "ingredient1": "Telaprevir", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally.  Relugolix is a substrate for intestinal P-gp.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided.  If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours.  Patients should be monitored more frequently for adverse effects.  Alternatively, when relugolix is used as monotherapy for the treatment of prostate cancer, the prescribing information states that treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.  Following interruption of relugolix for more than 7 days, the manufacturer recommends restarting therapy with a loading dose of 360 mg on the first day, then continuing with a dose of 120 mg once daily.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284368/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Tamoxifen, Anastrozole, Fulvestrant, Abarelix, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 243760, "ingredient1": "Telaprevir", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.  Close clinical monitoring of the virologic response to the HCV NS3/4A protease inhibitor is recommended.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284369/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 243761, "ingredient1": "Testosterone (topical)", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with telaprevir may increase the plasma concentrations of drugs that are metabolized by CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telaprevir.", "source": "DDInter", "management_text": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telaprevir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if telaprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284372/", "reference_text": "[1] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone", "updated_at": 1767369485}, {"id": 243762, "ingredient1": "Troglitazone", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, which are metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.  Close clinical monitoring of the virologic response to the HCV NS3/4A protease inhibitor is recommended.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284373/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Cobicistat, Acyclovir, Brincidofovir, Stavudine, Famciclovir, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "updated_at": 1767369485}, {"id": 243763, "ingredient1": "Troleandomycin", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration of a macrolide or ketolide antibiotic (clarithromycin, erythromycin, telithromycin) with a hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) is expected to increase the plasma concentrations of both drugs.  The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284374/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 243764, "ingredient1": "Inebilizumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284404/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243765, "ingredient1": "Inebilizumab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284451/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243766, "ingredient1": "Acrivastine", "ingredient2": "Valbenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284515/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine", "alternatives_b": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 243767, "ingredient1": "Valbenazine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284518/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 243768, "ingredient1": "Anisindione", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.  If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits.  Close clinical and laboratory observation for bleeding complications is recommended.  Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.  The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284529/", "reference_text": "[1] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[2] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[3] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[4] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[5] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[6] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):[7] \"Product Information. Arixtra (fondaparinux).\" Organon  (2002):", "alternatives_a": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243769, "ingredient1": "Anistreplase", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.  If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits.  Close clinical and laboratory observation for bleeding complications is recommended.  Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.  The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284530/", "reference_text": "[1] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[2] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[3] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[4] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[5] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[6] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):[7] \"Product Information. Arixtra (fondaparinux).\" Organon  (2002):", "alternatives_a": "Tinzaparin, Acenocoumarol, Selexipag", "alternatives_b": "Alteplase, Dicoumarol, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "updated_at": 1767369485}, {"id": 243770, "ingredient1": "Bromfenac", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs).  The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.  Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.", "mechanism_text": "Synergism", "recommendation": "Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284531/", "reference_text": "[1] Bang CJ, Riedel B, Talstad I, Berstad A \"Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans.\" Scand J Gastroenterol 27 (1992):  489-94[2] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[3] Walker AM \"Predictors of bleeding during heparin therapy.\" JAMA 244 (1980):  1209-12[4] Heiden D, Rodvien R, Mielke CH \"Heparin bleeding, platelet dysfunction, and aspirin.\" JAMA 246 (1981):  330-1[5] Theroux P, Ouimet H, McCans J, et al. \"Aspirin, heparin, or both to treat acute unstable angina.\" N Engl J Med 319 (1988):  1105-6[6] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[7] Weale AE, Warwick DJ, Durant N, Prothero D \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  35-7[8] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[9] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[10] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[11] Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S \"Interaction between the LMWH reviparin and aspirin in healthy volunteers.\" Br J Clin Pharmacol 49 (2000):  337-41[12] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "alternatives_b": "Abciximab, Tirofiban, Dicoumarol, Eptifibatide, Protein C, Acenocoumarol, Selexipag, Anistreplase", "updated_at": 1767369485}, {"id": 243771, "ingredient1": "Dexfenfluramine", "ingredient2": "Tinzaparin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors may potentiate the risk of bleeding in patients receiving heparin therapy.  The exact mechanism is unknown but may involve a pharmacodynamic interaction, as serotonin reuptake inhibitors have been reported to interfere with platelet function.", "source": "DDInter", "management_text": "Caution is recommended if a serotonin reuptake inhibitor is administered with heparin therapy, especially in the elderly and patients with renal impairment.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if a serotonin reuptake inhibitor is administered with heparin therapy, especially in the elderly and patients with renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284532/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[3] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[4] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[5] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[6] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[7] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[9] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[10] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[11] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[12] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[13] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[14] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[15] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[16] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[18] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[19] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[20] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[21] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[22] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[23] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[24] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[25] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[26] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[27] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Dicoumarol, Protein C, Acenocoumarol, Selexipag, Anistreplase", "updated_at": 1767369485}, {"id": 243772, "ingredient1": "Dextran (-1)", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.  If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits.  Close clinical and laboratory observation for bleeding complications is recommended.  Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.  The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284533/", "reference_text": "[1] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[2] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[3] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[4] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[5] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[6] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):[7] \"Product Information. Arixtra (fondaparinux).\" Organon  (2002):", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Argatroban, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243773, "ingredient1": "Dicoumarol", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.  If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits.  Close clinical and laboratory observation for bleeding complications is recommended.  Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.  The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284534/", "reference_text": "[1] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[2] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[3] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[4] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[5] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[6] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):[7] \"Product Information. Arixtra (fondaparinux).\" Organon  (2002):", "alternatives_a": "Tinzaparin, Acenocoumarol, Selexipag", "alternatives_b": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase", "updated_at": 1767369485}, {"id": 243774, "ingredient1": "Tinzaparin", "ingredient2": "Phenylbutazone", "severity": "Major", "effect": "In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs).  The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.  Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.", "mechanism_text": "Synergism", "recommendation": "Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284537/", "reference_text": "[1] Bang CJ, Riedel B, Talstad I, Berstad A \"Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans.\" Scand J Gastroenterol 27 (1992):  489-94[2] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[3] Walker AM \"Predictors of bleeding during heparin therapy.\" JAMA 244 (1980):  1209-12[4] Heiden D, Rodvien R, Mielke CH \"Heparin bleeding, platelet dysfunction, and aspirin.\" JAMA 246 (1981):  330-1[5] Theroux P, Ouimet H, McCans J, et al. \"Aspirin, heparin, or both to treat acute unstable angina.\" N Engl J Med 319 (1988):  1105-6[6] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[7] Weale AE, Warwick DJ, Durant N, Prothero D \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  35-7[8] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[9] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[10] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[11] Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S \"Interaction between the LMWH reviparin and aspirin in healthy volunteers.\" Br J Clin Pharmacol 49 (2000):  337-41[12] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Clopidogrel, Dicoumarol, Protein C, Acenocoumarol, Selexipag, Anistreplase", "updated_at": 1767369485}, {"id": 243775, "ingredient1": "Tinzaparin", "ingredient2": "Plicamycin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.  If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits.  Close clinical and laboratory observation for bleeding complications is recommended.  Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.  The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284539/", "reference_text": "[1] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[2] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[3] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[4] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[5] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[6] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):[7] \"Product Information. Arixtra (fondaparinux).\" Organon  (2002):", "alternatives_a": "Idarubicin, Valrubicin, Ixabepilone, Mitoxantrone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Clopidogrel, Cilostazol, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Desirudin, More", "updated_at": 1767369485}, {"id": 243776, "ingredient1": "Tinzaparin", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.", "source": "DDInter", "management_text": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.  Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.", "mechanism_text": "Synergism", "recommendation": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284540/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Drotrecogin alfa, Selexipag, Desirudin", "updated_at": 1767369485}, {"id": 243777, "ingredient1": "Tositumomab", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.  Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.  A complete blood count (CBC) with differential and platelet count should be obtained prior to and at least weekly for a minimum of 10 weeks after treatment.", "mechanism_text": "Synergism", "recommendation": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284543/", "reference_text": "[1] \"Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab).\" GlaxoSmithKline  (2022):[2] \"Product Information. BexxarTherapy (tositumomab).\" GlaxoSmithKline Inc  (2006):", "alternatives_a": "Dicoumarol, Desirudin, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243778, "ingredient1": "Urokinase", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.  If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits.  Close clinical and laboratory observation for bleeding complications is recommended.  Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.  The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284544/", "reference_text": "[1] \"Product Information. Lovenox (enoxaparin).\" Rhone Poulenc Rorer  (2002):[2] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn  (2001):[3] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995):  395[4] \"Product Information. Orgaran (danaparoid).\" Organon  (2001):[5] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories  (2001):[6] \"Product Information. Innohep (tinzaparin).\" DuPont Pharmaceuticals  (2001):[7] \"Product Information. Arixtra (fondaparinux).\" Organon  (2002):", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Tinzaparin, Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 243779, "ingredient1": "Interferon alfa-2b", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284579/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243780, "ingredient1": "Paliperidone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284589/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Propiomazine, Nitrazepam", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 243781, "ingredient1": "Rifapentine", "ingredient2": "Paliperidone", "severity": "Major", "effect": "Coadministration with dual potent inducers of CYP450 3A4 and P-glycoprotein (P-gp) may decrease the plasma concentrations of paliperidone.  In vitro studies suggest that CYP450 2D6 and 3A4 are involved in paliperidone metabolism.  However, in vivo data indicate that these isoenzymes play a limited role in the overall elimination of paliperidone and contribute to only a small fraction of total body clearance.", "source": "DDInter", "management_text": "When paliperidone is administered orally, the prescribing information recommends re-evaluating the dosage and increasing if necessary following the addition of a dual potent CYP450 3A4 and P-gp inducer.  For patients receiving extended-release injectable formulations of paliperidone, concomitant use of potent inducers should be avoided.  If coadministration is required, consideration should be given to use of oral extended-release paliperidone.  Changes in efficacy and safety should be carefully monitored with any dosage adjustment.  Upon discontinuation of the inducer, paliperidone dosage should be reassessed and readjusted accordingly based on clinical response.  The prescribing information for individual paliperidone products should be consulted for specific recommendations regarding concomitant use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "When paliperidone is administered orally, the prescribing information recommends re-evaluating the dosage and increasing if necessary following the addition of a dual potent CYP450 3A4 and P-gp inducer.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284593/", "reference_text": "[1] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2022):[2] \"Product Information. Invega Hafyera (paliperidone).\" Janssen Pharmaceuticals  (2021):[3] \"Product Information. Invega Sustenna (paliperidone).\" Janssen Pharmaceuticals  (2022):[4] \"Product Information. Invega Trinza (paliperidone).\" Janssen Pharmaceuticals  (2022):[5] Helland A, Spigset O \"Serum concentrations of paliperidone after administration of the long-acting injectable formulation.\" Ther Drug Monit 39 (2017):  659-62", "alternatives_a": "Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Prochlorperazine, Asenapine, Thiothixene, Thioridazine, Clozapine, Perphenazine, More", "alternatives_b": "Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 243782, "ingredient1": "Iodixanol", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.  Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity.  Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered.  Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy.  Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium.  It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284609/", "reference_text": "[1] \"Product Information. Lasix (furosemide).\" sanofi-aventis  (2007):[2] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992):  413-5[3] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994):  1416-20[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12[5] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999):  403-11[6] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006):  379-86[7] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006):  S30-S38[8] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006):  1799-806[9] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006):  2060-80[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006):  59-77[11] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006):  420[12] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008):  284-94[13] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008):  S166-71[14] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008):  310-20[15] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008):  1140-50", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 243783, "ingredient1": "Iodixanol", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.  Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity.  Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered.  Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy.  Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium.  It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284610/", "reference_text": "[1] \"Product Information. Lasix (furosemide).\" sanofi-aventis  (2007):[2] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992):  413-5[3] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994):  1416-20[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12[5] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999):  403-11[6] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006):  379-86[7] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006):  S30-S38[8] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006):  1799-806[9] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006):  2060-80[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006):  59-77[11] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006):  420[12] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008):  284-94[13] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008):  S166-71[14] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008):  310-20[15] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008):  1140-50", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "alternatives_b": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "updated_at": 1767369485}, {"id": 243784, "ingredient1": "Iodixanol", "ingredient2": "Bromfenac", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284611/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "alternatives_b": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "updated_at": 1767369485}, {"id": 243785, "ingredient1": "Iodixanol", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284612/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, More", "alternatives_b": "Iodipamide, Iodamide, Tyropanoic acid, Iopanoic acid, Iopodic acid, Metrizamide", "updated_at": 1767369485}, {"id": 243786, "ingredient1": "Iopanoic acid", "ingredient2": "Iodixanol", "severity": "Moderate", "effect": "Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Synergism", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284613/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Omniscan (gadodiamide).\" Novation  (2004):", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, Iopamidol, More", "updated_at": 1767369485}, {"id": 243787, "ingredient1": "Iodixanol", "ingredient2": "Iopodic acid", "severity": "Moderate", "effect": "Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Synergism", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284614/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Omniscan (gadodiamide).\" Novation  (2004):", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, Iopamidol, More", "updated_at": 1767369485}, {"id": 243788, "ingredient1": "Iodixanol", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284615/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243789, "ingredient1": "Iodixanol", "ingredient2": "Methoxyflurane", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284616/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Salicylic acid, Choline salicylate, Ziconotide", "updated_at": 1767369485}, {"id": 243790, "ingredient1": "Iodixanol", "ingredient2": "Netilmicin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284617/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 243791, "ingredient1": "Iodixanol", "ingredient2": "Phenylbutazone", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284618/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243792, "ingredient1": "Iodixanol", "ingredient2": "Rofecoxib", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284619/", "reference_text": "[1] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA \"Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview\"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008):  2001", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 243793, "ingredient1": "Iodixanol", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.  Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity.  Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered.  Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy.  Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium.  It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284622/", "reference_text": "[1] \"Product Information. Lasix (furosemide).\" sanofi-aventis  (2007):[2] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992):  413-5[3] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994):  1416-20[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12[5] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999):  403-11[6] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006):  379-86[7] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006):  S30-S38[8] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006):  1799-806[9] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006):  2060-80[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006):  59-77[11] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006):  420[12] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008):  284-94[13] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008):  S166-71[14] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008):  310-20[15] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008):  1140-50", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 243794, "ingredient1": "Iodixanol", "ingredient2": "Tyropanoic acid", "severity": "Moderate", "effect": "Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Synergism", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284623/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex Laboratories  (2001):[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc  (2001):[3] \"Product Information. Omniscan (gadodiamide).\" Novation  (2004):", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, Iopamidol, More", "updated_at": 1767369485}, {"id": 243795, "ingredient1": "Irinotecan", "ingredient2": "Pegloticase", "severity": "Moderate", "effect": "Antibodies that develop during pegloticase therapy may theoretically affect the pharmacologic effects of other pegylated agents.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for diminished effects of other pegylated agents (including certain formulations of recombinant antihemophilic factor and coagulation factor IX as well as some liposomal formulations of chemotherapeutic agents such as doxorubicin and irinotecan) following treatment with pegloticase.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for diminished effects of other pegylated agents (including certain formulations of recombinant antihemophilic factor and coagulation factor IX as well as some liposomal formulations of chemotherapeutic agents such as doxorubicin and irinotecan) following treatment with pegloticase.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284737/", "reference_text": "[1] \"Product Information. Krystexxa (pegloticase).\" Savient Pharmaceuticals  (2010):", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Lesinurad, Febuxostat, Colchicine, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 243796, "ingredient1": "Irinotecan", "ingredient2": "Pegvaliase", "severity": "Moderate", "effect": "Coadministration of pegvaliase with other PEGylated products may increase the risk of hypersensitivity reactions, including anaphylaxis.", "source": "DDInter", "management_text": "Close monitoring for anaphylaxis and other hypersensitivity reactions is recommended during concomitant use of pegvaliase with other PEGylated products or products that contain polyethylene glycol (e.g., certolizumab pegol; doxorubicin liposomal; eflapegrastim; epoetin beta-methoxy polyethylene glycol; irinotecan liposomal; medroxyprogesterone acetate suspension; naloxegol; pegademase bovine; pegaptanib; pegaspargase; pegfilgrastim; peginesatide; peginterferons; pegloticase; pegvisomant; certain formulations of recombinant antihemophilic factor and coagulation factor IX).", "mechanism_text": "Synergism", "recommendation": "Close monitoring for anaphylaxis and other hypersensitivity reactions is recommended during concomitant use of pegvaliase with other PEGylated products or products that contain polyethylene glycol (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284738/", "reference_text": "[1] \"Product Information. Palynziq (pegvaliase).\" BioMarin Pharmaceutical Inc  (2018):", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 243797, "ingredient1": "Isatuximab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284740/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243798, "ingredient1": "Isatuximab", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284753/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 243799, "ingredient1": "Isatuximab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284787/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243800, "ingredient1": "Isocarboxazid", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284801/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243801, "ingredient1": "Isocarboxazid", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284802/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "alternatives_b": "Tropicamide, Ketorolac", "updated_at": 1767369485}, {"id": 243802, "ingredient1": "Isocarboxazid", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284806/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 243803, "ingredient1": "Bacillus calmette-guerin substrain tice live antigen", "ingredient2": "Natalizumab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284824/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243804, "ingredient1": "Natalizumab", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain caused by John Cunningham Virus (JCV).", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic, or other myelosuppressive agents have not been established.  In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections.  For patients with Crohn's disease who start natalizumab while on chronic corticosteroid therapy, begin steroid withdrawal as soon as a therapeutic benefit is achieved.  Natalizumab should be discontinued if patient is unable to stop using systemic corticosteroids within six months.  All patients treated with natalizumab should be monitored closely during and for at least six months following discontinuation of treatment.  The drug should be discontinued immediately at the first sign or symptom suggestive of PML, although it is not known if early detection of PML and discontinuation of natalizumab will mitigate the disease.  Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.  Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic, or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284838/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc  (2004):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243805, "ingredient1": "Promazine", "ingredient2": "Natalizumab", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain caused by John Cunningham Virus (JCV).", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic, or other myelosuppressive agents have not been established.  In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections.  For patients with Crohn's disease who start natalizumab while on chronic corticosteroid therapy, begin steroid withdrawal as soon as a therapeutic benefit is achieved.  Natalizumab should be discontinued if patient is unable to stop using systemic corticosteroids within six months.  All patients treated with natalizumab should be monitored closely during and for at least six months following discontinuation of treatment.  The drug should be discontinued immediately at the first sign or symptom suggestive of PML, although it is not known if early detection of PML and discontinuation of natalizumab will mitigate the disease.  Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.  Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic, or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284849/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc  (2004):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 243806, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Natalizumab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284874/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243807, "ingredient1": "Remifentanil", "ingredient2": "Oxitriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284875/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Viloxazine", "alternatives_b": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More", "updated_at": 1767369485}, {"id": 243808, "ingredient1": "Acrivastine", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284877/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 243809, "ingredient1": "Remifentanil", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284881/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 243810, "ingredient1": "Rizatriptan", "ingredient2": "Remifentanil", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284884/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 243811, "ingredient1": "Upadacitinib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284886/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243812, "ingredient1": "Dexrazoxane", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.  Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling.  Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination.  If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284889/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2019):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, More", "updated_at": 1767369485}, {"id": 243813, "ingredient1": "Upadacitinib", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.  Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling.  Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination.  If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284901/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243814, "ingredient1": "Upadacitinib", "ingredient2": "Promazine", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.  Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling.  Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination.  If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284914/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2019):", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 243815, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284943/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243816, "ingredient1": "Rifapentine", "ingredient2": "Nintedanib", "severity": "Major", "effect": "Coadministration with inducers of P-glycoprotein (P-gp) and CYP450 3A4 may decrease the plasma concentrations of nintedanib, which is a substrate of the efflux transporter and a minor substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of nintedanib with P-gp and CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of nintedanib with P-gp and CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284973/", "reference_text": "[1] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Alectinib, Lenvatinib, Trametinib, Dacomitinib", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "updated_at": 1767369485}, {"id": 243817, "ingredient1": "Rifapentine", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284975/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "updated_at": 1767369485}, {"id": 243818, "ingredient1": "Etidocaine", "ingredient2": "Primaquine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284982/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243819, "ingredient1": "Primaquine", "ingredient2": "Procaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284984/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil", "alternatives_b": "Meloxicam, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 243820, "ingredient1": "Ropivacaine", "ingredient2": "Primaquine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284987/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 243821, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Primaquine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284988/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243822, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Primaquine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284989/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243823, "ingredient1": "Tolazoline", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284990/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More", "updated_at": 1767369485}, {"id": 243824, "ingredient1": "Tolazoline", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284991/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More", "updated_at": 1767369485}, {"id": 243825, "ingredient1": "Tolazoline", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284994/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More", "updated_at": 1767369485}, {"id": 243826, "ingredient1": "Tolazoline", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284995/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More", "updated_at": 1767369485}, {"id": 243827, "ingredient1": "Triflupromazine", "ingredient2": "Tolazoline", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284998/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 243828, "ingredient1": "Alimemazine", "ingredient2": "Tolazoline", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/284999/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More", "updated_at": 1767369485}, {"id": 243829, "ingredient1": "Deserpidine", "ingredient2": "Naphazoline (nasal)", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285002/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine, Methyldopa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243830, "ingredient1": "Ergometrine", "ingredient2": "Naphazoline (nasal)", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors.  Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.  If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly.  Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285003/", "reference_text": "[1] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977):  55-6[2] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  63-9[3] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[4] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[5] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation  (2001):[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003):  92-4", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243831, "ingredient1": "Isoetharine", "ingredient2": "Naphazoline (nasal)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285004/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243832, "ingredient1": "Ritodrine", "ingredient2": "Naphazoline (nasal)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285006/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243833, "ingredient1": "Botulinum toxin type A", "ingredient2": "Propantheline", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285008/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 243834, "ingredient1": "Botulinum toxin type B", "ingredient2": "Propantheline", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285009/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243835, "ingredient1": "Abarelix", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285010/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243836, "ingredient1": "Probucol", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285011/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243837, "ingredient1": "Bepridil", "ingredient2": "Probucol", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.  Caution and clinical monitoring are recommended if concomitant use is required.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285012/", "reference_text": "[1] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories  (2002):[2] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical  (2002):[3] \"Product Information. Procan SR (procainamide).\" Parke-Davis  (2001):[4] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[5] \"Product Information. Betapace (sotalol).\" Berlex Laboratories  (2001):[6] \"Product Information. Norpace (disopyramide).\" Searle  (2001):[7] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000):  509-32[8] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003):  421-38[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):[13] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006):  345-6", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243838, "ingredient1": "Cisapride", "ingredient2": "Probucol", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285014/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Metoclopramide", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Cerivastatin, Lomitapide, Ezetimibe, Niacin, Atorvastatin, More", "updated_at": 1767369485}, {"id": 243839, "ingredient1": "Grepafloxacin", "ingredient2": "Probucol", "severity": "Major", "effect": "Grepafloxacin can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285015/", "reference_text": "[1] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996):  77-81[2] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[3] Lode H, Vogel F, Elies W \"Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance.\" Clin Ther 21 (1999):  61-74[4] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000):  557-9[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Cerivastatin, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More", "updated_at": 1767369485}, {"id": 243840, "ingredient1": "Isoetharine", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285016/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243841, "ingredient1": "Probucol", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Levomethadyl acetate may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285017/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate).\" Roxane Laboratories Inc  (2001):[2] Deamer RL, Wilson DR, Clark DS, Prichard JG \"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).\" J Addict Dis 20 (2001):  7-14[3] Krantz MJ, Mehler PS \"Synthetic opioids and QT prolongation.\" Arch Intern Med 163 (2003):  1615; author reply 1615[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243842, "ingredient1": "Probucol", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285018/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243843, "ingredient1": "Probucol", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285019/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243844, "ingredient1": "Probucol", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285020/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243845, "ingredient1": "Promazine", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285022/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243846, "ingredient1": "Relugolix", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285023/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Ezetimibe, Niacin, Atorvastatin, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 243847, "ingredient1": "Ritodrine", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285024/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243848, "ingredient1": "Triflupromazine", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285025/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243849, "ingredient1": "Alimemazine", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285026/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003):  58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "updated_at": 1767369485}, {"id": 243850, "ingredient1": "Procainamide", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285031/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 243851, "ingredient1": "Propafenone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may substantially increase the plasma concentrations of melatonin.  Data from available studies suggest that melatonin is primarily metabolized by CYP450 1A2, with possible contribution from CYP450 2C19 and 2C9.  Coadministration of fluvoxamine, a potent CYP450 1A2 inhibitor that also inhibits CYP450 2C19 and 2C9, increased melatonin systemic exposure (AUC) by 17-fold and maximum plasma concentration (Cmax) by 12-fold.  Contraceptives containing ethinyl estradiol, which can inhibit CYP450 1A2, may lead to a 4- to 5-fold increase in melatonin concentration.", "source": "DDInter", "management_text": "Caution is advised when melatonin is used concomitantly with CYP450 1A2 inhibitors.  Patients should be monitored closely for adverse effects such as excessive drowsiness, headache, lethargy, dizziness, irritability, nervousness, restlessness, anxiety, abdominal pain, and dyspepsia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when melatonin is used concomitantly with CYP450 1A2 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285039/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Lemborexant, More", "alternatives_b": "Quinidine, Lidocaine, Dronedarone, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 243852, "ingredient1": "Abarelix", "ingredient2": "Cisapride", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285043/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Metoclopramide", "updated_at": 1767369485}, {"id": 243853, "ingredient1": "Anisindione", "ingredient2": "Cisapride", "severity": "Moderate", "effect": "Cisapride may enhance the effects of oral anticoagulants.  The mechanism is unknown.  Increases in coagulation times have been reported following the initiation of cisapride therapy in patients stabilized on anticoagulant therapy.  However, other studies have reported increased warfarin requirements in patients taking cisapride.", "source": "DDInter", "management_text": "It is recommended that the INR or PT be monitored if cisapride is added, cisapride is discontinued, or the dosage is adjusted in a patient receiving anticoagulants.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Others", "recommendation": "It is recommended that the INR or PT be monitored if cisapride is added, cisapride is discontinued, or the dosage is adjusted in a patient receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285044/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[3] Darlington MR \"Hypoprothrombinemia induced by warfarin sodium and cisapride.\" Am J Health Syst Pharm 54 (1997):  320-1", "alternatives_a": "Metoclopramide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243854, "ingredient1": "Cisapride", "ingredient2": "Astemizole", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285045/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Metoclopramide", "updated_at": 1767369485}, {"id": 243855, "ingredient1": "Cisapride", "ingredient2": "Benzthiazide", "severity": "Major", "effect": "Some diuretics may produce hypokalemia and hypomagnesemia which could potentiate the risk of cisapride-induced arrhythmias in patients receiving both drugs concomitantly.", "source": "DDInter", "management_text": "Cisapride is contraindicated in patients with uncorrected hypokalemia and hypomagnesemia, such as those taking potassium-wasting diuretics.", "mechanism_text": "Synergism", "recommendation": "Cisapride is contraindicated in patients with uncorrected hypokalemia and hypomagnesemia, such as those taking potassium-wasting diuretics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285046/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, More", "alternatives_b": "Metoclopramide", "updated_at": 1767369485}, {"id": 243856, "ingredient1": "Cisapride", "ingredient2": "Bepridil", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285047/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Metoclopramide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243857, "ingredient1": "Dicoumarol", "ingredient2": "Cisapride", "severity": "Moderate", "effect": "Cisapride may enhance the effects of oral anticoagulants.  The mechanism is unknown.  Increases in coagulation times have been reported following the initiation of cisapride therapy in patients stabilized on anticoagulant therapy.  However, other studies have reported increased warfarin requirements in patients taking cisapride.", "source": "DDInter", "management_text": "It is recommended that the INR or PT be monitored if cisapride is added, cisapride is discontinued, or the dosage is adjusted in a patient receiving anticoagulants.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Others", "recommendation": "It is recommended that the INR or PT be monitored if cisapride is added, cisapride is discontinued, or the dosage is adjusted in a patient receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285049/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[3] Darlington MR \"Hypoprothrombinemia induced by warfarin sodium and cisapride.\" Am J Health Syst Pharm 54 (1997):  320-1", "alternatives_a": "Metoclopramide", "alternatives_b": "Betrixaban, Apixaban, Clopidogrel, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "updated_at": 1767369485}, {"id": 243858, "ingredient1": "Grepafloxacin", "ingredient2": "Cisapride", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285050/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Metoclopramide", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "updated_at": 1767369485}, {"id": 243859, "ingredient1": "Isoetharine", "ingredient2": "Cisapride", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285051/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Metoclopramide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243860, "ingredient1": "Cisapride", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285052/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243861, "ingredient1": "Cisapride", "ingredient2": "Lomefloxacin", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285053/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Metoclopramide", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 243862, "ingredient1": "Cisapride", "ingredient2": "Methotrimeprazine", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285054/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243863, "ingredient1": "Cisapride", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285057/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Metoclopramide", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 243864, "ingredient1": "Cisapride", "ingredient2": "Promazine", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285059/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243865, "ingredient1": "Cisapride", "ingredient2": "Relugolix", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285060/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Metoclopramide", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 243866, "ingredient1": "Cisapride", "ingredient2": "Ritodrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285061/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Metoclopramide", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243867, "ingredient1": "Cisapride", "ingredient2": "Trichlormethiazide", "severity": "Major", "effect": "Some diuretics may produce hypokalemia and hypomagnesemia which could potentiate the risk of cisapride-induced arrhythmias in patients receiving both drugs concomitantly.", "source": "DDInter", "management_text": "Cisapride is contraindicated in patients with uncorrected hypokalemia and hypomagnesemia, such as those taking potassium-wasting diuretics.", "mechanism_text": "Synergism", "recommendation": "Cisapride is contraindicated in patients with uncorrected hypokalemia and hypomagnesemia, such as those taking potassium-wasting diuretics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285062/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):", "alternatives_a": "Metoclopramide", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, More", "updated_at": 1767369485}, {"id": 243868, "ingredient1": "Cisapride", "ingredient2": "Triflupromazine", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285063/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243869, "ingredient1": "Alimemazine", "ingredient2": "Cisapride", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285064/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243870, "ingredient1": "Cisapride", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.", "source": "DDInter", "management_text": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285065/", "reference_text": "[1] \"Product Information. Rezulin (troglitazone).\" Parke-Davis  (2001):[2] Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP \"Potential interaction of troglitazone and cyclosporine.\" Transplantation 65 (1998):  1399-400[3] Burgess SJ, Singer GG, Brennan DC \"Effect of troglitazone on cyclosporine whole blood levels.\" Transplantation 66 (1998):  272[4] Frantz RP, Nguyen TT \"Rezulin (troglitazone) greatly increases cyclosporine metabolism.\" J Heart Lung Transplant 17 (1998):  1037-8[5] Terra SG, Washam JB, May DB \"Comment: troglitazone drug interactions.\" Ann Pharmacother 32 (1998):  1111[6] Fraser CG, Fierro L \"Comment: troglitazone.\" Ann Pharmacother 32 (1998):  1111-2[7] Park MH, Pelegrin D, Haug MT, Young JB \"Troglitazone, a new antidiabetic agent, decreases cyclosporine level.\" J Heart Lung Transplant 17 (1998):  1139-40", "alternatives_a": "Metoclopramide", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "updated_at": 1767369485}, {"id": 243871, "ingredient1": "Cisapride", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with the ketolide, telithromycin, as well as certain macrolide antibiotics may significantly increase the plasma concentrations of cisapride.  The mechanism is inhibition of cisapride metabolism via CYP450 3A4.  High plasma levels of cisapride have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death.  Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the use of cisapride with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the use of cisapride with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285066/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995):  765-8[3] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995):  906-17[4] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996):  279-81[5] Bedford TA, Rowbotham DJ \"Cisapride: drug interactions of clinical significance.\" Drug Saf 15 (1996):  167-75[6] Jenkins IR, Gibson J \"Cisapride, erythromycin and arrhythmia.\" Anaesth Intensive Care 24 (1996):  728[7] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[8] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998):  1053-6[9] Gray VS \"Syncopal episodes associated with cisapride and concurrent drugs.\" Ann Pharmacother 32 (1998):  648-51[10] Vitola J, Vukanovic J, Roden DM \"Cisapride-induced torsades de pointes.\" J Cardiovasc Electrophysiol 9 (1998):  1109-13[11] vanHaarst AD, vantKlooster GAE, vanGerven JMA, Schoemaker RC, vanOene JC, Burggraaf J, Coene MC, Cohen AF \"The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.\" Clin Pharmacol Ther 64 (1998):  542-6[12] Piquette RK \"Torsade de pointes induced by cisapride/clarithromycin interaction.\" Ann Pharmacother 33 (1999):  22-6[13] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000):  41-57[15] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000):  789-800[16] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[17] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals  (2004):[18] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2)  http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm\"   (2004):[19] Sekkarie MA \"Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin.\" Am J Kidney Dis 30 (1997):  437-9", "alternatives_a": "Metoclopramide", "alternatives_b": "Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 243872, "ingredient1": "Pemigatinib", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "Coadministration of pemigatinib with proton pump inhibitors may result in a reduction in the plasma concentrations of pemigatinib.  The mechanism for this interaction has not been delineated.", "source": "DDInter", "management_text": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.  Patients should be monitored for potentially reduced efficacy.", "mechanism_text": "Others", "recommendation": "Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285074/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 243873, "ingredient1": "Etidocaine", "ingredient2": "Quinine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285079/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, More", "updated_at": 1767369485}, {"id": 243874, "ingredient1": "Quinine", "ingredient2": "Levobupivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285080/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, More", "updated_at": 1767369485}, {"id": 243875, "ingredient1": "Quinine", "ingredient2": "Procaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285085/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Prednisolone, Betamethasone, Fluorometholone, More", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, More", "updated_at": 1767369485}, {"id": 243876, "ingredient1": "Ropivacaine", "ingredient2": "Quinine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285087/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 243877, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285088/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243878, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285089/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243879, "ingredient1": "Acrivastine", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285157/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243880, "ingredient1": "Ramelteon", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285159/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ramelteon, Nitrazepam, Zopiclone", "alternatives_b": "Melatonin, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 243881, "ingredient1": "Efalizumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285165/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243882, "ingredient1": "Efalizumab", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285166/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243883, "ingredient1": "Efalizumab", "ingredient2": "Candida albicans", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity.  Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Antagonism", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285168/", "reference_text": "[1] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc  (2001):[2] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc  (2001):[3] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc  (2001):[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals  (2001):[6] \"Product Information. Tuberculin Tine Test (tuberculin purified protein derivative).\" Connaught Laboratories Inc", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243884, "ingredient1": "Efalizumab", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285170/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243885, "ingredient1": "Efalizumab", "ingredient2": "Coccidioides immitis spherule", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity.  Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Antagonism", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285171/", "reference_text": "[1] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc  (2001):[2] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc  (2001):[3] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc  (2001):[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals  (2001):[6] \"Product Information. Tuberculin Tine Test (tuberculin purified protein derivative).\" Connaught Laboratories Inc", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243886, "ingredient1": "Efalizumab", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.  Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression.  The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285183/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech  (2003):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243887, "ingredient1": "Efalizumab", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285186/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243888, "ingredient1": "Efalizumab", "ingredient2": "Muromonab", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.  Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression.  The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285187/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech  (2003):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Efalizumab", "updated_at": 1767369485}, {"id": 243889, "ingredient1": "Efalizumab", "ingredient2": "Plicamycin", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.  Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression.  The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285189/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech  (2003):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 243890, "ingredient1": "Efalizumab", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.  Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression.  The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285197/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech  (2003):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 243891, "ingredient1": "Efalizumab", "ingredient2": "Tositumomab", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.  Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression.  The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285217/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech  (2003):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 243892, "ingredient1": "Efalizumab", "ingredient2": "Uracil mustard", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections.  Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.  Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression.  The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285221/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech  (2003):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243893, "ingredient1": "Efalizumab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285223/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243894, "ingredient1": "Relugolix", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285237/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 243895, "ingredient1": "Bepridil", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally.  Relugolix is a substrate for intestinal P-gp.  In vitro, it is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should be avoided when possible.  In addition, the benefits of androgen deprivation therapy such as relugolix should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval, many of which are also P-gp inhibitors (e.g., amiodarone, azithromycin, bepridil, cabozantinib, clarithromycin, crizotinib, dronedarone, elagolix, erythromycin, ketoconazole, lapatinib, mifepristone, nilotinib, osimertinib, propafenone, quinidine, quinine, ranolazine, tacrolimus, telithromycin, valbenazine, vemurafenib).  If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.  Alternatively, when relugolix is used as monotherapy for the treatment of prostate cancer, the prescribing information states that treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.  Following interruption of relugolix for more than 7 days, the manufacturer recommends restarting therapy with a loading dose of 360 mg on the first day, then continuing with a dose of 120 mg once daily.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should be avoided when possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285238/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Gonadorelin, Darolutamide, Anastrozole, Fulvestrant, Letrozole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243896, "ingredient1": "Butalbital", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285240/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 243897, "ingredient1": "Ethinylestradiol", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration of hormonal contraceptives may decrease the efficacy of the fixed-dose oral formulation of relugolix, estradiol, and norethindrone when used for the management of uterine fibroids in premenopausal women.", "source": "DDInter", "management_text": "It is recommended that hormonal contraceptives (particularly those containing estrogen) should be discontinued prior to starting treatment with the fixed-dose oral formulation containing relugolix, estradiol, and norethindrone (brand name Myfembree).  Some authorities consider their concomitant use to be contraindicated (UK).  The manufacturer of Myfembree recommends using effective non-hormonal contraception during treatment and for one week after the final dose.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Antagonism", "recommendation": "It is recommended that hormonal contraceptives (particularly those containing estrogen) should be discontinued prior to starting treatment with the fixed-dose oral formulation containing relugolix, estradiol, and norethindrone (brand name Myfembree).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285241/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):[3] \"Product Information. Myfembree (estradiol/norethindrone/relugolix).\" Myovant Sciences, Inc.  (2021):[4] Hsin-Yuan C, Mohamed A, Yi-Fen C, et al. \"An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.  https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2030705\"   (2022):", "alternatives_a": "Norelgestromin, Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Tamoxifen, More", "updated_at": 1767369485}, {"id": 243898, "ingredient1": "Grepafloxacin", "ingredient2": "Relugolix", "severity": "Major", "effect": "Grepafloxacin can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285243/", "reference_text": "[1] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996):  77-81[2] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[3] Lode H, Vogel F, Elies W \"Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance.\" Clin Ther 21 (1999):  61-74[4] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000):  557-9[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 243899, "ingredient1": "Isoetharine", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285244/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243900, "ingredient1": "Relugolix", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Levomethadyl acetate may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285245/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate).\" Roxane Laboratories Inc  (2001):[2] Deamer RL, Wilson DR, Clark DS, Prichard JG \"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).\" J Addict Dis 20 (2001):  7-14[3] Krantz MJ, Mehler PS \"Synthetic opioids and QT prolongation.\" Arch Intern Med 163 (2003):  1615; author reply 1615[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 243901, "ingredient1": "Relugolix", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285246/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 243902, "ingredient1": "Relugolix", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285247/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 243903, "ingredient1": "Relugolix", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285251/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Tamoxifen, More", "updated_at": 1767369485}, {"id": 243904, "ingredient1": "Relugolix", "ingredient2": "Phenylbutazone", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285252/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 243905, "ingredient1": "Relugolix", "ingredient2": "Pirbuterol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285254/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 243906, "ingredient1": "Relugolix", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285256/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 243907, "ingredient1": "Ritodrine", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285257/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "alternatives_b": "Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243908, "ingredient1": "Somatrem", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285258/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 243909, "ingredient1": "Triflupromazine", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285259/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243910, "ingredient1": "Alimemazine", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285260/", "reference_text": "[1] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc  (2002):[2] \"Product Information. Zoladex (goserelin).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Trelstar (triptorelin).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 243911, "ingredient1": "Troglitazone", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285261/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Ganirelix, Cetrorelix, Nafarelin, Gonadorelin, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "updated_at": 1767369485}, {"id": 243912, "ingredient1": "Acrivastine", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285263/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Dexchlorpheniramine, Phenindamine, Astemizole, Meclizine, Terfenadine, Pheniramine", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 243913, "ingredient1": "Chlorcyclizine", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285265/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Dexchlorpheniramine, Phenindamine, Astemizole, Meclizine, Terfenadine, Pheniramine", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 243914, "ingredient1": "Ropinirole", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285267/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Thiopental, Ethchlorvynol, Dichloralphenazone, Nitrazepam", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243915, "ingredient1": "Rifampicin", "ingredient2": "Obeticholic acid", "severity": "Moderate", "effect": "Coadministration with inhibitors of the bile salt efflux pump (BSEP) may increase accumulation of conjugated bile salts in the liver, including the glycine and taurine conjugates of obeticholic acid.  Following daily administration of obeticholic acid, there was accumulation of the glycine and taurine conjugates, which have in vitro pharmacological activities similar to the parent drug.  The metabolite-to-parent ratios of the glycine and taurine conjugates of obeticholic acid were 13.8 and 12.3 respectively, with chronic administration.  In vitro data indicate that the taurine conjugate of obeticholic acid (tauro-obeticholic acid) is a substrate of BSEP.  Consequently, concomitant use of medications that inhibit the BSEP, a canalicular membrane bile acid transporter, may result in further accumulation of tauro-obeticholic acid and other conjugated bile salts in the liver.  Clinical symptoms and toxicities may occur.  Additionally, obeticholic acid and its conjugates are selective and potent agonists for the farnesoid X receptor (FXR), the activation of which leads to induction of BSEP.  Thus, inhibitors of BSEP may theoretically diminish the pharmacologic effects of obeticholic acid.", "source": "DDInter", "management_text": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.  If coadministration is required, serum transaminases and bilirubin should be closely monitored.", "mechanism_text": "Others", "recommendation": "Concomitant use of obeticholic acid with BSEP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285434/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Ocaliva (obeticholic acid).\" Intercept Pharmaceuticals, Inc.  (2016):", "alternatives_a": "Cholic Acid, Odevixibat, Maralixibat, Chenodeoxycholic acid", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, More", "updated_at": 1767369485}, {"id": 243916, "ingredient1": "Ripretinib", "ingredient2": "Methoxsalen", "severity": "Moderate", "effect": "Concomitant use of methoxsalen with other known photosensitizing agents may increase the risk of photosensitivity reactions.  These agents include anthralin, coal tar or coal tar derivatives, griseofulvin, hypericin extracts (e.g., St John's Wort), fluoroquinolones, phenothiazines, retinoids, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, sulfonylureas, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal, and methyl orange.", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.  Patients should be advised to avoid sun exposure, even through window glass or cloud cover, for at least 8 hours after methoxsalen ingestion and during the 24 hours following photochemotherapy or photopheresis treatment.  Protective devices should be used if sun exposure cannot be avoided, such as a hat and gloves and/or sunscreens containing ingredients that filter out UVA radiation (e.g., benzophenone and/or PABA esters).  Sunscreens must be applied to all areas that might be exposed to the sun, including the lips.  For the treatment of psoriasis, sunscreens should not be applied to areas affected by psoriasis until after treatment in the UVA chamber.  In addition, UVA-absorbing wrap-around sunglasses should be worn during daylight for 24 hours after methoxsalen ingestion and during the 24 hours following photochemotherapy or photopheresis treatment to prevent the irreversible binding of methoxsalen to proteins and DNA components of the lens, which can lead to formation of cataracts.  The glasses should be worn any time patients are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.  Because erythema and/or burning due to photochemotherapy and sunburn due to sun exposure are additive, patients should not sunbathe for 48 hours after photochemotherapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285443/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Oxsoralen (methoxsalen).\" ICN Pharmaceuticals Inc  (2001):[3] \"Product Information. Uvadex (methoxsalen).\" Therakos Inc  (2006):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020):  589-600[6] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivity update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019):  827-47", "alternatives_a": "Acitretin, Etretinate, Trioxsalen, Tazarotene, Calcipotriol, Trioxsalen, Calcitriol", "alternatives_b": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 243917, "ingredient1": "Ripretinib", "ingredient2": "Methyl aminolevulinate (topical)", "severity": "Moderate", "effect": "Concomitant use of aminolevulinate topical preparations with other known photosensitizing agents may enhance the phototoxic reaction to photodynamic therapy.  Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.  Patients should be advised to avoid exposure of treated areas to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) during the period between application of aminolevulinic acid or methyl aminolevulinate and photoactivation, and for 48 hours post-illumination.  Concomitant use with other topical medicinal products should be avoided.  Some authorities recommend avoiding use of hypericin-containing products for 2 weeks prior to treatment with topical aminolevulinic acid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285444/", "reference_text": "[1] \"Product Information. Levulan Kerastick (aminolevulinic acid).\" Berlex Laboratories  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Metvixia (methyl aminolevulinate topical).\" Galderma Laboratories Inc  (2008):[5] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020):  589-600[6] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivity update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019):  827-47", "alternatives_a": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243918, "ingredient1": "Ripretinib", "ingredient2": "Porfimer sodium", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.  Following treatment with porfimer, patients should follow measures outlined in the manufacturer's product labeling for light and sun exposure.  Before exposing skin to direct sunlight or bright indoor light, patients should test for residual photosensitivity as described in porfimer's product labeling.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285447/", "reference_text": "[1] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020):  589-600[4] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivity update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019):  827-47", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Niraparib, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 243919, "ingredient1": "Verteporfin", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions.  Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.  Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285448/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Visudyne (verteporfin).\" Valeant Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020):  589-600[5] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivity update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019):  827-47", "alternatives_a": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Aflibercept, Bevacizumab", "updated_at": 1767369485}, {"id": 243920, "ingredient1": "Abarelix", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285450/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243921, "ingredient1": "Ritodrine", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285451/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine", "updated_at": 1767369485}, {"id": 243922, "ingredient1": "Ritodrine", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285452/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243923, "ingredient1": "Bepridil", "ingredient2": "Ritodrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285453/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Bremelanotide, Black cohosh, Flibanserin, Bromocriptine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243924, "ingredient1": "Carteolol", "ingredient2": "Ritodrine", "severity": "Major", "effect": "The use of a nonselective beta blocker with ritodrine (a beta-2 agonist) may result in mutually antagonistic effects, negating the effect of one or both drugs.", "source": "DDInter", "management_text": "In general, the use of beta blockers with ritodrine is discouraged.  Selective beta blockers (e.g. acebutolol, atenolol, betaxolol, bisoprolol, metoprolol) may be preferable if the use of a beta blocker is unavoidable.", "mechanism_text": "Antagonism", "recommendation": "In general, the use of beta blockers with ritodrine is discouraged.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285455/", "reference_text": "[1] \"Product Information. Yutopar (ritodrine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Bremelanotide, Black cohosh, Flibanserin, Cabergoline", "updated_at": 1767369485}, {"id": 243925, "ingredient1": "Ephedrine (nasal)", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285456/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, More", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243926, "ingredient1": "Grepafloxacin", "ingredient2": "Ritodrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285457/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Bremelanotide, Black cohosh, Cabergoline", "updated_at": 1767369485}, {"id": 243927, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285458/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243928, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285459/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243929, "ingredient1": "Isoetharine", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285460/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243930, "ingredient1": "Ritodrine", "ingredient2": "Levmetamfetamine (nasal)", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285461/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243931, "ingredient1": "Ritodrine", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Major", "effect": "The use of a nonselective beta blocker with ritodrine (a beta-2 agonist) may result in mutually antagonistic effects, negating the effect of one or both drugs.", "source": "DDInter", "management_text": "In general, the use of beta blockers with ritodrine is discouraged.  Selective beta blockers (e.g. acebutolol, atenolol, betaxolol, bisoprolol, metoprolol) may be preferable if the use of a beta blocker is unavoidable.", "mechanism_text": "Antagonism", "recommendation": "In general, the use of beta blockers with ritodrine is discouraged.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285462/", "reference_text": "[1] \"Product Information. Yutopar (ritodrine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243932, "ingredient1": "Ritodrine", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285463/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243933, "ingredient1": "Ritodrine", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285464/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine", "updated_at": 1767369485}, {"id": 243934, "ingredient1": "Ritodrine", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285466/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Dexfenfluramine, Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243935, "ingredient1": "Ritodrine", "ingredient2": "Mephentermine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285467/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243936, "ingredient1": "Ritodrine", "ingredient2": "Metaraminol", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285468/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243937, "ingredient1": "Ritodrine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285469/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Bremelanotide, Black cohosh, Ibuprofen, Naproxen", "updated_at": 1767369485}, {"id": 243938, "ingredient1": "Ritodrine", "ingredient2": "Methoxamine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285470/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243939, "ingredient1": "Ritodrine", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.  Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption.  Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285471/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991):  66-80[2] Coleman JJ, Vollmer WM, Barker AF, et al. \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986):  45-51[3] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987):  289-96[4] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988):  162-5[5] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988):  285-93[6] Garty M, Paul-Keslin L, Ilfeld DN, et al. \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989):  25-8[7] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992):  786-9[8] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988):  444-5[9] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988):  571-8[10] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984):  386-95[11] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990):  54-7[12] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989):  119-25[13] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986):  451-3[14] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980):  429-35[15] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981):  19-20[16] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981):  756-7[17] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987):  523-9[18] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984):  373-5[19] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982):  360-4[20] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985):  469-71[21] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980):  207-12[22] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[23] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[24] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982):  674-6[25] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989):  1317-20[26] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "updated_at": 1767369485}, {"id": 243940, "ingredient1": "Ritodrine", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285473/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Bremelanotide, Black cohosh, Ibuprofen, Naproxen", "updated_at": 1767369485}, {"id": 243941, "ingredient1": "Triflupromazine", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285476/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Bremelanotide, Black cohosh, Ibuprofen, Naproxen", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 243942, "ingredient1": "Alimemazine", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285477/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Bremelanotide, Black cohosh, Ibuprofen, Naproxen", "updated_at": 1767369485}, {"id": 243943, "ingredient1": "Troglitazone", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285478/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Bremelanotide, Naproxen, Ibuprofen, Cabergoline", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 243944, "ingredient1": "Xylometazoline (nasal)", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285479/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243945, "ingredient1": "Anisindione", "ingredient2": "Interferon alfa-2a, Recombinant", "severity": "Moderate", "effect": "Interferons may increase the plasma concentrations and pharmacologic effects of warfarin and other oral anticoagulants.  At least one case of this interaction has been reported in the literature.  The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes.  Physiologic events and drugs that induce interferon synthesis (e.g., viral infection, influenza vaccination) have also been reported to decrease metabolism and potentiate the effects of certain drugs including warfarin.", "source": "DDInter", "management_text": "Caution is advised if oral anticoagulants are administered with an interferon.  The INR should be monitored closely and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Others", "recommendation": "Caution is advised if oral anticoagulants are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285489/", "reference_text": "[1] Kramer P, Tsuru M, Cook CE, et al. \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984):  416-8[2] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993):  65-9[3] Adachi Y, Yokoyama Y, Nanno T, Yamamoto T \"Potentiation of warfarin by interferon.\" BMJ 311 (1995):  292[4] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992):  381-6", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243946, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Aurothioglucose", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of agents with neurotoxic effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285490/", "reference_text": "[1] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):", "alternatives_a": "Penicillamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243947, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Cerivastatin", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of agents with neurotoxic effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285491/", "reference_text": "[1] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243948, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Dicoumarol", "severity": "Moderate", "effect": "Interferons may increase the plasma concentrations and pharmacologic effects of warfarin and other oral anticoagulants.  At least one case of this interaction has been reported in the literature.  The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes.  Physiologic events and drugs that induce interferon synthesis (e.g., viral infection, influenza vaccination) have also been reported to decrease metabolism and potentiate the effects of certain drugs including warfarin.", "source": "DDInter", "management_text": "Caution is advised if oral anticoagulants are administered with an interferon.  The INR should be monitored closely and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Others", "recommendation": "Caution is advised if oral anticoagulants are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285492/", "reference_text": "[1] Kramer P, Tsuru M, Cook CE, et al. \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984):  416-8[2] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993):  65-9[3] Adachi Y, Yokoyama Y, Nanno T, Yamamoto T \"Potentiation of warfarin by interferon.\" BMJ 311 (1995):  292[4] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992):  381-6", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243949, "ingredient1": "Interferon alfa-n1", "ingredient2": "Interferon alfa-2a, Recombinant", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of agents with neurotoxic effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285494/", "reference_text": "[1] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243950, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil).  Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine).  Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285495/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine).\" Organon  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243951, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285496/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Uracil mustard", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243952, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline.  The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.  Physiologic events and drugs that induce interferon synthesis (e.g., viral infection, influenza vaccination) have also been reported to decrease metabolism and potentiate the effects of certain drugs including theophylline.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.  Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen.  Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285498/", "reference_text": "[1] Kramer P, Tsuru M, Cook CE, et al. \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984):  416-8[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991):  135-50[3] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987):  939-41[4] Jonkman JH, Nicholson KG, Farrow PR, et al. \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989):  795-802[5] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993):  65-9[6] \"Product Information. Intron A (interferon alfa-2b).\" Schering Corporation  (2001):[7] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992):  381-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243953, "ingredient1": "Ifosfamide", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285502/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 243954, "ingredient1": "Isosorbide", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285503/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243955, "ingredient1": "Ropivacaine", "ingredient2": "Nitric Oxide", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285505/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Doxapram, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 243956, "ingredient1": "Ropivacaine", "ingredient2": "Nitrous oxide", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285506/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Ketamine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 243957, "ingredient1": "Ropivacaine", "ingredient2": "Rasburicase", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285508/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 243958, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Ropivacaine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285509/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243959, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Ropivacaine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285510/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243960, "ingredient1": "Sulfamethizole", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285511/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "Sorbitol, Sodium citrate, Magnesium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Tamsulosin, Tinidazole, Ascorbic acid, More", "updated_at": 1767369485}, {"id": 243961, "ingredient1": "Sulfamethoxazole", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285512/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Streptomycin, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Tamsulosin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243962, "ingredient1": "Tafenoquine", "ingredient2": "Ropivacaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285513/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 243963, "ingredient1": "Rotavirus vaccine", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285520/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243964, "ingredient1": "Acrivastine", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285543/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 243965, "ingredient1": "Chlorcyclizine", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285545/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Cabergoline", "updated_at": 1767369485}, {"id": 243966, "ingredient1": "Rotigotine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285546/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 243967, "ingredient1": "Rucaparib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285547/", "reference_text": "[1] \"Product Information. Meruvax II (rubella virus vaccine).\" Merck & Co., Inc  (2022):[2] \"Product Information. Attenuvax (measles virus vaccine).\" Merck & Co., Inc  (2022):[3] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] \"Product Information. DENGVAXIA (dengue vaccine).\" sanofi pasteur  (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243968, "ingredient1": "Venetoclax", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when venetoclax is used with inhibitors of CYP450 3A4.  Close clinical and laboratory monitoring for the development of tumor lysis syndrome and myelosuppression is recommended following the addition of a CYP450 3A4 inhibitor, and the venetoclax dosage adjusted if necessary.  The dosage may be readjusted 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when venetoclax is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285596/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC  (2016):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, More", "updated_at": 1767369485}, {"id": 243969, "ingredient1": "Varicella Zoster Vaccine (Recombinant)", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285597/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243970, "ingredient1": "Perampanel", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285612/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 243971, "ingredient1": "Acrivastine", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285614/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 243972, "ingredient1": "Nalbuphine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285618/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 243973, "ingredient1": "Phenelzine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285641/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ethchlorvynol, Zopiclone, Nitrazepam", "alternatives_b": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine", "updated_at": 1767369485}, {"id": 243974, "ingredient1": "Phenelzine", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285642/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Tropicamide, Ketorolac", "alternatives_b": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Viloxazine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 243975, "ingredient1": "Polymyxin B", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285655/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Miltefosine, Fexinidazole, Nifurtimox, Benznidazole", "alternatives_b": "Tetracycline, Rifamycin, Miconazole, Chloramphenicol, Gentamicin, Chlorhexidine, Neomycin, Tetracycline, Chloramphenicol, Gentamicin, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 243976, "ingredient1": "Acetohexamide", "ingredient2": "Nalidixic acid", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285661/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin", "updated_at": 1767369485}, {"id": 243977, "ingredient1": "Anisindione", "ingredient2": "Nalidixic acid", "severity": "Major", "effect": "Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants.  The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.", "source": "DDInter", "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285663/", "reference_text": "[1] Linville D, Emory C, Graves L \"Ciprofloxacin and warfarin interaction.\" Am J Med 90 (1991):  765[2] Renzi R, Finkbeiner S \"Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect.\" Am J Emerg Med 9 (1991):  551-2[3] Mott FE, Murphy S, Hunt V \"Ciprofloxacin and warfarin.\" Ann Intern Med 111 (1989):  542-3[4] Kamada AK \"Possible interaction between ciprofloxacin and warfarin.\" DICP 24 (1990):  27-8[5] Jolson HM, Tanner LA, Green L, Grasela TH \"Adverse reaction reporting of interaction between warfarin and fluoroquinolones.\" Arch Intern Med 151 (1991):  1003-4[6] Linville T, Matanin D \"Norfloxacin and warfarin.\" Ann Intern Med 110 (1989):  751-2[7] Kaplan DS \"Norfloxacin and protime elevation.\" Am J Gastroenterol 85 (1990):  901[8] Leor J, Matezki S \"Ofloxacin and warfarin.\" Ann Intern Med 109 (1988):  761[9] Leor J, Levartowsky D, Sharon C \"Interaction between nalidixic acid and warfarin.\" Ann Intern Med 107 (1987):  601[10] Toon S, Hopkins KJ, Garstang FM, et al. \"Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.\" Clin Pharmacol Ther 42 (1987):  33-41[11] McLeod AD, Burgess C \"Drug interaction between warfarin and enoxacin.\" N Z Med J 101 (1988):  216[12] Rocci ML Jr, Vlasses PH, Distelrath LM, et al. \"Norfloxacin does not alter warfarin's disposition or anticoagulant effect.\" J Clin Pharmacol 30 (1990):  728-32[13] Potasman I, Bassan H \"Nicoumalone and nalidixic acid interaction.\" Ann Intern Med 92 (1980):  571[14] Gleckman R, Alvarez S, Joubert DW, Matthews SJ \"Drug therapy reviews: nalidixic acid.\" Am J Hosp Pharm 36 (1979):  1071-6[15] Loeliger EA, van der Esch B, Mattern MJ, Hemker HC \"The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever.\" Thromb Diath Haemorrh 10 (1963):  267-77[16] Marchbanks CR \"Drug-drug interactions with fluoroquinolones.\" Pharmacotherapy 13 (1993):  s23-8[17] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[18] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[19] \"Product Information. Maxaquin (lomefloxacin).\" Searle  (2002):[20] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals[21] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[22] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[23] Roush MK, Bussey HL, Bianco TM \"Do fluoroquinolones alter the effects of warfarin therapy?\" Arch Intern Med 152 (1992):  1533-4[24] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc  (2001):[25] Baciewicz AM, Ashar BH, Locke TW \"Interaction of ofloxacin and warfarin.\" Ann Intern Med 119 (1993):  1223[26] Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Pol \"Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.\" Clin Infect Dis 22 (1996):  251-6[27] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[28] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[29] \"Product Information. Zagam (sparfloxacin).\" Rhone Poulenc Rorer  (2001):[30] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[31] Liao S, Palmer M, Fowler C, Nayak RK \"Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.\" J Clin Pharmacol 36 (1996):  1072-7[32] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[33] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[34] Goel K, Menzies D, Cunha BA \"Elevated international normalized ratio associated with trovafloxacin.\" Ann Intern Med 131 (1999):  72[35] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[36] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[37] Ellis RJ, Mayo MS, Bodensteiner DM \"Ciprofloxacin-warfarin coagulopathy: A case series.\" Am J Hematol 63 (2000):  28-31[38] Ravnan SL, Locke C \"Levofloxacin and warfarin interaction.\" Pharmacotherapy 21 (2001):  884-5[39] Randinitis EJ, Alvey CW, Koup JR, et al. \"Drug interactions with clinafloxacin.\" Antimicrob Agents Chemother 45 (2001):  2543-52[40] Gheno G, Cinetto L \"Levofloxacin-warfarin interaction.\" Eur J Clin Pharmacol 57 (2001):  427[41] Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S \"Possible interaction between gatifloxacin and warfarin.\" Am J Health Syst Pharm 59 (2002):  1205-6[42] Millar E, Coles S, Wyld P, Nimmo W \"Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.\" Clin Pharmacokinet 22(Suppl 1) (1992):  102-6[43] Jones CB, Fugate SE \"Levofloxacin and warfarin interaction.\" Ann Pharmacother 36 (2002):  1554-7[44] Rindone JP, Kelley CL, Jones WN, Garewell HS \"Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin.\" Clin Pharm 10 (1991):  136-8[45] Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW \"Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation.\" Pharmacotherapy 12 (1992):  435-9[46] Efthymiopoulos C, Bramer SL, Maroli A, Blum B \"Theophylline and warfarin interaction studies with grepafloxacin.\" Clin Pharmacokinet 33(Suppl 1) (1997):  39-46[47] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002):  705-10[48] Yamreudeewong W, Lower DL, Kilpatrick DM, Enlow AM, Burrows MM, Greenwood MC \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy.\" Pharmacotherapy 23 (2003):  333-8[49] Davy M, Bird N, Rost KL, Fuder H \"Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.\" Chemotherapy 45 (1999):  491-5[50] Glasheen JJ, Fugit RV, Prochazka AV \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy--a comment.\" Pharmacotherapy 23 (2003):  1079-80; discussion 1080[51] Elbe DH, Chang SW \"Moxifloxacin-warfarin interaction: a series of five case reports.\" Ann Pharmacother 39 (2005):  361-4[52] McCall KL, Scott JC, Anderson HG \"Retrospective evaluation of a possible interaction between warfarin and levofloxacin.\" Pharmacotherapy 25 (2005):  67-73[53] Andriole VT, Haverstock DC, Choudhri SH \"Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.\" Drug Saf 28 (2005):  443-52[54] Arnold LM, Nissen LR, Ng TM \"Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction.\" Pharmacotherapy 25 (2005):  904-7[55] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44[56] Djelouah I, Wilcox D, Morawiecka I \"Fluoroquinolones and warfarin: suspected interactions.  http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adrv14n3_e.html\"   (2005):[57] Stroud LF, Mamdami MM, Kopp A, Bell CM \"The safety of levofloxacin in elderly patients on warfarin.\" Am J Med 118 (2005):  1417[58] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005):  653-6[59] Chock AW, Stading JA \"Indeterminable International Normalized Ratio with concurrent use of warfarin and gatifloxacin.\" Am J Health Syst Pharm 63 (2006):  1539-42[60] Mathews S, Cole J, Ryono RA \"Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin.\" Pharmacotherapy 26 (2006):  1446-52[61] Yildiz F, Kurtaran B, Cayli M, Candevir A, Sumbul Z \"A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve.\" Heart Vessels 23 (2008):  286-8", "alternatives_a": "Enoxacin, Delafloxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243978, "ingredient1": "Attapulgite", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285664/", "reference_text": "[1] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin", "updated_at": 1767369485}, {"id": 243979, "ingredient1": "Axicabtagene ciloleucel", "ingredient2": "Nalidixic acid", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285665/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin", "updated_at": 1767369485}, {"id": 243980, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285666/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243981, "ingredient1": "Bromfenac", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285667/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin", "updated_at": 1767369485}, {"id": 243982, "ingredient1": "Calcium glycerophosphate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285668/", "reference_text": "[1] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals", "alternatives_a": "Enoxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243983, "ingredient1": "Copper gluconate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285670/", "reference_text": "[1] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals", "alternatives_a": "Enoxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243984, "ingredient1": "Dicoumarol", "ingredient2": "Nalidixic acid", "severity": "Major", "effect": "Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants.  The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.", "source": "DDInter", "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.", "mechanism_text": "Synergism", "recommendation": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285671/", "reference_text": "[1] Linville D, Emory C, Graves L \"Ciprofloxacin and warfarin interaction.\" Am J Med 90 (1991):  765[2] Renzi R, Finkbeiner S \"Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect.\" Am J Emerg Med 9 (1991):  551-2[3] Mott FE, Murphy S, Hunt V \"Ciprofloxacin and warfarin.\" Ann Intern Med 111 (1989):  542-3[4] Kamada AK \"Possible interaction between ciprofloxacin and warfarin.\" DICP 24 (1990):  27-8[5] Jolson HM, Tanner LA, Green L, Grasela TH \"Adverse reaction reporting of interaction between warfarin and fluoroquinolones.\" Arch Intern Med 151 (1991):  1003-4[6] Linville T, Matanin D \"Norfloxacin and warfarin.\" Ann Intern Med 110 (1989):  751-2[7] Kaplan DS \"Norfloxacin and protime elevation.\" Am J Gastroenterol 85 (1990):  901[8] Leor J, Matezki S \"Ofloxacin and warfarin.\" Ann Intern Med 109 (1988):  761[9] Leor J, Levartowsky D, Sharon C \"Interaction between nalidixic acid and warfarin.\" Ann Intern Med 107 (1987):  601[10] Toon S, Hopkins KJ, Garstang FM, et al. \"Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.\" Clin Pharmacol Ther 42 (1987):  33-41[11] McLeod AD, Burgess C \"Drug interaction between warfarin and enoxacin.\" N Z Med J 101 (1988):  216[12] Rocci ML Jr, Vlasses PH, Distelrath LM, et al. \"Norfloxacin does not alter warfarin's disposition or anticoagulant effect.\" J Clin Pharmacol 30 (1990):  728-32[13] Potasman I, Bassan H \"Nicoumalone and nalidixic acid interaction.\" Ann Intern Med 92 (1980):  571[14] Gleckman R, Alvarez S, Joubert DW, Matthews SJ \"Drug therapy reviews: nalidixic acid.\" Am J Hosp Pharm 36 (1979):  1071-6[15] Loeliger EA, van der Esch B, Mattern MJ, Hemker HC \"The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever.\" Thromb Diath Haemorrh 10 (1963):  267-77[16] Marchbanks CR \"Drug-drug interactions with fluoroquinolones.\" Pharmacotherapy 13 (1993):  s23-8[17] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[18] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[19] \"Product Information. Maxaquin (lomefloxacin).\" Searle  (2002):[20] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals[21] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[22] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[23] Roush MK, Bussey HL, Bianco TM \"Do fluoroquinolones alter the effects of warfarin therapy?\" Arch Intern Med 152 (1992):  1533-4[24] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc  (2001):[25] Baciewicz AM, Ashar BH, Locke TW \"Interaction of ofloxacin and warfarin.\" Ann Intern Med 119 (1993):  1223[26] Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Pol \"Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.\" Clin Infect Dis 22 (1996):  251-6[27] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[28] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[29] \"Product Information. Zagam (sparfloxacin).\" Rhone Poulenc Rorer  (2001):[30] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[31] Liao S, Palmer M, Fowler C, Nayak RK \"Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.\" J Clin Pharmacol 36 (1996):  1072-7[32] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[33] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[34] Goel K, Menzies D, Cunha BA \"Elevated international normalized ratio associated with trovafloxacin.\" Ann Intern Med 131 (1999):  72[35] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[36] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[37] Ellis RJ, Mayo MS, Bodensteiner DM \"Ciprofloxacin-warfarin coagulopathy: A case series.\" Am J Hematol 63 (2000):  28-31[38] Ravnan SL, Locke C \"Levofloxacin and warfarin interaction.\" Pharmacotherapy 21 (2001):  884-5[39] Randinitis EJ, Alvey CW, Koup JR, et al. \"Drug interactions with clinafloxacin.\" Antimicrob Agents Chemother 45 (2001):  2543-52[40] Gheno G, Cinetto L \"Levofloxacin-warfarin interaction.\" Eur J Clin Pharmacol 57 (2001):  427[41] Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S \"Possible interaction between gatifloxacin and warfarin.\" Am J Health Syst Pharm 59 (2002):  1205-6[42] Millar E, Coles S, Wyld P, Nimmo W \"Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.\" Clin Pharmacokinet 22(Suppl 1) (1992):  102-6[43] Jones CB, Fugate SE \"Levofloxacin and warfarin interaction.\" Ann Pharmacother 36 (2002):  1554-7[44] Rindone JP, Kelley CL, Jones WN, Garewell HS \"Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin.\" Clin Pharm 10 (1991):  136-8[45] Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW \"Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation.\" Pharmacotherapy 12 (1992):  435-9[46] Efthymiopoulos C, Bramer SL, Maroli A, Blum B \"Theophylline and warfarin interaction studies with grepafloxacin.\" Clin Pharmacokinet 33(Suppl 1) (1997):  39-46[47] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002):  705-10[48] Yamreudeewong W, Lower DL, Kilpatrick DM, Enlow AM, Burrows MM, Greenwood MC \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy.\" Pharmacotherapy 23 (2003):  333-8[49] Davy M, Bird N, Rost KL, Fuder H \"Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.\" Chemotherapy 45 (1999):  491-5[50] Glasheen JJ, Fugit RV, Prochazka AV \"Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy--a comment.\" Pharmacotherapy 23 (2003):  1079-80; discussion 1080[51] Elbe DH, Chang SW \"Moxifloxacin-warfarin interaction: a series of five case reports.\" Ann Pharmacother 39 (2005):  361-4[52] McCall KL, Scott JC, Anderson HG \"Retrospective evaluation of a possible interaction between warfarin and levofloxacin.\" Pharmacotherapy 25 (2005):  67-73[53] Andriole VT, Haverstock DC, Choudhri SH \"Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.\" Drug Saf 28 (2005):  443-52[54] Arnold LM, Nissen LR, Ng TM \"Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction.\" Pharmacotherapy 25 (2005):  904-7[55] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44[56] Djelouah I, Wilcox D, Morawiecka I \"Fluoroquinolones and warfarin: suspected interactions.  http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adrv14n3_e.html\"   (2005):[57] Stroud LF, Mamdami MM, Kopp A, Bell CM \"The safety of levofloxacin in elderly patients on warfarin.\" Am J Med 118 (2005):  1417[58] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005):  653-6[59] Chock AW, Stading JA \"Indeterminable International Normalized Ratio with concurrent use of warfarin and gatifloxacin.\" Am J Health Syst Pharm 63 (2006):  1539-42[60] Mathews S, Cole J, Ryono RA \"Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin.\" Pharmacotherapy 26 (2006):  1446-52[61] Yildiz F, Kurtaran B, Cayli M, Candevir A, Sumbul Z \"A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve.\" Heart Vessels 23 (2008):  286-8", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Enoxacin, Delafloxacin, Lomefloxacin, Grepafloxacin", "updated_at": 1767369485}, {"id": 243985, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Nalidixic acid", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285674/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243986, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Nalidixic acid", "severity": "Major", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285675/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243987, "ingredient1": "Iron protein succinylate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285677/", "reference_text": "[1] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Enoxacin, Lomefloxacin, Grepafloxacin", "updated_at": 1767369485}, {"id": 243988, "ingredient1": "Nalidixic acid", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil).  Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine).  Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285681/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine).\" Organon  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Enoxacin, Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin, Ofloxacin", "updated_at": 1767369485}, {"id": 243989, "ingredient1": "Nalidixic acid", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285682/", "reference_text": "[1] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals", "alternatives_a": "Enoxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243990, "ingredient1": "Nalidixic acid", "ingredient2": "Magnesium glycinate", "severity": "Moderate", "effect": "Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285685/", "reference_text": "[1] \"Product Information. Neggram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals", "alternatives_a": "Enoxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243991, "ingredient1": "Nalidixic acid", "ingredient2": "Melphalan flufenamide", "severity": "Major", "effect": "Serious gastrointestinal toxicity such as hemorrhagic ulcerative colitis and intestinal necrosis has been reported with the concomitant use of nalidixic acid and melphalan.", "source": "DDInter", "management_text": "The concomitant use of nalidixic acid in patients undergoing therapy with melphalan or other related cancer chemotherapeutic alkylating agents is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "The concomitant use of nalidixic acid in patients undergoing therapy with melphalan or other related cancer chemotherapeutic alkylating agents is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285687/", "reference_text": "[1] \"Product Information. NegGram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243992, "ingredient1": "Phenylbutazone", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285693/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Enoxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 243993, "ingredient1": "Plicamycin", "ingredient2": "Nalidixic acid", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.", "mechanism_text": "Absorption", "recommendation": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285694/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al. \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990):  837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243994, "ingredient1": "Polymyxin B", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285695/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, More", "alternatives_b": "Tetracycline, Rifamycin, Miconazole, Ciprofloxacin, Chloramphenicol, Gentamicin, Chlorhexidine, Neomycin, Ofloxacin, Tetracycline, Ciprofloxacin, More", "updated_at": 1767369485}, {"id": 243995, "ingredient1": "Rofecoxib", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285696/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243996, "ingredient1": "Telavancin", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285699/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Trovafloxacin, Delafloxacin, Cinoxacin", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 243997, "ingredient1": "Troglitazone", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285701/", "reference_text": "[1] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[2] \"Product Information. Noroxin (norfloxacin).\" Merck & Co., Inc  (2001):[3] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[4] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[5] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[6] \"Product Information. Trovan (trovafloxacin).\" Pfizer U.S. Pharmaceuticals  (2001):[7] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988):  194-204[8] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[9] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86[10] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000):  160-3[11] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001):  3-8[12] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002):  232-4[13] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002):  1722-6[14] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[15] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003):  64[16] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004):  602-5[17] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004):  926-31[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004):  455-7[19] Gavin JR 3rd, Kubin R, Choudhri S, et al. \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004):  671-86[20] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004):  111-7[21] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004):  295-7[22] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004):  1807-12[23] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004):  969[24] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004):  968-9[25] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005):  1210-1[26] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005):  1349-52[27] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005):  635-6[28] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005):  1296-302[29] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005):  1269-76[30] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005):  250-3[31] McMorran M, Morrison H, Letourneau G \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\"   (2006):[32] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006):  1352-61[33] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006):  334-5[34] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006):  1716-7[35] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006):  2087-2092[36] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006):  437-465[37] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006):  1857-66[38] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007):  644-7[39] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010):  e5-6[40] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Inc.  (2017):", "alternatives_a": "Enoxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 243998, "ingredient1": "Uracil mustard", "ingredient2": "Nalidixic acid", "severity": "Major", "effect": "Serious gastrointestinal toxicity such as hemorrhagic ulcerative colitis and intestinal necrosis has been reported with the concomitant use of nalidixic acid and melphalan.", "source": "DDInter", "management_text": "The concomitant use of nalidixic acid in patients undergoing therapy with melphalan or other related cancer chemotherapeutic alkylating agents is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "The concomitant use of nalidixic acid in patients undergoing therapy with melphalan or other related cancer chemotherapeutic alkylating agents is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285702/", "reference_text": "[1] \"Product Information. NegGram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Enoxacin, Lomefloxacin, Grepafloxacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 243999, "ingredient1": "Acrivastine", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285704/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 244000, "ingredient1": "Halazepam", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/285707/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}]